{
  "filename": "2022 ESC_ERS Guidelines for the diagnosis and treatment of pulmonary hypertension _ European Heart Journal _ Oxford Academic.pdf",
  "title": null,
  "type": "pulmonary_hypertension",
  "year": 2022,
  "chapters": [
    {
      "number": "1",
      "title": "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension",
      "start_page": 0,
      "end_page": 5,
      "content": "2022 ESC/ERS Guidelines for the diagnosis and\ntreatment of pulmonary hypertension\nDeveloped by the task force for the diagnosis and treatment of\npulmonary hypertension of the European Society of Cardiology\n(ESC) and the European Respiratory Society (ERS).\nEndorsed by the International Society for Heart and Lung\nTransplantation (ISHLT) and the European Reference Network\non rare respiratory diseases (ERN-LUNG).\nAuthors/Task Force Members: Marc Humbert\n(France), Gabor Kovacs (Austria),\nMarius M. Hoeper (Germany), Roberto Badagliacca (Italy), Rolf M.F. Berger\n(Netherlands), Margarita Brida (Croatia), Jørn Carlsen (Denmark),\nAndrew J.S. Coats (United Kingdom), Pilar Escribano-Subias (Spain),\nPisana Ferrari (Italy), Diogenes S. Ferreira (Brazil), Hossein Ardeschir Ghofrani\n(Germany), George Giannakoulas (Greece), David G. Kiely (United Kingdom),\nEckhard Mayer (Germany), Gergely Meszaros (Hungary), Blin Nagavci (Germany),\nKaren M. Olsson (Germany), Joanna Pepke-Zaba (United Kingdom),\nJennifer K. Quint (United Kingdom), Göran Rådegran (Sweden),\nGerald Simonneau (France), Olivier Sitbon (France), Thomy Tonia (Switzerland),\nMark Toshner (United Kingdom), Jean-Luc Vachiery (Belgium),\nAnton Vonk Noordegraaf (Netherlands), Marion Delcroix\n*† (ERS Chairperson)\n(Belgium), Stephan Rosenkranz\n*† (ESC Chairperson) (Germany), and ESC/ERS\nScientiﬁc Document Group\n* Corresponding authors: Stephan Rosenkranz, Clinic III for Internal Medicine (Department of Cardiology, Pulmonology and Intensive Care Medicine), and Cologne Cardiovascular\nResearch Center (CCRC), Heart Center at the University Hospital Cologne, Kerpener Str. 62, 50937 Köln, Germany. Tel.: +49-221-478-32356. Email: stephan.rosenkranz@uk-\nkoeln.de; and\nMarion Delcroix, Clinical Department of Respiratory Diseases, Centre of Pulmonary Vascular Diseases, University Hospitals of Leuven, Herestraat 49, 3000 Leuven, Belgium. Tel.: +32 16\n346813. Email: marion.delcroix@uzleuven.be\n† The two chairpersons contributed equally to the document and are joint corresponding authors.\nAuthor/Task Force Member afﬁliations are listed in author information.\n1 Representing the Association for European Paediatric and Congenital Cardiology (AEPC)\nESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.\nESC subspecialty communities having participated in the development of this document:\nAssociations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), and Heart Failure Association (HFA).\nCouncils: Council on Cardiovascular Genomics.\nWorking Groups: Adult Congenital Heart Disease, Pulmonary Circulation and Right Ventricular Function, Thrombosis.\nPatient Forum\nThe content of these European Society of Cardiology (ESC)/European Respiratory Society (ERS) Guidelines has been published for personal and educational use only. No commercial use\nis authorized. No part of the ESC/ERS Guidelines may be translated or reproduced in any form without written permission from the ESC and the ERS. Permission can be obtained upon\nsubmission of a written request to Oxford University Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.\npermissions@oup.com).\nEuropean Heart Journal (2022) 43, 3618–3731\nhttps://doi.org/10.1093/eurheartj/ehac237\nESC/ERS GUIDELINES\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nDocument Reviewers: Markus Schwerzmann (ESC Review Coordinator) (Switzerland), Anh-Tuan Dinh-Xuan\n(ERS Review Coordinator) (France), Andy Bush (United Kingdom), Magdy Abdelhamid (Egypt), Victor Aboyans\n(France), Eloisa Arbustini (Italy), Riccardo Asteggiano (Italy), Joan-Albert Barberà (Spain), Maurice Beghetti\n(Switzerland), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), Robin Condliffe (United Kingdom),\nFrances de Man (Netherlands), Volkmar Falk (Germany), Laurent Fauchier (France), Sean Gaine (Ireland),\nNazzareno Galié (Italy), Wendy Gin-Sing (United Kingdom), John Granton (Canada), Ekkehard Grünig\n(Germany), Paul M. Hassoun (United States of America), Merel Hellemons (Netherlands), Tiny Jaarsma\n(Sweden), Barbro Kjellström (Sweden), Frederikus A. Klok (Netherlands), Aleksandra Konradi (Russian\nFederation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Irene Lang (Austria),\nBasil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip (United Kingdom), Maja-Lisa Løchen\n(Norway), Alexander G. Mathioudakis (United Kingdom), Richard Mindham (United Kingdom),\nShahin Moledina1 (United Kingdom), Robert Naeije (Belgium), Jens Cosedis Nielsen (Denmark),\nHorst Olschewski (Austria), Isabelle Opitz (Switzerland), Steffen E. Petersen (United Kingdom),\nEva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Abilio Reis (Portugal), Arsen D. Ristić (Serbia),\nNicolas Roche (France), Rita Rodrigues (Portugal), Christine Selton-Suty (France), Rogerio Souza (Brazil),\nAndrew J. Swift (United Kingdom), Rhian M. Touyz (Canada/United Kingdom), Silvia Ulrich (Switzerland),\nMartin R. Wilkins (United Kingdom), and Stephen John Wort (United Kingdom)\nAll experts involved in the development of these guidelines have submitted declarations of interest. These have\nbeen compiled in a report and simultaneously published in a supplementary document to the guidelines. The\nreport is also available on the ESC website www.escardio.org/Guidelines\nSee the European Heart Journal online for supplementary data that includes background information and\ndetailed discussion of the data that have provided the basis of the guidelines.\nKeywords\nGuidelines • Pulmonary hypertension • Pulmonary arterial hypertension • Chronic thrombo-embolic pulmonary\nhypertension • Left heart disease • Congenital heart disease • Lung disease • Connective tissue disease • Endothelin\nreceptor antagonists • Phosphodiesterase type 5 inhibitors • Soluble guanylate cyclase stimulators • Prostacyclin\nanalogues • Prostacyclin receptor agonists • Pulmonary endarterectomy • Balloon pulmonary angioplasty • Lung\ntransplantation\nTable of contents\n1. Preamble .............................................................................................................\n3624\n2. Introduction ......................................................................................................\n3625\n2.1. What is new ............................................................................................\n3625\n2.2. Methods ....................................................................................................\n3635\n3. Deﬁnitions and classiﬁcations ....................................................................\n3636\n3.1. Deﬁnitions ................................................................................................\n3636\n3.2. Classiﬁcations ..........................................................................................\n3637\n4. Epidemiology and risk factors ....................................................................\n3638\n4.1. Group 1, pulmonary arterial hypertension ................................\n3638\n4.2. Group 2, pulmonary hypertension associated with left heart\ndisease .................................................................................................................\n3640\n4.3. Group 3, pulmonary hypertension associated with lung\ndiseases and/or hypoxia ..............................................................................\n3640\n4.4. Group 4, pulmonary hypertension associated with chronic\npulmonary artery obstruction ..................................................................\n3640\n4.5. Group 5, pulmonary hypertension with unclear and/or\nmultifactorial mechanisms ..........................................................................\n3640\n5. Pulmonary hypertension diagnosis ..........................................................\n3640\n5.1. Diagnosis ...................................................................................................\n3640\n5.1.1. Clinical presentation ..................................................................... 3640\n5.1.2. Electrocardiogram ......................................................................... 3640\n5.1.3. Chest radiography ......................................................................... 3641\n5.1.4. Pulmonary function tests and arterial blood gases ......... 3641\n5.1.5. Echocardiography .......................................................................... 3642\nDisclaimer: The ESC/ERS Guidelines represent the views of the ESC and the ERS and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence\navailable at the time of their publication. The ESC and the ERS are not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC/ERS Guidelines and any\nother ofﬁcial recommendations or guidelines issued by the relevant public health authorities, particularly in relation to good use of health care or therapeutic strategies. Health profes-\nsionals are encouraged to take the ESC/ERS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and implementation of preventive, diag-\nnostic, or therapeutic medical strategies; however, the ESC/ERS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make\nappropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s care-\ngiver. The ESC/ERS Guidelines do not exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the\ncompetent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is\nalso the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.\nThis article has been co-published with permission in the European Heart Journal and European Respiratory Journal. © the European Society of Cardiology and the European Respiratory\nSociety 2022. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this\narticle. For permissions please e-mail: journals.permissions@oup.com.\nESC/ERS Guidelines\n3619\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n5.1.6. Ventilation/perfusion lung scan ................................................ 3643\n5.1.7. Non-contrast and contrast-enhanced chest computed\ntomography examinations, and digital subtraction\nangiography ................................................................................................... 3644\n5.1.8. Cardiac magnetic resonance imaging .................................... 3645\n5.1.9. Blood tests and immunology .................................................... 3646\n5.1.10. Abdominal ultrasound ............................................................... 3646\n5.1.11. Cardiopulmonary exercise testing ....................................... 3646\n5.1.12. Right heart catheterization, vasoreactivity, exercise, and\nﬂuid challenge .............................................................................................. 3646\n5.1.12.1. Right heart catheterization ............................................. 3646\n5.1.12.2. Vasoreactivity testing ........................................................ 3647\n5.1.12.3. Exercise right heart catheterization ........................... 3647\n5.1.12.4. Fluid challenge ...................................................................... 3647\n5.1.13. Genetic counselling and testing ............................................ 3648\n5.2. Diagnostic algorithm ............................................................................\n3648\n5.2.1 Step 1 (suspicion) ........................................................................... 3648\n5.2.2. Step 2 (detection) ......................................................................... 3648\n5.2.3. Step 3 (conﬁrmation) ................................................................... 3650\n5.3. Screening and early detection ..........................................................\n3652\n5.3.1. Systemic sclerosis .......................................................................... 3653\n5.3.2. BMPR2 mutation carriers ........................................................... 3653\n5.3.3. Portal hypertension ...................................................................... 3653\n5.3.4. Pulmonary embolism ................................................................... 3653\n6. Pulmonary arterial hypertension (group 1) .........................................\n3655\n6.1. Clinical characteristics .........................................................................\n3655\n6.2. Severity and risk assessment ............................................................\n3655\n6.2.1. Clinical parameters ....................................................................... 3655\n6.2.2. Imaging ................................................................................................ 3656\n6.2.2.1. Echocardiography .................................................................. 3656\n6.2.2.2. Cardiac magnetic resonance imaging ........................... 3656\n6.2.3. Haemodynamics ............................................................................. 3656\n6.2.4. Exercise capacity ............................................................................ 3657\n6.2.5. Biochemical markers .................................................................... 3658\n6.2.6. Patient-reported outcome measures ................................... 3658\n6.2.7. Comprehensive prognostic evaluation, risk assessment,\nand treatment goals .................................................................................. 3659\n6.3. Therapy .....................................................................................................\n3660\n6.3.1. General measures .......................................................................... 3660\n6.3.1.1. Physical activity and supervised rehabilitation .......... 3660\n6.3.1.2. Anticoagulation ...................................................................... 3660\n6.3.1.3. Diuretics .................................................................................... 3661\n6.3.1.4. Oxygen ...................................................................................... 3661\n6.3.1.5. Cardiovascular drugs ........................................................... 3661\n6.3.1.6. Anaemia and iron status .................................................... 3661\n6.3.1.7. Vaccination ............................................................................... 3661\n6.3.1.8. Psychosocial support ........................................................... 3661\n6.3.1.9. Adherence to treatments .................................................. 3661\n6.3.2. Special circumstances ................................................................... 3662\n6.3.2.1. Pregnancy and birth control ............................................. 3662\n6.3.2.1.1. Pregnancy ......................................................................... 3662\n6.3.2.1.2. Contraception ................................................................ 3662\n6.3.2.2. Surgical procedures .............................................................. 3662\n6.3.2.3. Travel and altitude ................................................................ 3662\n6.3.3. Pulmonary arterial hypertension therapies ........................ 3663\n6.3.3.1. Calcium channel blockers .................................................. 3663\n6.3.3.2. Endothelin receptor antagonists .................................... 3664\n6.3.3.2.1. Ambrisentan ................................................................... 3665\n6.3.3.2.2. Bosentan ........................................................................... 3665\n6.3.3.2.3. Macitentan ....................................................................... 3666\n6.3.3.3. Phosphodiesterase 5 inhibitors and guanylate cyclase\nstimulators ............................................................................................... 3666\n6.3.3.3.1. Sildenaﬁl ............................................................................ 3667\n6.3.3.3.2. Tadalaﬁl ............................................................................. 3667\n6.3.3.3.3. Riociguat ........................................................................... 3667\n6.3.3.4. Prostacyclin analogues and prostacyclin receptor\nagonists ...................................................................................................... 3667\n6.3.3.4.1. Epoprostenol .................................................................. 3667\n6.3.3.4.2. Iloprost .............................................................................. 3667\n6.3.3.4.3. Treprostinil ...................................................................... 3667\n6.3.3.4.4. Beraprost ......................................................................... 3667\n6.3.3.4.5. Selexipag ........................................................................... 3667\n6.3.4. Treatment strategies for patients with idiopathic,\nheritable, drug-associated, or connective tissue disease-\nassociated pulmonary arterial hypertension .................................. 3667\n6.3.4.1. Initial treatment decision in patients without\ncardiopulmonary comorbidities ...................................................... 3668\n6.3.4.2. Treatment decisions during follow-up in patients\nwithout cardiopulmonary comorbidities .................................... 3669\n6.3.4.3. Pulmonary arterial hypertension with\ncardiopulmonary comorbidities ...................................................... 3670\n6.3.5. Drug interactions ........................................................................... 3671\n6.3.6. Interventional therapy ................................................................. 3671\n6.3.6.1. Balloon atrial septostomy and Potts shunt ................ 3671\n6.3.6.2. Pulmonary artery denervation ........................................ 3671\n6.3.7. Advanced right ventricular failure .......................................... 3672\n6.3.7.1. Intensive care unit management ..................................... 3672\n6.3.7.2. Mechanical circulatory support ....................................... 3672\n6.3.8. Lung and heart–lung transplantation ..................................... 3672\n6.3.9. Evidence-based treatment algorithm .................................... 3673\n6.3.10. Diagnosis and treatment of pulmonary arterial\nhypertension complications ................................................................... 3673\n6.3.10.1. Arrhythmias .......................................................................... 3673\n6.3.10.2. Haemoptysis ......................................................................... 3673\n6.3.10.3. Mechanical complications ................................................ 3673\n6.3.11. End-of-life care and ethical issues ........................................ 3674\n6.3.12. New drugs in advanced clinical development (phase 3\nstudies) ........................................................................................................... 3674\n7. Speciﬁc pulmonary arterial hypertension subsets ............................\n3674\n7.1. Pulmonary arterial hypertension associated with drugs and\ntoxins ...................................................................................................................\n3674\n7.2. Pulmonary arterial hypertension associated with connective\ntissue disease ....................................................................................................\n3675\n7.2.1. Epidemiology and diagnosis ....................................................... 3675\n7.2.2. Therapy .............................................................................................. 3675\n7.3. Pulmonary arterial hypertension associated with human\nimmunodeﬁciency virus infection ............................................................\n3676\n7.3.1. Diagnosis ........................................................................................... 3676\n7.3.2. Therapy .............................................................................................. 3676\n7.4. Pulmonary arterial hypertension associated with portal\nhypertension ....................................................................................................\n3677\n7.4.1. Diagnosis ........................................................................................... 3677\n7.4.2. Therapy .............................................................................................. 3677\n7.4.2.1. Liver transplantation ............................................................ 3677\n7.5. Pulmonary arterial hypertension associated with adult\ncongenital heart disease ..............................................................................\n3678\n7.5.1. Diagnosis and risk assessment ................................................. 3678\n7.5.2. Therapy .............................................................................................. 3679\n7.6. Pulmonary arterial hypertension associated with\nschistosomiasis ................................................................................................\n3680\n3620\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n7.7. Pulmonary arterial hypertension with signs of venous/\ncapillary involvement ....................................................................................\n3680\n7.7.1. Diagnosis ........................................................................................... 3681\n7.7.2. Therapy .............................................................................................. 3681\n7.8. Paediatric pulmonary hypertension ...............................................\n3681\n7.8.1. Epidemiology and classiﬁcation ................................................ 3681\n7.8.2. Diagnosis and risk assessment ................................................. 3683\n7.8.3. Therapy .............................................................................................. 3683\n8. Pulmonary hypertension associated with left heart disease\n(group 2) ..................................................................................................................\n3685\n8.1. Deﬁnition, prognosis, and pathophysiology ...............................\n3685\n8.2. Diagnosis ...................................................................................................\n3687\n8.2.1. Diagnosis and control of the underlying left\nheart disease ................................................................................................ 3687\n8.2.2. Evaluation of pulmonary hypertension and patient\nphenotyping .................................................................................................. 3687\n8.2.3. Invasive assessment of haemodynamics ............................... 3687\n8.3. Therapy .....................................................................................................\n3688\n8.3.1. Pulmonary hypertension associated with left-sided heart\nfailure ............................................................................................................... 3688\n8.3.1.1. Heart failure with reduced ejection fraction ............. 3688\n8.3.1.2. Heart failure with preserved ejection fraction ......... 3688\n8.3.1.3. Interatrial shunt devices ..................................................... 3689\n8.3.1.4. Remote pulmonary arterial pressure monitoring in\nheart failure ............................................................................................. 3689\n8.3.2. Pulmonary hypertension associated with valvular heart\ndisease ............................................................................................................. 3689\n8.3.2.1. Mitral valve disease ............................................................... 3689\n8.3.2.2. Aortic stenosis ....................................................................... 3689\n8.3.2.3. Tricuspid regurgitation ........................................................ 3689\n8.3.3. Recommendations on the use of drugs approved for\nPAH in PH-LHD ......................................................................................... 3689\n9. Pulmonary hypertension associated with lung diseases and/or\nhypoxia (group 3) ................................................................................................\n3690\n9.1. Diagnosis ...................................................................................................\n3692\n9.2. Therapy .....................................................................................................\n3692\n9.2.1. Pulmonary hypertension associated with chronic\nobstructive pulmonary disease or emphysema ............................ 3692\n9.2.2. Pulmonary hypertension associated with interstitial lung\ndisease ............................................................................................................. 3692\n9.2.3. Recommendations on the use of drugs approved for\nPAH in PH associated with lung disease .......................................... 3693\n10. Chronic thrombo-embolic pulmonary hypertension (group 4)\n3693\n10.1. Diagnosis ................................................................................................\n3694\n10.2. Therapy ...................................................................................................\n3695\n10.2.1. Surgical treatment ....................................................................... 3695\n10.2.2. Medical therapy ............................................................................ 3695\n10.2.3. Interventional treatment .......................................................... 3696\n10.2.4. Multimodal treatment ............................................................... 3697\n10.2.5. Follow-up ........................................................................................ 3698\n10.3. Chronic thrombo-embolic pulmonary hypertension team\nand experience criteria ................................................................................\n3698\n11. Pulmonary hypertension with unclear and/or multifactorial\nmechanisms (group 5) .......................................................................................\n3699\n11.1. Haematological disorders ................................................................\n3699\n11.2. Systemic disorders .............................................................................\n3700\n11.3. Metabolic disorders ...........................................................................\n3700\n11.4. Chronic kidney failure ......................................................................\n3700\n11.5. Pulmonary tumour thrombotic microangiopathy ................\n3700\n11.6. Fibrosing mediastinitis .......................................................................\n3700\n12. Deﬁnition of a pulmonary hypertension centre .............................\n3701\n12.1. Facilities and skills required for a pulmonary hypertension\ncentre ..................................................................................................................\n3702\n12.2. European Reference Network .....................................................\n3702\n12.3. Patient associations and patient empowerment ...................\n3702\n13. Key messages .................................................................................................\n3703\n14. Gaps in evidence ...........................................................................................\n3703\n14.1. Pulmonary arterial hypertension (group 1) .............................\n3703\n14.2. Pulmonary hypertension associated with left heart disease\n(group 2) ............................................................................................................\n3703\n14.3. Pulmonary hypertension associated with lung diseases and/\nor hypoxia (group 3) ....................................................................................\n3704\n14.4. Chronic thrombo-embolic pulmonary hypertension\n(group 4) ............................................................................................................\n3704\n14.5. Pulmonary hypertension with unclear and/or multifactorial\nmechanisms (group 5) .................................................................................\n3704\n15. ‘What to do’ and ‘What not to do’ messages from\nthe Guidelines .......................................................................................................\n3704\n16. Quality indicators .........................................................................................\n3710\n17. Supplementary data .....................................................................................\n3711\n18. Data availability statement .......................................................................\n3711\n19. Author information .....................................................................................\n3711\n20. Appendix ..........................................................................................................\n3711\n21. References .......................................................................................................\n3712\nTables of Recommendations\nRecommendation Table 1 — Recommendations for right heart\ncatheterization and vasoreactivity testing ............................................\n3648\nRecommendation Table 2 — Recommendations for diagnostic\nstrategy ................................................................................................................\n3652\nRecommendation Table 3 — Recommendations for screening\nand improved detection of pulmonary arterial hypertension and\nchronic thrombo-embolic pulmonary hypertension .......................\n3654\nRecommendation Table 4 — Recommendations for evaluating\nthe disease severity and risk of death in patients with pulmonary\narterial hypertension .....................................................................................\n3660\nRecommendation Table 5 — Recommendations for general\nmeasures and special circumstances .......................................................\n3662\nRecommendation Table 6 — Recommendations for women of\nchildbearing potential ....................................................................................\n3663\nRecommendation Table 7 — Recommendations for the\ntreatment of vasoreactive patients with idiopathic, heritable, or\ndrug-associated pulmonary arterial hypertension ............................\n3664\nRecommendation Table 8 — Recommendations for the treatment\nof non-vasoreactive patients with idiopathic, heritable, or\ndrug-associated pulmonary arterial hypertension who present\nwithout cardiopulmonary comorbiditiesa ...................................................\n3668\nRecommendation Table 9 — Recommendations for initial oral\ndrug combination therapy for patients with idiopathic, heritable,\nor drug-associated pulmonary arterial hypertension without\ncardiopulmonary comorbidities ................................................................\n3669\nRecommendation Table 10 — Recommendations for sequential\ndrug combination therapy for patients with idiopathic, heritable,\nor drug-associated pulmonary arterial hypertension ......................\n3670\nRecommendation Table 11 — Recommendations for the\ntreatment of non-vasoreactive patients with idiopathic, heritable,\nor drug-associated pulmonary arterial hypertension who present\nwith cardiopulmonary comorbiditiesa ....................................................\n3671\nESC/ERS Guidelines\n3621\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nRecommendation Table 12 — Recommendations for intensive\ncare management for pulmonary arterial hypertension ..................... 3672\nRecommendation Table 13 — Recommendations for lung\ntransplantation .................................................................................................\n3673\nRecommendation Table 14 — Recommendations for pulmonary\narterial hypertension associated with drugs or toxins ...................\n3674\nRecommendation Table 15 — Recommendations for pulmonary\narterial hypertension associated with connective tissue disease\n3675\nRecommendation Table 16 — Recommendations for pulmonary\narterial hypertension associated with human immunodeﬁciency\nvirus infection ...................................................................................................\n3676\nRecommendation Table 17 — Recommendations for pulmonary\narterial hypertension associated with portal hypertension ..........\n3677\nRecommendation Table 18 — Recommendations for shunt\nclosure in patients with pulmonary–systemic ﬂow ratio .1.5:1\nbased on calculated pulmonary vascular resistance .........................\n3680\nRecommendation Table 19 — Recommendations for pulmonary\narterial hypertension associated with adult congenital heart disease\n3680\nRecommendation Table 20 — Recommendations for pulmonary\narterial hypertension with signs of venous/capillary involvement\n3681\nRecommendation Table 21 — Recommendations for paediatric\npulmonary hypertension ..............................................................................\n3685\nRecommendation Table 22 — Recommendations for pulmonary\nhypertension associated with left heart disease ................................\n3690\nRecommendation Table 23 — Recommendations for pulmonary\nhypertension associated with lung disease and/or hypoxia ..........\n3693\nRecommendation Table 24 — Recommendations for chronic\nthrombo-embolic pulmonary hypertension and chronic thrombo-\nembolic pulmonary disease without pulmonary hypertension ........\n3698\nRecommendation Table 25 — Recommendations for pulmonary\nhypertension centres .....................................................................................\n3702\nList of tables\nTable 1 Strength of the recommendations according to GRADE\n3635\nTable 2 Quality of evidence grades and their deﬁnitions ..............\n3635\nTable 3 Classes of recommendations ....................................................\n3636\nTable 4 Levels of evidence ..........................................................................\n3636\nTable 5 Haemodynamic deﬁnitions of pulmonary hypertension\n3637\nTable 6 Clinical classiﬁcation of pulmonary hypertension ............\n3638\nTable 7 Drugs and toxins associated with pulmonary arterial\nhypertension .....................................................................................................\n3640\nTable 8 Electrocardiogram abnormalities in patients with\npulmonary hypertension ..............................................................................\n3643\nTable 9 Radiographic signs of pulmonary hypertension and\nconcomitant abnormalities .........................................................................\n3643\nTable 10 Additional echocardiographic signs suggestive of\npulmonary hypertension ..............................................................................\n3645\nTable 11 Haemodynamic measures obtained during right heart\ncatheterization ..................................................................................................\n3646\nTable 12 Route of administration, half-life, dosages, and duration\nof administration of the recommended test compounds for\nvasoreactivity testing in pulmonary arterial hypertension .............\n3647\nTable 13 Phenotypic features associated with pulmonary arterial\nhypertension mutations ...............................................................................\n3649\nTable 14 Characteristic diagnostic features of patients with\ndifferent forms of pulmonary hypertension ........................................\n3651\nTable 15 World Health Organization classiﬁcation of functional\nstatus of patients with pulmonary hypertension ...............................\n3656\nTable 16 Comprehensive risk assessment in pulmonary arterial\nhypertension (three-strata model) ..........................................................\n3657\nTable 17 Suggested assessment and timing for the follow-up of\npatients with pulmonary arterial hypertension ..................................\n3658\nTable 18 Variables used to calculate the simpliﬁed four-strata\nrisk-assessment tool .......................................................................................\n3659\nTable 19 Dosing of pulmonary arterial hypertension medication\nin adults ...............................................................................................................\n3664\nTable 20 Criteria for lung transplantation and listing in patients\nwith pulmonary arterial hypertension ...................................................\n3672\nTable 21 Clinical classiﬁcation of pulmonary arterial hypertension\nassociated with congenital heart disease ..............................................\n3678\nTable 22 Use of pulmonary arterial hypertension therapies in\nchildren ................................................................................................................\n3684\nTable 23 Patient phenotyping and likelihood for left heart disease\nas cause of pulmonary hypertension ......................................................\n3688\nTable 24 Pulmonary hypertension with unclear and/or\nmultifactorial mechanisms ...........................................................................\n3699\nList of ﬁgures\nFigure 1 Central illustration ........................................................................\n3639\nFigure 2 Symptoms in patients with pulmonary hypertension ...\n3641\nFigure 3 Clinical signs in patients with pulmonary hypertension\n3642\nFigure 4 Transthoracic echocardiographic parameters in the\nassessment of pulmonary hypertension ................................................\n3644\nFigure 5 Echocardiographic probability of pulmonary\nhypertension and recommendations for further assessment ......\n3645\nFigure 6 Diagnostic algorithm of patients with unexplained\ndyspnoea and/or suspected pulmonary hypertension ....................\n3650\nFigure 7 Pathophysiology and current therapeutic targets of\npulmonary arterial hypertension (group 1) .........................................\n3655\nFigure 8 Vasoreactivity testing algorithm of patients with\npresumed diagnosis of idiopathic, heritable, or drug-associated\npulmonary arterial hypertension ..............................................................\n3665\nFigure 9 Evidence-based pulmonary arterial hypertension\ntreatment algorithm for patients with idiopathic, heritable,\ndrug-associated, and connective tissue disease-associated\npulmonary arterial hypertension ..............................................................\n3666\nFigure 10 Neonatal and paediatric vs. adult pulmonary\nhypertension .....................................................................................................\n3682\nFigure 11 Pathophysiology of pulmonary hypertension associated\nwith left heart disease (group 2) ..............................................................\n3686\nFigure 12 Pathophysiology of pulmonary hypertension associated\nwith lung disease (group 3) ........................................................................\n3691\nFigure 13 Diagnostic strategy in chronic thrombo-embolic\npulmonary hypertension ..............................................................................\n3694\nFigure 14 Management strategy in chronic thrombo-embolic\npulmonary hypertension ..............................................................................\n3696\nFigure 15 Overlap in treatments/multimodality approaches in\nchronic thrombo-embolic pulmonary hypertension .......................\n3697\nFigure 16 Pulmonary hypertension centre schematic .....................\n3701\nAbbreviations and acronyms\n6MWD\n6-minute walking distance\n6MWT\n6-minute walking test\nABG\nArterial blood gas analysis\nACEi\nAngiotensin-converting enzyme inhibitor\n3622\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "aortic stenosis",
        "angiography",
        "heart failure",
        "recommended",
        "pulmonary hypertension",
        "physical activity",
        "diagnosis",
        "guidelines",
        "anticoagulation",
        "hypertension",
        "echocardiography",
        "treatment",
        "electrocardiogram",
        "aortic",
        "tricuspid",
        "catheterization",
        "genetic",
        "calcium channel",
        "ejection fraction",
        "pulmonary embolism",
        "pulmonary",
        "stenosis",
        "exercise"
      ],
      "tables": [
        {
          "title": "ESC/ERS Guidelines 3619",
          "page_number": 1,
          "content": " |  | m/eurheartj/article/43/38\n | Keywords Guidelines • Pulmonary hypertension • Pulmonary arterial hypertension • Chronic thrombo-embolic pulmonary\nhypertension • Left heart disease • Congenital heart disease • Lung disease • Connective tissue disease • Endothelin\nreceptor antagonists • Phosphodiesterase type 5 inhibitors • Soluble guanylate cyclase stimulators • Prostacyclin\nanalogues • Prostacyclin receptor agonists • Pulmonary endarterectomy • Balloon pulmonary angioplasty • Lung\ntransplantation | \n |  | ",
          "bbox": [
            0.0,
            350.6339477539062,
            595.260009765625,
            433.9639892578125
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "Abbreviations and acronyms",
      "start_page": 4,
      "end_page": 8,
      "content": "Recommendation Table 12 — Recommendations for intensive\ncare management for pulmonary arterial hypertension ..................... 3672\nRecommendation Table 13 — Recommendations for lung\ntransplantation .................................................................................................\n3673\nRecommendation Table 14 — Recommendations for pulmonary\narterial hypertension associated with drugs or toxins ...................\n3674\nRecommendation Table 15 — Recommendations for pulmonary\narterial hypertension associated with connective tissue disease\n3675\nRecommendation Table 16 — Recommendations for pulmonary\narterial hypertension associated with human immunodeﬁciency\nvirus infection ...................................................................................................\n3676\nRecommendation Table 17 — Recommendations for pulmonary\narterial hypertension associated with portal hypertension ..........\n3677\nRecommendation Table 18 — Recommendations for shunt\nclosure in patients with pulmonary–systemic ﬂow ratio .1.5:1\nbased on calculated pulmonary vascular resistance .........................\n3680\nRecommendation Table 19 — Recommendations for pulmonary\narterial hypertension associated with adult congenital heart disease\n3680\nRecommendation Table 20 — Recommendations for pulmonary\narterial hypertension with signs of venous/capillary involvement\n3681\nRecommendation Table 21 — Recommendations for paediatric\npulmonary hypertension ..............................................................................\n3685\nRecommendation Table 22 — Recommendations for pulmonary\nhypertension associated with left heart disease ................................\n3690\nRecommendation Table 23 — Recommendations for pulmonary\nhypertension associated with lung disease and/or hypoxia ..........\n3693\nRecommendation Table 24 — Recommendations for chronic\nthrombo-embolic pulmonary hypertension and chronic thrombo-\nembolic pulmonary disease without pulmonary hypertension ........\n3698\nRecommendation Table 25 — Recommendations for pulmonary\nhypertension centres .....................................................................................\n3702\nList of tables\nTable 1 Strength of the recommendations according to GRADE\n3635\nTable 2 Quality of evidence grades and their deﬁnitions ..............\n3635\nTable 3 Classes of recommendations ....................................................\n3636\nTable 4 Levels of evidence ..........................................................................\n3636\nTable 5 Haemodynamic deﬁnitions of pulmonary hypertension\n3637\nTable 6 Clinical classiﬁcation of pulmonary hypertension ............\n3638\nTable 7 Drugs and toxins associated with pulmonary arterial\nhypertension .....................................................................................................\n3640\nTable 8 Electrocardiogram abnormalities in patients with\npulmonary hypertension ..............................................................................\n3643\nTable 9 Radiographic signs of pulmonary hypertension and\nconcomitant abnormalities .........................................................................\n3643\nTable 10 Additional echocardiographic signs suggestive of\npulmonary hypertension ..............................................................................\n3645\nTable 11 Haemodynamic measures obtained during right heart\ncatheterization ..................................................................................................\n3646\nTable 12 Route of administration, half-life, dosages, and duration\nof administration of the recommended test compounds for\nvasoreactivity testing in pulmonary arterial hypertension .............\n3647\nTable 13 Phenotypic features associated with pulmonary arterial\nhypertension mutations ...............................................................................\n3649\nTable 14 Characteristic diagnostic features of patients with\ndifferent forms of pulmonary hypertension ........................................\n3651\nTable 15 World Health Organization classiﬁcation of functional\nstatus of patients with pulmonary hypertension ...............................\n3656\nTable 16 Comprehensive risk assessment in pulmonary arterial\nhypertension (three-strata model) ..........................................................\n3657\nTable 17 Suggested assessment and timing for the follow-up of\npatients with pulmonary arterial hypertension ..................................\n3658\nTable 18 Variables used to calculate the simpliﬁed four-strata\nrisk-assessment tool .......................................................................................\n3659\nTable 19 Dosing of pulmonary arterial hypertension medication\nin adults ...............................................................................................................\n3664\nTable 20 Criteria for lung transplantation and listing in patients\nwith pulmonary arterial hypertension ...................................................\n3672\nTable 21 Clinical classiﬁcation of pulmonary arterial hypertension\nassociated with congenital heart disease ..............................................\n3678\nTable 22 Use of pulmonary arterial hypertension therapies in\nchildren ................................................................................................................\n3684\nTable 23 Patient phenotyping and likelihood for left heart disease\nas cause of pulmonary hypertension ......................................................\n3688\nTable 24 Pulmonary hypertension with unclear and/or\nmultifactorial mechanisms ...........................................................................\n3699\nList of ﬁgures\nFigure 1 Central illustration ........................................................................\n3639\nFigure 2 Symptoms in patients with pulmonary hypertension ...\n3641\nFigure 3 Clinical signs in patients with pulmonary hypertension\n3642\nFigure 4 Transthoracic echocardiographic parameters in the\nassessment of pulmonary hypertension ................................................\n3644\nFigure 5 Echocardiographic probability of pulmonary\nhypertension and recommendations for further assessment ......\n3645\nFigure 6 Diagnostic algorithm of patients with unexplained\ndyspnoea and/or suspected pulmonary hypertension ....................\n3650\nFigure 7 Pathophysiology and current therapeutic targets of\npulmonary arterial hypertension (group 1) .........................................\n3655\nFigure 8 Vasoreactivity testing algorithm of patients with\npresumed diagnosis of idiopathic, heritable, or drug-associated\npulmonary arterial hypertension ..............................................................\n3665\nFigure 9 Evidence-based pulmonary arterial hypertension\ntreatment algorithm for patients with idiopathic, heritable,\ndrug-associated, and connective tissue disease-associated\npulmonary arterial hypertension ..............................................................\n3666\nFigure 10 Neonatal and paediatric vs. adult pulmonary\nhypertension .....................................................................................................\n3682\nFigure 11 Pathophysiology of pulmonary hypertension associated\nwith left heart disease (group 2) ..............................................................\n3686\nFigure 12 Pathophysiology of pulmonary hypertension associated\nwith lung disease (group 3) ........................................................................\n3691\nFigure 13 Diagnostic strategy in chronic thrombo-embolic\npulmonary hypertension ..............................................................................\n3694\nFigure 14 Management strategy in chronic thrombo-embolic\npulmonary hypertension ..............................................................................\n3696\nFigure 15 Overlap in treatments/multimodality approaches in\nchronic thrombo-embolic pulmonary hypertension .......................\n3697\nFigure 16 Pulmonary hypertension centre schematic .....................\n3701\nAbbreviations and acronyms\n6MWD\n6-minute walking distance\n6MWT\n6-minute walking test\nABG\nArterial blood gas analysis\nACEi\nAngiotensin-converting enzyme inhibitor\n3622\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nALAT\nAlanine aminotransferase\nARB\nAngiotensin receptor blocker\nARNI\nAngiotensin receptor–neprilysin inhibitor\nASAT\nAspartate aminotransferase\nASIG\nAustralian Scleroderma Interest Group\nBNP\nBrain natriuretic peptide\nBPA\nBalloon pulmonary angioplasty\nBPD\nBronchopulmonary dysplasia\nCAMPHOR\nCambridge Pulmonary Hypertension Outcome\nReview\nCCB\nCalcium channel blocker\nCDH\nCongenital diaphragmatic hernia\ncGMP\nCyclic guanosine monophosphate\nCHD\nCongenital heart disease\nCI\nCardiac index; Conﬁdence interval\ncMRI\nCardiac magnetic resonance imaging\nCO\nCardiac output\nCOMPERA\nComparative, Prospective Registry of Newly\nInitiated Therapies for PH\nCOPD\nChronic obstructive pulmonary disease\nCpcPH\nCombined post- and pre-capillary pulmonary\nhypertension\nCPET\nCardiopulmonary exercise testing\nCPFE\nCombined pulmonary ﬁbrosis and emphysema\nCT\nComputed tomography\nCTD\nConnective tissue disease\nCTEPD\nChronic thrombo-embolic pulmonary disease\nCTEPH\nChronic thrombo-embolic pulmonary\nhypertension\nCTPA\nComputed tomography pulmonary angiography\nDECT\nDual-energy computed tomography\nDLCO\nLung diffusion capacity for carbon monoxide\nDPAH\nDrug- or toxin-associated pulmonary arterial\nhypertension\ndPAP\nDiastolic pulmonary arterial pressure\nDPG\nDiastolic pressure gradient\nDSA\nDigital subtraction angiography\nECG\nElectrocardiogram\nECMO\nExtracorporeal membrane oxygenation\nEHJ\nEuropean Heart Journal\nEMA\nEuropean Medicines Agency\nEOV\nExercise oscillatory ventilation\nERA\nEndothelin receptor antagonist\nERJ\nEuropean Respiratory Journal\nERN\nEuropean Reference Network\nERN-LUNG\nEuropean Reference Network on rare\nrespiratory diseases\nERS\nEuropean Respiratory Society\nESC\nEuropean Society of Cardiology\nEtD\nEvidence to Decision\nFPHR\nFrench Pulmonary Hypertension Registry\nFVC\nForced vital capacity\nGRADE\nGrading of Recommendations, Assessment,\nDevelopment, and Evaluations\nHAART\nHighly active antiretroviral therapy\nHb\nHaemoglobin\nHF\nHeart failure\nHFpEF\nHeart failure with preserved ejection fraction\nHIV\nHuman immunodeﬁciency virus\nHPAH\nHeritable pulmonary arterial hypertension\nHPS\nHepatopulmonary syndrome\nHR\nHazard ratio\nHR-QoL\nHealth-related quality of life\nICU\nIntensive care unit\nIgG4\nImmunogolobulin G4\nILD\nInterstitial lung disease\nIPAH\nIdiopathic pulmonary arterial hypertension\nIpcPH\nIsolated post-capillary pulmonary hypertension\nIP receptor\nProstacyclin I2 receptor\nISWT\nIncremental shuttle walking test\ni.v.\nIntravenous\nLA\nLeft atrium/left atrial\nLAS\nLung allocation score\nLHD\nLeft heart disease\nLTx\nLung transplantation\nLV\nLeft ventricle/left ventricular\nLVAD\nLeft ventricular assist device\nmPAP\nMean pulmonary arterial pressure\nMR\nMagnetic resonance\nMRI\nMagnetic resonance imaging\nNOAC\nNovel oral anticoagulant\nNT-proBNP\nN-terminal pro-brain natriuretic peptide\nOR\nOdds ratio\nPA\nPulmonary artery\nPAC\nPulmonary arterial compliance\nPaCO2\nPartial pressure of arterial carbon dioxide\nPADN\nPulmonary artery denervation\nPAH\nPulmonary arterial hypertension\nPAH-CTD\nPulmonary arterial hypertension associated with\nconnective tissue disease\nPAH-SSc\nPulmonary arterial hypertension associated with\nsystemic sclerosis\nPAH-SYMPACT\nPulmonary Arterial Hypertension-Symptoms\nand Impact\nPaO2\nPartial pressure of arterial oxygen\nPAP\nPulmonary arterial pressure\nPAVM\nPulmonary arteriovenous malformation\nPAWP\nPulmonary arterial wedge pressure\nPCH\nPulmonary capillary haemangiomatosis\nPDE5i\nPhosphodiesterase 5 inhibitor\nPE\nPulmonary embolism\nPEA\nPulmonary endarterectomy\nPET\nPositron emission tomography\nPETCO2\nEnd-tidal partial pressure of carbon dioxide\nPFT\nPulmonary function test\nPH\nPulmonary hypertension\nPH-LHD\nPulmonary hypertension associated with left\nheart disease\nPICO\nPopulation, Intervention, Comparator, Outcome\nPoPH\nPorto-pulmonary hypertension\nPPHN\nPersistent pulmonary hypertension of the\nnewborn\nPROM\nPatient-reported outcome measure\nPVD\nPulmonary vascular disease\nESC/ERS Guidelines\n3623\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nPVOD\nPulmonary veno-occlusive disease\nPVR\nPulmonary vascular resistance\nPVRI\nPulmonary vascular resistance index\nQI\nQuality indicator\nQp/Qs\nPulmonary blood ﬂow/systemic blood ﬂow\nRA\nRight atrium/right atrial\nRAP\nRight atrial pressure\nRCT\nRandomized controlled trial\nREVEAL\nRegistry to Evaluate Early and Long-Term PAH\nDisease Management\nRHC\nRight heart catheterization\nRR\nRelative risk\nRV\nRight ventricle/right ventricular\nRVEF\nRight ventricular ejection fraction\nRV-FAC\nRight ventricular fractional area change\nRVOT AT\nRight ventricular outﬂow tract acceleration time\nSaO2\nArterial oxygen saturation\ns.c.\nSubcutaneous\nSCD\nSickle cell disease\nsGC\nSoluble guanylate cyclase\nSGLT-2i\nSodium–glucose cotransporter-2 inhibitor\nSLE\nSystemic lupus erythematosus\nSPAHR\nSwedish Pulmonary Arterial Hypertension Registry\nsPAP\nSystolic pulmonary arterial pressure\nSPECT\nSingle-photon emission computed tomography\nSSc\nSystemic sclerosis\nSV\nStroke volume\nSVI\nStroke volume index\nSvO2\nMixed venous oxygen saturation\nTAPSE\nTricuspid annular plane systolic excursion\nTGF-β\nTransforming growth factor-β\nTPR\nTotal pulmonary resistance\nTR\nTricuspid regurgitation\nTRPG\nTricuspid regurgitation pressure gradient\nTRV\nTricuspid regurgitation velocity\nTSH\nThyroid-stimulating hormone\nV/Q\nVentilation perfusion\nVE/VCO2\nVentilatory equivalent for carbon dioxide\nVKA\nVitamin K antagonist\nVO2\nOxygen uptake\nVO2/HR\nOxygen pulse\nVTE\nVenous thrombo-embolism\nWHO-FC\nWorld Health Organization functional class\nWSPH\nWorld Symposium on Pulmonary Hypertension\nWU\nWood units\n1. Preamble\nGuidelines summarize and evaluate available evidence, with the aim of\nassisting health professionals in proposing the best management strat-\negies for an individual patient with a given condition. Guidelines and\ntheir recommendations should facilitate decision-making of health\nprofessionals in their daily practice. However, guidelines are not a\nsubstitute for the patient’s relationship with their practitioner. The ﬁ-\nnal decisions concerning an individual patient must be made by the re-\nsponsible health professional(s), based on what they consider to be\nthe most appropriate in the circumstances. These decisions are\nmade in consultation with the patient and caregiver as appropriate.\nGuidelines are intended for use by health professionals. To ensure that\nall physicians have access to the most recent recommendations, both the\nEuropean Society of Cardiology (ESC) and European Respiratory Society\n(ERS) make their guidelines freely available in their own journals. The ESC\nand ERS warn non-medical readers that the technical language may be\nmisinterpreted and decline any responsibility in this respect.\nMany Guidelines have been issued in recent years by the ESC and\nERS. Because of their impact on clinical practice, quality criteria for\nthe development of guidelines have been established in order to\nmake all decisions transparent to the user. The ERS and ESC guid-\nance and procedure to formulate and issue clinical practice recom-\nmendations can be found on the societies’ relevant website or\njournal (https://www.escardio.org/Guidelines and https://openres.\nersjournals.com/content/8/1/00655-2021).\nThe\nESC\nand\nERS\nGuidelines represent the ofﬁcial position of the ESC and ERS on a gi-\nven topic and are regularly updated.\nThe panel of experts of these speciﬁc guidelines comprised an\nequal number of ERS and ESC members, including representatives\nfrom relevant subspecialty groups involved in the medical care of pa-\ntients with this pathology.\nThe experts of the writing and reviewing panels provided declar-\nation of interest forms for all relationships that might be perceived\nas real or potential sources of conﬂicts of interest. Their declarations\nof interest were reviewed according to the ESC declaration of interest\nrules and can be found on the ESC website (http://www.escardio.org/\nGuidelines). They have been compiled in a report and co-published in a\nsupplementary document of the guidelines. This process ensures\ntransparency and prevents potential biases in the development and re-\nview processes. Any changes in declarations of interest that arose dur-\ning the writing period were notiﬁed to the ESC and updated. The Task\nForce received its entire ﬁnancial support from the ESC and ERS with-\nout any involvement from the health care industry.\nThe ESC Clinical Practice Guidelines (CPG) Committee and the ERS\nGuidelines Director reporting to the ERS Science Council supervise\nand co-ordinate the preparation of new guidelines. These Guidelines\nunderwent extensive review by the ESC CPG Committee, the ERS\nGuidelines Working Group, and external experts. The guidelines\nwere developed after careful consideration of the scientiﬁc and medical\nknowledge and the evidence available at the time of drafting. After ap-\npropriate revisions, the guidelines were signed off by all the experts in\nthe Task Force. The ﬁnalized document was signed off by the ESC CPG\nCommittee and endorsed by the ERS Executive Committee before\nbeing simultaneously published in the European Heart Journal (EHJ)\nand the European Respiratory Journal (ERJ). The decision to publish the\nguidelines in both journals was made to ensure adequate dissemination\nof the recommendations in both the cardiology and respiratory ﬁelds.\nThe task of developing the ESC/ERS Guidelines also included creat-\ning educational tools and implementation programmes for the recom-\nmendations, including condensed pocket guidelines versions, summary\nslides, a lay summary, and an electronic version for digital applications\n(smartphones, etc.). These versions are abridged and thus, for more\ndetailed information, the user should always access the full-text version\nof the guidelines, which is freely available via the ESC and ERS websites,\nand hosted on the EHJ and ERJ websites. The National Cardiac\nSocieties of the ESC are encouraged to endorse, adopt, translate,\n3624\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nand implement all ESC Guidelines. Pulmonary national societies are\nalso encouraged to share these guidelines with their members and de-\nvelop a summary or editorials in their own language, if appropriate.\nImplementation programmes are needed because it has been shown\nthat the outcome of disease may be favourably inﬂuenced by the thor-\nough application of clinical recommendations.\nHealth professionals are encouraged to take the ESC/ERS Guidelines\nfully into account when exercising their clinical judgement, as well as in\ndetermining and implementing preventive, diagnostic, or therapeutic\nmedical strategies. However, the ESC/ERS Guidelines do not override,\nin any way, the individual responsibility of health professionals to make\nappropriate and accurate decisions in considering each patient’s health\ncondition and in consulting with that patient or the patient’s caregiver\nwhere appropriate and/or necessary. It is also the health professional’s\nresponsibility to verify the rules and regulations applicable to drugs and\ndevices at the time of prescription and, where appropriate, to respect\nthe ethical rules of their profession in each country.\nOff-label use of medication may be presented in these guidelines if\na sufﬁcient level of evidence shows that it can be considered medic-\nally appropriate to a given condition and if patients could beneﬁt\nfrom the recommended therapy. However, the ﬁnal decisions con-\ncerning an individual patient must be made by the responsible health\nprofessional, giving special consideration to:\n• The speciﬁc situation of the patient. In this respect, it is speciﬁed\nthat, unless otherwise provided for by national regulations, off-\nlabel use of medication should be limited to situations where it\nis in the patient’s interest to do so, with regards to the quality,\nsafety, and efﬁcacy of care, and only after the patient has been fully\ninformed and provided consent.\n• Country-speciﬁc health regulations, indications by governmental\ndrug regulatory agencies, and the ethical rules to which health pro-\nfessionals are subject, where applicable.\n2. Introduction\nPulmonary hypertension (PH) is a pathophysiological disorder that\nmay involve multiple clinical conditions and may be associated with a\nvariety of cardiovascular and respiratory diseases. The complexity of\nmanaging PH requires a multifaceted, holistic, and multidisciplinary ap-\nproach, with active involvement of patients with PH in partnership\nwith clinicians. Streamlining the care of patients with PH in daily clinical\npractice is a challenging but essential requirement for effectively man-\naging PH. In recent years, substantial progress has been made in detect-\ning and managing PH, and new evidence has been timeously integrated\nin this fourth edition of the ESC/ERS Guidelines for the diagnosis and\ntreatment of pulmonary hypertension. Reﬂecting the multidisciplinary\ninput into managing patients with PH and interpreting new evidence,\nthe Task Force included cardiologists and pneumologists, a thoracic\nsurgeon, methodologists, and patients. These comprehensive clinical\npractice guidelines cover the whole spectrum of PH, with an emphasis\non diagnosing and treating pulmonary arterial hypertension (PAH) and\nchronic thrombo-embolic pulmonary hypertension (CTEPH).\n2.1. What is new\nOne of the most important proposals from the 6th World\nSymposium on Pulmonary Hypertension (WSPH) was to reconsider\nthe haemodynamic deﬁnition of PH.1 After careful evaluation, the\nnew deﬁnitions of PH have been endorsed and expanded in these\nguidelines, including a revised cut-off level for pulmonary vascular re-\nsistance (PVR) and a deﬁnition of exercise PH.\nThe classiﬁcation of PH has been updated, including repositioning\nof vasoreactive patients with idiopathic pulmonary arterial hyperten-\nsion (IPAH) and a revision of group 5 PH, including repositioning of\nPH in lymphangioleiomyomatosis in group 3.\nConcerning the diagnosis of PH, a new algorithm has been devel-\noped aiming at earlier detection of PH in the community. In addition,\nexpedited referral is recommended for high-risk or complex pa-\ntients. Screening strategies are also proposed.\nThe risk-stratiﬁcation table has been expanded to include additional\nechocardiographic and cardiac magnetic resonance imaging (cMRI)\nprognostic indicators. The recommendations for initial drug therapies\nhave been simpliﬁed, building on this revised, three-strata, multipara-\nmetric risk model to replace functional classiﬁcation. At follow-up, a\nfour-strata risk-assessment tool is now proposed based on reﬁned\ncut-off levels for World Health Organization functional class\n(WHO-FC), 6-minute walking distance (6MWD), and N-terminal\npro-brain natriuretic peptide (NT-proBNP), categorizing patients as\nlow, intermediate–low, intermediate–high, or high risk.\nThe PAH treatment algorithm has been modiﬁed, highlighting the im-\nportance of cardiopulmonary comorbidities, risk assessment both at\ndiagnosis and follow-up, and the importance of combination therapies.\nTreatment strategies during follow-up have been based on the four-\nstrata model intended to facilitate more granular decision-making.\nThe recommendations for managing PH associated with left heart dis-\nease (PH-LHD) and lung disease have been updated, including a new\nhaemodynamic deﬁnition of severe PH in patients with lung disease.\nIn group 4 PH, the term chronic thrombo-embolic pulmonary dis-\nease (CTEPD) with or without PH has been introduced, acknow-\nledging the presence of similar symptoms, perfusion defects, and\norganized ﬁbrotic obstructions in patients with or without PH at\nrest. Interventional treatment by balloon pulmonary angioplasty\n(BPA) in combination with medical therapy has been upgraded in\nthe therapeutic algorithm of CTEPH.\nNew standards for PH centres have been presented and, for the\nﬁrst time, patient representatives were actively involved in develop-\ning these guidelines.\nQuestions with direct consequences for clinical practitioners regard-\ning each PH classiﬁcation subgroup were selected and addressed, name-\nly guidance on: initial treatment strategy for group 1 PH (Population,\nIntervention, Control, Outcome [PICO] I); use of oral phosphodiester-\nase 5 inhibitors (PDE5is) for the treatment of group 2 PH (PICO II); use\nof oral PDE5is for the treatment of group 3 PH (PICO III); and use of PH\ndrugs prior to BPA for the treatment of group 4 PH (PICO IV). These\nquestions were considered to be important because: most contempor-\nary PH registries describe variable use of initial oral monotherapy and\ncombination therapy; large case series show widespread use of\nPDE5is in group 2 PH, despite a class III recommendation in the 2015\nESC/ERS Guidelines for the diagnosis and treatment of pulmonary\nhypertension; large case series show widespread use of PDE5is in group\n3 PH, despite a class III recommendation in the 2015 ESC/ERS\nGuidelines for the diagnosis and treatment of pulmonary hypertension;\nand there is no clear guidance for therapy with PH drugs in patients with\ninoperable CTEPH prior to BPA.\nESC/ERS Guidelines\n3625\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "acronyms",
        "mri",
        "anticoagulant",
        "angiography",
        "heart failure",
        "recommended",
        "pulmonary hypertension",
        "ecg",
        "class iii",
        "hfpef",
        "abbreviations",
        "glucose",
        "scd",
        "hypertension",
        "bnp",
        "vte",
        "diastolic",
        "electrocardiogram",
        "nt-probnp",
        "arb",
        "tricuspid",
        "catheterization",
        "calcium channel",
        "ejection fraction",
        "systolic",
        "pulmonary embolism",
        "exercise"
      ],
      "tables": [
        {
          "title": "3626 ESC/ERS Guidelines",
          "page_number": 8,
          "content": "New or\nrevised |  | Recommendation in 2015 version | Classa | Recommendation in 2022 version | Classa | \n | Right heart catheterization and vasoreactivity testing – Recommendation Table 1 |  |  |  |  | \nN |  |  |  | It is recommended that RHC comprises a complete set of\nhaemodynamics and is performed following standardized\nprotocols | I | \nR |  | Adenosine should be considered for performing\nvasoreactivity testing as an alternative\nInhaled iloprost may be considered for performing\nvasoreactivity testing as an alternative | IIa | Inhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol\nare recommended for performing vasoreactivity testing | I | \n | Diagnostic strategy – Recommendation Table 2 |  |  |  |  | \nN |  |  |  | It is recommended to assign an echocardiographic\nprobability of PH, based on an abnormal TRV and the\npresence of other echocardiographic signs suggestive of\nPH (see Table 10) | I | \nN |  |  |  | It is recommended to maintain the current threshold for\nTRV (.2.8 m/s) for echocardiographic probability of PH\naccording to the updated haemodynamic definition | I | \nN |  |  |  | Based on the probability of PH by echocardiography,\nfurther testing should be considered in the clinical\ncontext (i.e. symptoms and risk factors or associated\nconditions for PAH/CTEPH) | IIa | \nN |  |  |  | In symptomatic patients with intermediate\nechocardiographic probability of PH, CPET may be\nconsidered to further determine the likelihood of PH | IIb | \n | Screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension –\nRecommendation Table 3 |  |  |  |  | \nN |  |  |  | In patients with SSc, an annual evaluation of the risk of\nhaving PAH is recommended | I | \nR |  | Resting echocardiography is recommended as a screening\ntest in asymptomatic patients with SSc, followed by annual\nscreening with echocardiography, DLCO, and biomarkers | I | In adult patients with SSc of .3 years’ disease duration,\nan FVC ≥40%, and a DLCO ,60%, the DETECT\nalgorithm is recommended to identify asymptomatic\npatients with PAH | I | \nN |  |  |  | In patients with SSc, where breathlessness remains\nunexplained following non-invasive assessment, RHC is\nrecommended to exclude PAH | I | \nN |  |  |  | Assessing the risk of having PAH, based on an evaluation\nof breathlessness, in combination with echocardiogram\nor PFTs and BNP/NT-proBNP, should be considered in\npatients with SSc | IIa | \nN |  |  |  | Policies to evaluate the risk of having PAH should be\nconsidered in hospitals managing patients with SSc | IIa | \nR |  | RHC is recommended in all cases of suspected PAH\nassociated with CTD | I | In symptomatic patients with SSc, exercise\nechocardiography or CPET, or CMR may be considered\nto aid decisions to perform RHC | IIb | \nN |  |  |  | In patients with CTD with overlap features of SSc, an\nannual evaluation of the risk of PAH may be considered | IIb | \nR |  | In PE survivors with exercise dyspnoea, CTEPH should be\nconsidered | IIa | In patients with persistent or new-onset dyspnoea or\nexercise limitation following PE, further diagnostic\nevaluation to assess for CTEPH/CTEPD is recommended | I | ",
          "bbox": [
            42.999998304578995,
            74.0,
            547.2743559337798,
            710.6345062255859
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "2",
      "title": "3. Definitions and classifications",
      "start_page": 18,
      "end_page": 21,
      "content": "the recommendation provided and the quality of evidence sup-\nporting the recommendation. The Task Force discussed each\ndraft recommendation during web-based conference calls dedi-\ncated to speciﬁc sections, followed by consensus modiﬁcations\nand an online vote on each recommendation. Only recommen-\ndations that were supported by at least 75% of the Task Force\nmembers were included in the guidelines. The recommendation\ntables were colour-coded for ease of interpretation.\n3. Deﬁnitions and classiﬁcations\n3.1. Deﬁnitions\nThe deﬁnitions for PH are based on haemodynamic assessment by\nright heart catheterization (RHC). Although haemodynamics re-\npresent the central element of characterizing PH, the ﬁnal diagnosis\nand classiﬁcation should reﬂect the whole clinical context and con-\nsider the results of all investigations.\nTable 3\nClasses of recommendations\n©ESC/ERS 2022\nClasses of recommendations\nClass I \nEvidence and/or general agreement\nthat a given treatment or procedure is\nbeneficial, useful, effective.\nefficacy of the given treatment or procedure.\nfavour of usefulness/efficacy.\nUsefulness/efficacy is less well\nuseful/effective, and in some cases\nConﬂicting evidence and/or a divergence of opinion about the usefulness/ \n \nIs recommended or is indicated\nWording to use\nDeﬁnition\nClass III \nEvidence or general agreement that the\ngiven treatment or procedure is not\nmay be harmful. \nIs not recommended\n     Class IIb\nestablished by evidence/opinion.\nMay be considered\n \n   Class IIa\nWeight of evidence/opinion is in\nShould be considered\nClass II \n© ESC/ERS 2022\nTable 4\nLevels of evidence\nLevel of\nevidence A\nLevel of\nevidence B\nLevel of\nevidence C\nData derived from multiple randomized clinical trials\nor meta-analyses.\nData derived from a single randomized clinical trial\nor large non-randomized studies.\nConsensus of opinion of the experts and/or small studies,\nretrospective studies, registries.\n©ESC/ERS 2022\n© ESC/ERS 2022\n3636\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nPulmonary hypertension is deﬁned by a mean pulmonary arterial\npressure (mPAP) .20 mmHg at rest (Table 5). This is supported\nby studies assessing the upper limit of normal pulmonary arterial\npressure (PAP) in healthy subjects,7–9 and by studies investigating\nthe prognostic relevance of increased PAP (key narrative question\n1, Supplementary Data, Section 3.1).10–12\nIt is essential to include PVR and pulmonary arterial wedge pres-\nsure (PAWP) in the deﬁnition of pre-capillary PH, in order to dis-\ncriminate elevated PAP due to pulmonary vascular disease (PVD)\nfrom that due to left heart disease (LHD), elevated pulmonary blood\nﬂow, or increased intrathoracic pressure (Table 5). Based on the\navailable data, the upper limit of normal PVR and the lowest prognos-\ntically relevant threshold of PVR is ≏2 Wood units (WU).7,8,13,14\nPulmonary vascular resistance depends on body surface area and\nage, with elderly healthy subjects having higher values. The available\ndata on the best threshold for PAWP discriminating pre- and post-\ncapillary PH are contradictory. Although the upper limit of normal\nPAWP is considered to be 12 mmHg,15 previous ESC/ERS\nGuidelines for the diagnosis and treatment of PH, as well as the re-\ncent consensus recommendation of the ESC Heart Failure\nAssociation,16 suggest a higher threshold for the invasive diagnosis\nof heart failure (HF) with preserved ejection fraction (HFpEF)\n(PAWP ≥15 mmHg). In addition, almost all therapeutic studies of\nPAH have used the PAWP ≤15 mmHg threshold. Therefore, it is re-\ncommended keeping PAWP ≤15 mmHg as the threshold for pre-\ncapillary PH, while acknowledging that any PAWP threshold is arbi-\ntrary and that the patient phenotype, risk factors, and echocardio-\ngraphic ﬁndings, including left atrial (LA) volume, need to be\nconsidered when distinguishing pre- from post-capillary PH.\nPatients with PAH are haemodynamically characterized by pre-\ncapillary PH in the absence of other causes of pre-capillary PH,\nsuch as CTEPH and PH associated with lung diseases. All PH groups\nmay comprise both pre- and post-capillary components contributing\nto PAP elevation. In particular, older patients may present with sev-\neral conditions predisposing them to PH. The primary classiﬁcation\nshould be based on the presumed predominant cause of the pulmon-\nary pressure increase.\nPost-capillary\nPH\nis\nhaemodynamically\ndeﬁned\nas\nmPAP\n.20 mmHg and PAWP .15 mmHg. Pulmonary vascular resistance\nis used to differentiate between patients with post-capillary PH who\nhave a signiﬁcant pre-capillary component (PVR .2 WU—com-\nbined post- and pre-capillary PH [CpcPH]) and those who do not\n(PVR ≤2 WU—isolated post-capillary PH [IpcPH]).\nThere are patients with elevated mPAP (.20 mmHg) but low\nPVR (≤2 WU) and low PAWP (≤15 mmHg). These patients are fre-\nquently characterized by elevated pulmonary blood ﬂow and, al-\nthough they have PH, they do not fulﬁl the criteria of pre- or\npost-capillary PH. This haemodynamic condition may be described\nby the term ‘unclassiﬁed PH’. Patients with unclassiﬁed PH may pre-\nsent with congenital heart disease (CHD), liver disease, airway dis-\nease, lung disease, or hyperthyroidism explaining their mPAP\nelevation. Clinical follow-up of these patients is generally recom-\nmended. In the case of elevated pulmonary blood ﬂow, its aetiology\nshould be explored.\nAs the groups of PH according to clinical classiﬁcation represent\ndifferent clinical conditions, there may be additional clinically relevant\nhaemodynamic thresholds (e.g. for PVR) for the individual PH groups\nbesides the general thresholds of the haemodynamic deﬁnition of\nPH, which are discussed in the corresponding sections.\nExercise PH, deﬁned by an mPAP/cardiac output (CO) slope\n.3 mmHg/L/min between rest and exercise,17 has been re-\nintroduced. The mPAP/CO slope is strongly age dependent and its\nupper limit of normal ranges from 1.6–3.3 mmHg/L/min in the supine\nposition.17 An mPAP/CO slope .3 mmHg/L/min is not physiological\nin subjects aged ,60 years and may rarely be present in healthy sub-\njects aged .60 years.17 A pathological increase in pulmonary pres-\nsure during exercise is associated with impaired prognosis in\npatients with exercise dyspnoea18 and in several cardiovascular con-\nditions.19–22 Although an increased mPAP/CO slope deﬁnes an ab-\nnormal haemodynamic response to exercise, it does not allow for\ndifferentiation between pre- and post-capillary causes. The PAWP/\nCO slope with a threshold .2 mmHg/L/min may best differentiate\nbetween pre- and post-capillary causes of exercise PH.23,24\n3.2. Classiﬁcations\nThe basic structure of the classiﬁcation from the 2015 ESC/ERS\nGuidelines for the diagnosis and treatment of PH25,26 and the\nProceedings of the 6th WSPH1 has been kept (Table 6). The general\npurpose of the clinical classiﬁcation of PH remains to categorize clin-\nical conditions associated with PH, based on similar pathophysio-\nlogical\nmechanisms,\nclinical\npresentation,\nhaemodynamic\ncharacteristics, and therapeutic management (Figure 1). The main\nchanges are as follows:\n(i) The subgroups ‘non-responders at vasoreactivity testing’ and\n‘acute responders at vasoreactivity testing’ have been added\nto IPAH as compared with the 2015 ESC/ERS Guidelines for\nthe diagnosis and treatment of PH.25,26 In addition to patients\nwith IPAH, some patients with heritable PAH (HPAH) or\nTable 5\nHaemodynamic deﬁnitions of pulmonary\nhypertension\nDeﬁnition\nHaemodynamic characteristics\nPH\nmPAP .20 mmHg\nPre-capillary PH\nmPAP .20 mmHg\nPAWP ≤15 mmHg\nPVR .2 WU\nIpcPH\nmPAP .20 mmHg\nPAWP .15 mmHg\nPVR ≤2 WU\nCpcPH\nmPAP .20 mmHg\nPAWP .15 mmHg\nPVR .2 WU\nExercise PH\nmPAP/CO slope between rest and exercise\n.3 mmHg/L/min\n© ESC/ERS 2022\nCO, cardiac output; CpcPH, combined post- and pre-capillary pulmonary hypertension;\nIpcPH, isolated post-capillary pulmonary hypertension; mPAP, mean pulmonary arterial\npressure; PAWP, pulmonary arterial wedge pressure; PH, pulmonary hypertension;\nPVR, pulmonary vascular resistance; WU, Wood units.\nSome patients present with elevated mPAP (.20 mmHg) but low PVR (≤2 WU) and\nlow PAWP (≤15 mmHg); this haemodynamic condition may be described by the term\n‘unclassiﬁed PH’ (see text for further details).\nESC/ERS Guidelines\n3637\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\ndrug- or toxin-associated PAH (DPAH) might be acute\nresponders.\n(ii) The groups ‘PAH with features of venous/capillary (pulmonary\nveno-occlusive disease/pulmonary capillary haemangiomatosis\n[PVOD/PCH]) involvement’ and ‘persistent PH of the new-\nborn (PPHN)’ have been included in group 1 (PAH) as com-\npared with the 2015 ESC/ERS Guidelines for the diagnosis\nand treatment of PH and in line with the Proceedings of the\n6th WSPH.1\n(iii) Instead of the general term ‘sleep-disordered breathing’, the\nterm ‘hypoventilation syndromes’ should be used within group\n3 to describe conditions with increased risk of PH. Sole noctur-\nnal obstructive sleep apnoea is generally not a cause of PH, but\nPH is frequent in patients with hypoventilation syndromes caus-\ning daytime hypercapnia.\n4. Epidemiology and risk factors\nPulmonary hypertension is a major global health issue. All age groups\nare affected. Present estimates suggest a PH prevalence of ≏1% of\nthe global population. Due to the presence of cardiac and pulmonary\ncauses of PH, prevalence is higher in individuals aged .65 years.29\nGlobally, LHD is the leading cause of PH.29 Lung disease, especially\nchronic obstructive pulmonary disease (COPD), is the second\nmost common cause.29 In the UK, the observed PH prevalence\nhas doubled in the last 10 years and is currently 125 cases/million in-\nhabitants.30 Irrespective of the underlying condition, developing PH\nis associated with worsening symptoms and increased mortality.29\nIn developing countries, CHD, some infectious diseases (schistosom-\niasis, human immunodeﬁciency virus [HIV]), and high altitude re-\npresent important but under-studied causes of PH.29\n4.1. Group 1, pulmonary arterial\nhypertension\nRecent registry data from economically developed countries indicate\na PAH incidence and prevalence of ≏6 and 48–55 cases/million\nadults, respectively.31 It has been thought to predominantly affect\nyounger individuals, mostly females;32,33 this is currently true for\nHPAH, which affects twice as many females as males. However, re-\ncent data from the USA and Europe suggest that PAH is now fre-\nquently diagnosed in older patients (i.e. those aged ≥65 years,\nwho often present with cardiovascular comorbidities, resulting in a\nmore equal distribution between sexes).32 In most PAH registries,\nIPAH was the most common subtype (50–60% of all cases), followed\nby PAH associated with connective tissue disease (CTD), CHD, and\nportal hypertension (porto-pulmonary hypertension [PoPH]).32\nA number of drugs and toxins are associated with the develop-\nment of PAH.1,34–45 The association between exposure to drugs\nand toxins and PAH is classiﬁed as deﬁnite or possible, as proposed\nat the 6th WSPH (Table 7).1 There is a deﬁnite association with\ndrugs, with available data based on outbreaks, epidemiological case-\ncontrol studies, or large multicentre series. A possible association is\nsuggested by multiple case series or cases with drugs with similar me-\nchanisms of action.1\nTable\n6\nClinical\nclassiﬁcation\nof\npulmonary\nhypertension\nGROUP 1 Pulmonary arterial hypertension (PAH)\n1.1 Idiopathic\n1.1.1 Non-responders at vasoreactivity testing\n1.1.2 Acute responders at vasoreactivity testing\n1.2 Heritablea\n1.3 Associated with drugs and toxinsa\n1.4 Associated with:\n1.4.1 Connective tissue disease\n1.4.2 HIV infection\n1.4.3 Portal hypertension\n1.4.4 Congenital heart disease\n1.4.5 Schistosomiasis\n1.5 PAH with features of venous/capillary (PVOD/PCH) involvement\n1.6 Persistent PH of the newborn\nGROUP 2 PH associated with left heart disease\n2.1 Heart failure:\n2.1.1 with preserved ejection fraction\n2.1.2 with reduced or mildly reduced ejection fractionb\n2.2 Valvular heart disease\n2.3 Congenital/acquired cardiovascular conditions leading to\npost-capillary PH\nGROUP 3 PH associated with lung diseases and/or hypoxia\n3.1 Obstructive lung disease or emphysema\n3.2 Restrictive lung disease\n3.3 Lung disease with mixed restrictive/obstructive pattern\n3.4 Hypoventilation syndromes\n3.5 Hypoxia without lung disease (e.g. high altitude)\n3.6 Developmental lung disorders\nGROUP 4 PH associated with pulmonary artery obstructions\n4.1 Chronic thrombo-embolic PH\n4.2 Other pulmonary artery obstructionsc\nGROUP 5 PH with unclear and/or multifactorial mechanisms\n5.1 Haematological disordersd\n5.2 Systemic disorderse\n5.3 Metabolic disordersf\n5.4 Chronic renal failure with or without haemodialysis\n5.5 Pulmonary tumour thrombotic microangiopathy\n5.6 Fibrosing mediastinitis\n© ESC/ERS 2022\nHF, heart failure; HIV, human immunodeﬁciency virus; PAH, pulmonary arterial\nhypertension;\nPCH,\npulmonary\ncapillary\nhaemangiomatosis;\nPH,\npulmonary\nhypertension; PVOD, pulmonary veno-occlusive disease.\naPatients with heritable PAH or PAH associated with drugs and toxins might be acute\nresponders.\nbLeft ventricular ejection fraction for HF with reduced ejection fraction: ≤40%; for HF\nwith mildly reduced ejection fraction: 41–49%.\ncOther causes of pulmonary artery obstructions include: sarcomas (high or\nintermediate grade or angiosarcoma), other malignant tumours (e.g. renal carcinoma,\nuterine carcinoma, germ-cell tumours of the testis), non-malignant tumours (e.g.\nuterine leiomyoma), arteritis without connective tissue disease, congenital pulmonary\narterial stenoses, and hydatidosis.\ndIncluding\ninherited\nand\nacquired\nchronic\nhaemolytic\nanaemia\nand\nchronic\nmyeloproliferative disorders.\neIncluding sarcoidosis, pulmonary Langerhans’s cell histiocytosis, and neuroﬁbromatosis\ntype 1.\nfIncluding glycogen storage diseases and Gaucher disease.\n3638\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "class i",
        "elderly",
        "heart failure",
        "recommended",
        "pulmonary hypertension",
        "classifications",
        "class iii",
        "hfpef",
        "hypertension",
        "should be considered",
        "class ii",
        "older",
        "may be considered",
        "weight",
        "catheterization",
        "ejection fraction",
        "definitions",
        "age",
        "exercise"
      ],
      "tables": [
        {
          "title": "3636 ESC/ERS Guidelines",
          "page_number": 18,
          "content": "Class I | Evidence and/or general agreement\nthat a given treatment or procedure is\nbeneficial, useful, effective. | Is recommended or is indicated",
          "bbox": [
            109.89859924316406,
            102.24896240234375,
            495.37233479817706,
            155.85797119140625
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3636 ESC/ERS Guidelines",
          "page_number": 18,
          "content": "Class II | Conflicting evidence and/or a divergence of opinion about the usefulness/\nefficacy of the given treatment or procedure. |  |  | \n |  |  |  | \nClass IIa |  | Weight of evidence/opinion is in\nfavour of usefulness/efficacy. | Should be considered | \n |  |  |  | \nClass IIb |  | Usefulness/efficacy is less well\nestablished by evidence/opinion. | May be considered | ",
          "bbox": [
            109.89859924316406,
            162.03549194335938,
            495.37233479817706,
            264.2823181152344
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3636 ESC/ERS Guidelines",
          "page_number": 18,
          "content": "Class III | Evidence or general agreement that the\ngiven treatment or procedure is not\nuseful/effective, and in some cases\nmay be harmful. | Is not recommended",
          "bbox": [
            109.89859924316406,
            270.0957885742188,
            495.37233479817706,
            324.1503845214844
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC/ERS Guidelines 3637",
          "page_number": 19,
          "content": "Definition | Haemodynamic characteristics\nPH | mPAP .20 mmHg\nPre-capillary PH | mPAP .20 mmHg\nPAWP ≤15 mmHg\nPVR .2 WU\nIpcPH | mPAP .20 mmHg\nPAWP .15 mmHg\nPVR ≤2 WU\nCpcPH | mPAP .20 mmHg\nPAWP .15 mmHg\nPVR .2 WU\nExercise PH | mPAP/CO slope between rest and exercise\n.3 mmHg/L/min",
          "bbox": [
            48.000005449567524,
            499.5509948730469,
            288.0,
            670.5499877929688
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "4. Epidemiology and risk factors",
      "start_page": 20,
      "end_page": 21,
      "content": "drug- or toxin-associated PAH (DPAH) might be acute\nresponders.\n(ii) The groups ‘PAH with features of venous/capillary (pulmonary\nveno-occlusive disease/pulmonary capillary haemangiomatosis\n[PVOD/PCH]) involvement’ and ‘persistent PH of the new-\nborn (PPHN)’ have been included in group 1 (PAH) as com-\npared with the 2015 ESC/ERS Guidelines for the diagnosis\nand treatment of PH and in line with the Proceedings of the\n6th WSPH.1\n(iii) Instead of the general term ‘sleep-disordered breathing’, the\nterm ‘hypoventilation syndromes’ should be used within group\n3 to describe conditions with increased risk of PH. Sole noctur-\nnal obstructive sleep apnoea is generally not a cause of PH, but\nPH is frequent in patients with hypoventilation syndromes caus-\ning daytime hypercapnia.\n4. Epidemiology and risk factors\nPulmonary hypertension is a major global health issue. All age groups\nare affected. Present estimates suggest a PH prevalence of ≏1% of\nthe global population. Due to the presence of cardiac and pulmonary\ncauses of PH, prevalence is higher in individuals aged .65 years.29\nGlobally, LHD is the leading cause of PH.29 Lung disease, especially\nchronic obstructive pulmonary disease (COPD), is the second\nmost common cause.29 In the UK, the observed PH prevalence\nhas doubled in the last 10 years and is currently 125 cases/million in-\nhabitants.30 Irrespective of the underlying condition, developing PH\nis associated with worsening symptoms and increased mortality.29\nIn developing countries, CHD, some infectious diseases (schistosom-\niasis, human immunodeﬁciency virus [HIV]), and high altitude re-\npresent important but under-studied causes of PH.29\n4.1. Group 1, pulmonary arterial\nhypertension\nRecent registry data from economically developed countries indicate\na PAH incidence and prevalence of ≏6 and 48–55 cases/million\nadults, respectively.31 It has been thought to predominantly affect\nyounger individuals, mostly females;32,33 this is currently true for\nHPAH, which affects twice as many females as males. However, re-\ncent data from the USA and Europe suggest that PAH is now fre-\nquently diagnosed in older patients (i.e. those aged ≥65 years,\nwho often present with cardiovascular comorbidities, resulting in a\nmore equal distribution between sexes).32 In most PAH registries,\nIPAH was the most common subtype (50–60% of all cases), followed\nby PAH associated with connective tissue disease (CTD), CHD, and\nportal hypertension (porto-pulmonary hypertension [PoPH]).32\nA number of drugs and toxins are associated with the develop-\nment of PAH.1,34–45 The association between exposure to drugs\nand toxins and PAH is classiﬁed as deﬁnite or possible, as proposed\nat the 6th WSPH (Table 7).1 There is a deﬁnite association with\ndrugs, with available data based on outbreaks, epidemiological case-\ncontrol studies, or large multicentre series. A possible association is\nsuggested by multiple case series or cases with drugs with similar me-\nchanisms of action.1\nTable\n6\nClinical\nclassiﬁcation\nof\npulmonary\nhypertension\nGROUP 1 Pulmonary arterial hypertension (PAH)\n1.1 Idiopathic\n1.1.1 Non-responders at vasoreactivity testing\n1.1.2 Acute responders at vasoreactivity testing\n1.2 Heritablea\n1.3 Associated with drugs and toxinsa\n1.4 Associated with:\n1.4.1 Connective tissue disease\n1.4.2 HIV infection\n1.4.3 Portal hypertension\n1.4.4 Congenital heart disease\n1.4.5 Schistosomiasis\n1.5 PAH with features of venous/capillary (PVOD/PCH) involvement\n1.6 Persistent PH of the newborn\nGROUP 2 PH associated with left heart disease\n2.1 Heart failure:\n2.1.1 with preserved ejection fraction\n2.1.2 with reduced or mildly reduced ejection fractionb\n2.2 Valvular heart disease\n2.3 Congenital/acquired cardiovascular conditions leading to\npost-capillary PH\nGROUP 3 PH associated with lung diseases and/or hypoxia\n3.1 Obstructive lung disease or emphysema\n3.2 Restrictive lung disease\n3.3 Lung disease with mixed restrictive/obstructive pattern\n3.4 Hypoventilation syndromes\n3.5 Hypoxia without lung disease (e.g. high altitude)\n3.6 Developmental lung disorders\nGROUP 4 PH associated with pulmonary artery obstructions\n4.1 Chronic thrombo-embolic PH\n4.2 Other pulmonary artery obstructionsc\nGROUP 5 PH with unclear and/or multifactorial mechanisms\n5.1 Haematological disordersd\n5.2 Systemic disorderse\n5.3 Metabolic disordersf\n5.4 Chronic renal failure with or without haemodialysis\n5.5 Pulmonary tumour thrombotic microangiopathy\n5.6 Fibrosing mediastinitis\n© ESC/ERS 2022\nHF, heart failure; HIV, human immunodeﬁciency virus; PAH, pulmonary arterial\nhypertension;\nPCH,\npulmonary\ncapillary\nhaemangiomatosis;\nPH,\npulmonary\nhypertension; PVOD, pulmonary veno-occlusive disease.\naPatients with heritable PAH or PAH associated with drugs and toxins might be acute\nresponders.\nbLeft ventricular ejection fraction for HF with reduced ejection fraction: ≤40%; for HF\nwith mildly reduced ejection fraction: 41–49%.\ncOther causes of pulmonary artery obstructions include: sarcomas (high or\nintermediate grade or angiosarcoma), other malignant tumours (e.g. renal carcinoma,\nuterine carcinoma, germ-cell tumours of the testis), non-malignant tumours (e.g.\nuterine leiomyoma), arteritis without connective tissue disease, congenital pulmonary\narterial stenoses, and hydatidosis.\ndIncluding\ninherited\nand\nacquired\nchronic\nhaemolytic\nanaemia\nand\nchronic\nmyeloproliferative disorders.\neIncluding sarcoidosis, pulmonary Langerhans’s cell histiocytosis, and neuroﬁbromatosis\ntype 1.\nfIncluding glycogen storage diseases and Gaucher disease.\n3638\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "risk",
        "ejection fraction",
        "hypertension",
        "heart failure",
        "age",
        "factors",
        "pulmonary hypertension",
        "older",
        "epidemiology"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "5. Pulmonary hypertension diagnosis",
      "start_page": 22,
      "end_page": 23,
      "content": "4.2. Group 2, pulmonary hypertension\nassociated with left heart disease\nIn 2013, the Global Burden of Disease Study reported 61.7 million\ncases of HF worldwide, which represented almost a doubling since\n1990.46 In Europe and the USA, .80% of patients with HF are\naged ≥65 years. Post-capillary PH, either isolated or combined\nwith a pre-capillary component, is a frequent complication mainly\nin HFpEF, affecting at least 50% of these patients.47,48 The prevalence\nof PH increases with severity of left-sided valvular diseases, and PH\ncan be found in 60–70% of patients with severe and symptomatic mi-\ntral valve disease49 and in up to 50% of those with symptomatic aor-\ntic stenosis.50\n4.3. Group 3, pulmonary hypertension\nassociated with lung diseases and/or\nhypoxia\nMild PH is common in advanced parenchymal and interstitial lung dis-\nease. Studies have reported that ≏1–5% of patients with advanced\nCOPD with chronic respiratory failure or candidates for lung volume\nreduction surgery or lung transplantation (LTx) have an mPAP .35–\n40 mmHg.51,52\nIn\nidiopathic\npulmonary\nﬁbrosis,\nan\nmPAP\n≥25 mmHg has been reported in 8–15% of patients upon initial\nwork-up, with greater prevalence in advanced (30–50%) and end-\nstage (.60%) disease.52 Hypoxia is a public health problem for the\nestimated 120 million people living at altitudes .2500 m. Altitude\ndwellers are at risk of developing PH and chronic mountain sickness.\nHowever, it remains unclear to what extent PH and right HF are\npublic health problems in high-altitude communities; this should be\naddressed with updated methodology and large-scale population\nstudies.53\n4.4. Group 4, pulmonary hypertension\nassociated with chronic pulmonary\nartery obstruction\nThe number of patients diagnosed with CTEPH is increasing, probably\ndue to a deeper understanding of the disease and more active screening\nfor this condition in patients who remain dyspnoeic after pulmonary\nembolism (PE) or who have risk factors for developing CTEPH.\nRegistry data indicate a CTEPH incidence and prevalence of 2–6 and\n26–38 cases/million adults, respectively.31,54,55 Patients with chronic\nthrombo-embolic pulmonary disease (CTEPD) without PH still re-\npresent a small proportion of the patients referred to CTEPH centres.56\n4.5. Group 5, pulmonary hypertension\nwith unclear and/or multifactorial\nmechanisms\nGroup 5 PH consists of a complex group of disorders that are asso-\nciated with PH.57 The cause is often multifactorial and can be secondary\nto increased pre- and post-capillary pressure, as well as direct effects on\npulmonary vasculature. The incidence and prevalence of PH in most of\nthese disorders are unknown. However, high-quality registries have re-\ncently enabled estimation of PH prevalence in adult patients with sar-\ncoidosis.58,59 Studies suggest that PH can be common and its presence\nis often associated with increased morbidity and mortality.58,59\n5. Pulmonary hypertension\ndiagnosis\n5.1. Diagnosis\nThe diagnostic approach to PH is mainly focused on two tasks. The\nprimary goal is to raise early suspicion of PH and ensure fast-track\nreferral to PH centres in patients with a high likelihood of PAH,\nCTEPH, or other forms of severe PH. The second objective is to\nidentify underlying diseases, especially LHD (group 2 PH) and lung\ndisease (group 3 PH), as well as comorbidities, to ensure proper clas-\nsiﬁcation, risk assessment, and treatment.\n5.1.1. Clinical presentation\nSymptoms of PH are mainly linked to right ventricle (RV) dysfunc-\ntion, and typically associated with exercise in the earlier course of\nthe disease.25,26 The cardinal symptom is dyspnoea on progressively\nminor exertion. Other common symptoms are related to the stages\nand severity of the disease, and are listed in Figure 2.60–62 Potential\nclinical signs and physical ﬁndings are summarized in Figure 3.60,61\nImportantly, the physical examination may also be the key to identi-\nfying the underlying cause of PH (see Figure 3).\n5.1.2. Electrocardiogram\nElectrocardiogram (ECG) abnormalities (Table 8) may raise suspicion\nof PH, deliver prognostic information, and detect arrhythmias and\nsigns of LHD. In adults with clinical suspicion of PH (e.g. unexplained\ndyspnoea on exertion), right axis deviation has a high predictive value\nfor PH.63 A normal ECG does not exclude the presence of PH, but a\nnormal ECG in combination with normal biomarkers (BNP/\nNT-proBNP) is associated with a low likelihood of PH in patients re-\nferred for suspected PH or at risk of PH (i.e. after acute PE).64,65\nTable 7\nDrugs and toxins associated with pulmonary\narterial hypertension\nDeﬁnite\nassociation\nPossible association\nAminorex\nBenﬂuorex\nDasatinib\nDexfenﬂuramine\nFenﬂuramine\nMethamphetamines\nToxic rapeseed oil\nAlkylating agents (cyclophosphamide,\nmitomycin C)a\nAmphetamines\nBosutinib\nCocaine\nDiazoxide\nDirect-acting antiviral agents against hepatitis\nC virus (sofosbuvir)\nIndirubin (Chinese herb Qing-Dai)\nInterferon alpha and beta\nLeﬂunomide\nL-tryptophan\nPhenylpropanolamine\nPonatinib\nSelective proteasome inhibitors (carﬁlzomib)\nSolvents (trichloroethylene)a\nSt John’s Wort\n© ESC/ERS 2022\naPulmonary veno-occlusive disease.\n3640\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "hfpef",
        "diagnosis",
        "electrocardiogram",
        "hypertension",
        "bnp",
        "nt-probnp",
        "pulmonary hypertension",
        "pulmonary",
        "ecg",
        "stenosis",
        "exercise"
      ],
      "tables": [
        {
          "title": "3640 ESC/ERS Guidelines",
          "page_number": 22,
          "content": "Definite\nassociation | Possible association\nAminorex\nBenfluorex\nDasatinib\nDexfenfluramine\nFenfluramine\nMethamphetamines\nToxic rapeseed oil | Alkylating agents (cyclophosphamide,\nmitomycin C)a\nAmphetamines\nBosutinib\nCocaine\nDiazoxide\nDirect-acting antiviral agents against hepatitis\nC virus (sofosbuvir)\nIndirubin (Chinese herb Qing-Dai)\nInterferon alpha and beta\nLeflunomide\nL-tryptophan\nPhenylpropanolamine\nPonatinib\nSelective proteasome inhibitors (carfilzomib)\nSolvents (trichloroethylene)a\nSt John’s Wort",
          "bbox": [
            43.0,
            84.0,
            283.0,
            322.9989929199219
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "6. Pulmonary arterial hypertension (group 1)",
      "start_page": 37,
      "end_page": 38,
      "content": "6. Pulmonary arterial\nhypertension (group 1)\n6.1. Clinical characteristics\nThe symptoms of PAH are non-speciﬁc and mainly related to pro-\ngressive RV dysfunction (see Section 5.1.1) as a consequence of pro-\ngressive pulmonary vasculopathy (Figure 7). The presentation of PAH\nmay be modiﬁed by diseases that are associated with PAH, as well as\ncomorbidities. More detailed descriptions of the individual PAH sub-\nsets are reported in Section 7.\n6.2. Severity and risk assessment\n6.2.1. Clinical parameters\nClinical assessment is a key part of evaluating patients with PAH, as it\nprovides valuable information for determining disease severity, im-\nprovement, deterioration, or stability. At follow-up, changes in\nWHO-FC (Table 15), episodes of chest pain, arrhythmias, haemop-\ntysis, syncope, and signs of right HF provide important information.\nPhysical examination should assess heart rate, rhythm, blood pres-\nsure, cyanosis, enlarged jugular veins, oedema, ascites, and pleural ef-\nfusions. The WHO-FC is one of the strongest predictors of survival,\nIntimal proliferation, fibrosis\nPulmonary vasculopathy\nRight heart failure\nMedial hypertrophy\nVascular remodelling\nPlexiform lesion\nThrombosis\nVasoconstriction\nPulmonary\nartery\nVascular\nobstruction\nRight ventricular\nremodelling /\ndysfunction\nCurrent therapeutic targets\nMedial\nhyperplasia\nIntimal\nproliferation\nPlexiform\nlesions\nNO-sGC-cGMP pathway\nEndothelin pathway\nProstacyclin pathway\nL-arginine\nNitric oxide\n(Vasodilatation and\nantiproliferation)\nsGC\nPDE5\nGTP\ncGMP\nGMP\nArachidonic acid\nProstacyclin\n(Vasodilatation and\nantiproliferation)\ncAMP\nIP receptor\nPro-endothelin-1\nEndothelin-1\n(Vasoconstriction\nand proliferation)\nEndothelin\nreceptor A\nEndothelin\nreceptor B\nP\nP\nMP\nG\nMP\nFigure 7 Pathophysiology and current therapeutic targets of pulmonary arterial hypertension (group 1). cAMP, cyclic adenosine monophosphate; (c)\nGMP, (cyclic) guanosine monophosphate; GTP, guanosine-5′-triphosphate; IP receptor, prostacyclin I2 receptor; NO, nitric oxide; PDE5, phospho-\ndiesterase 5; sGC, soluble guanylate cyclase.\nESC/ERS Guidelines\n3655\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "hypertension",
        "group",
        "heart failure",
        "syncope",
        "pulmonary",
        "arterial"
      ],
      "tables": [
        {
          "title": "ESC/ERS Guidelines 3655",
          "page_number": 37,
          "content": "Pulmonary vasculopathy Right heart failure\nPulmonary Vascular\nIntimal proliferation, fibrosis\nartery obstruction\nVascular remodelling\nMedial hypertrophy\nRight ventricular\nremodelling /\nThrombosis\ndysfunction\nPlexiform lesion\nVasoconstriction\nMedial Intimal Plexiform\nhyperplasia proliferation lesions\nCurrent therapeutic targets\nEndothelin pathway NO-sGC-cGMP pathway Prostacyclin pathway\nPro-endothelin-1 L-arginine Arachidonic acid\nEndothelin-1 Nitric oxide Prostacyclin\n(Vasoconstriction (Vasodilatation and (Vasodilatation and\nand proliferation) antiproliferation) antiproliferation)\nIP receptor\nsGC PDE5\nEndothelin Endothelin\nreceptor A receptor B\nGTP cGMP GMP cAMP |  | \n |  | \n |  | ",
          "bbox": [
            76.97798665364583,
            226.9999796549479,
            522.4514923095703,
            684.0819905598959
          ],
          "function_potential": "raw"
        },
        {
          "title": "3656 ESC/ERS Guidelines",
          "page_number": 38,
          "content": "Class | Descriptiona\nWHO-FC I | Patients with PH but without resulting limitation of\nphysical activity. Ordinary physical activity does not\ncause undue dyspnoea or fatigue, chest pain, or near\nsyncope\nWHO-FC II | Patients with PH resulting in slight limitation of physical\nactivity. They are comfortable at rest. Ordinary physical\nactivity causes undue dyspnoea or fatigue, chest pain, or\nnear syncope\nWHO-FC III | Patients with PH resulting in marked limitation of\nphysical activity. They are comfortable at rest. Less than\nordinary activity causes undue dyspnoea or fatigue,\nchest pain, or near syncope\nWHO-FC IV | Patients with PH with an inability to carry out any\nphysical activity without symptoms. These patients\nmanifest signs of right HF. Dyspnoea and/or fatigue may\neven be present at rest. Discomfort is increased by any\nphysical activity",
          "bbox": [
            43.0,
            94.0009765625,
            283.0,
            323.9989929199219
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "2",
      "title": "7. Specific pulmonary arterial hypertension subsets",
      "start_page": 56,
      "end_page": 57,
      "content": "For patients with left main coronary artery compression syn-\ndrome, percutaneous coronary stenting is an effective and safe treat-\nment.62 For patients with asymptomatic left main coronary artery\ncompression or non-severe compromise of its anatomy, evaluation\nwith intravascular ultrasound or coronary pressure wire may help\nto avoid unnecessary interventions.494\n6.3.11. End-of-life care and ethical issues\nThe clinical course of PAH may be characterized by progressive de-\nterioration and occasional episodes of acute decompensation. Life\nexpectancy is difﬁcult to predict, as patients may either die slowly be-\ncause of progressive right HF or experience sudden death.\nPatient-orientated care is essential in managing PAH. Information\nabout disease severity and possible prognosis should be provided at\ninitial diagnosis but empathic and hopeful communication, as well as\nyielding hope, is essential, in line with Section 6.3.1.8. At the right\ntime, open and sensitive communication will enable advanced plan-\nning and discussion of a patient’s fears, concerns, and wishes, and\nwill ultimately contribute to making the ﬁnal, well-informed, and joint\ndecision about treatment with the medical team.\nPatients approaching end of life require frequent assessment of\ntheir full needs by a multidisciplinary team. In advanced stages, recog-\nnizing that cardiopulmonary resuscitation in severe PAH has a poor\noutcome may enable a do not resuscitate order; this may facilitate\npatients being in their preferred place of care at end of life.\nAttention should be given to controlling distressing symptoms and\nprescribing appropriate drugs while withdrawing medication that is\nno\nlonger\nneeded,\nwhich\nmay\ninclude\nPAH\nmedication.\nWell-informed psychological, social, and spiritual support is also vital.\nSpecialist palliative care should be consulted for patients whose\nneeds are beyond the expertise of the PH team.346\n6.3.12. New drugs in advanced clinical development\n(phase 3 studies)\nPulmonary arterial hypertension remains an incurable condition with\na high mortality rate, despite use of PAH drugs mainly targeting im-\nbalance of vasoactive factors. Novel agents, which are currently in\nphase 3 development, are ralinepag and sotatercept. Ralinepag is\nan orally available prostacyclin receptor agonist, which, in a phase\n2 RCT that included 61 patients with PAH, improved PVR compared\nwith placebo after 22 weeks of therapy.495 Sotatercept—a fusion\nprotein comprising the extracellular domain of the human activin re-\nceptor type IIA linked to the Fc domain of human immunoglobulin\nG1—acts as a ligand trap for members of the transforming growth\nfactor (TGF)-β superfamily, thus restoring balance between growth-\npromoting and growth-inhibiting pathways.496 In a phase 2 RCT that\nincluded 106 patients with PAH treated over 24 weeks, s.c. sotater-\ncept reduced PVR in patients receiving background PAH therapy;496\nimprovements were also observed in 6MWD and NT-proBNP.496\n7. Speciﬁc pulmonary arterial\nhypertension subsets\n7.1. Pulmonary arterial hypertension\nassociated with drugs and toxins\nSeveral drugs and toxins are associated with developing PAH or\nPVOD/PCH. Historically, certain appetite suppressants and toxic\nrapeseed oil were the most prominent examples, whereas metham-\nphetamines, interferons, and some tyrosine kinase inhibitors are\nmore common causes nowadays (Table 7). Pulmonary arterial hyper-\ntension is a rare complication in patients exposed to these drugs, and\nmany of these drugs have also been linked to other pulmonary com-\nplications such as parenchymal lung disease or pleural effusions.\nThese pulmonary complications may occur concurrently.\nMethamphetamine-associated PAH has mainly been reported\nfrom the USA, where some centres have found that 20–29% of their\notherwise idiopathic cases of PAH were associated with metham-\nphetamine use.497,498 Compared with patients with IPAH, those\nwith methamphetamine-associated PAH had more severe haemo-\ndynamic impairment and a higher mortality risk.498 Alpha and beta\ninterferons have also been associated with developing PAH.499 The\nsame is true of some tyrosine kinase inhibitors, especially dasatinib,\nbut also bosutinib and ponatinib.40,500\nDrug- or toxin-induced PAH should always be considered in pa-\ntients presenting with unexplained exertional dyspnoea or other\nwarning signs. The diagnostic approach should be the same as in\nother forms of PH, and the diagnosis is usually made by excluding\nother forms of PH in patients who have been exposed to drugs as-\nsociated with developing PAH.\nTreatment of DPAH follows the same basic principles as treating\nother forms of PAH. Importantly, partial or full reversal of PAH has\nbeen reported after discontinuing the causative agent, at least for in-\nterferons and dasatinib.499,500 Hence, multidisciplinary management\nof the patient should include discontinuing the presumed causative\nagents once PAH is diagnosed (also see the 2022 ESC Guidelines\non Cardio-Oncology).501 In patients with mild PH and a low-risk pro-\nﬁle, discontinuing the trigger alone may be sufﬁcient, and it is recom-\nmended that these patients be observed over 3–4 months before\nconsidering PAH therapy. Pulmonary arterial hypertension therapy\nshould be initiated in patients who do not normalize their haemo-\ndynamics after withdrawing or in patients presenting with more ad-\nvanced PAH at diagnosis. Unlike in other forms of PAH, de-escalation\nof PAH therapy is often possible during the course of the disease.500\nPhysicians should bear in mind that DPAH may have features of\nPVOD/PCH, especially in patients treated with alkylating agents\nsuch as mitomycin C or cyclophosphamide. Health professional\nawareness is essential in identifying cases of DPAH and reporting ad-\nverse effects of pharmaceutical products.\nRecommendation Table 14 — Recommendations for\npulmonary\narterial\nhypertension\nassociated\nwith\ndrugs or toxins\nRecommendations\nClassa\nLevelb\nIt is recommended to make a diagnosis of drug- or\ntoxin-associated PAH in patients who had\nrelevant exposure and in whom other causes of\nPH have been excluded\nI\nC\nIn patients with suspected drug- or\ntoxin-associated PAH, it is recommended to\nimmediately discontinue the causative agent\nwhenever possible\nI\nC\nContinued\n3674\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "specific",
        "hypertension",
        "nt-probnp",
        "recommended",
        "subsets",
        "coronary artery",
        "pulmonary",
        "arterial"
      ],
      "tables": [
        {
          "title": "3674 ESC/ERS Guidelines",
          "page_number": 56,
          "content": "Recommendations | Classa | Levelb\nIt is recommended to make a diagnosis of drug- or\ntoxin-associated PAH in patients who had\nrelevant exposure and in whom other causes of\nPH have been excluded | I | C\nIn patients with suspected drug- or\ntoxin-associated PAH, it is recommended to\nimmediately discontinue the causative agent\nwhenever possible | I | C",
          "bbox": [
            307.27500697544644,
            607.551025390625,
            547.2749786376953,
            728.2047119140625
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC/ERS Guidelines 3675",
          "page_number": 57,
          "content": "Immediate PAH therapy should be considered in\npatients who present with intermediate-/high-risk\nPAH at diagnosis | IIa | C\nPatients with low-risk PAH should be re-evaluated\n3–4 months after discontinuing the suspected\ndrug or toxin, and PAH therapy may be\nconsidered when the haemodynamics have not\nnormalized | IIb | C",
          "bbox": [
            48.0,
            59.843994140625,
            288.0,
            156.843017578125
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC/ERS Guidelines 3675",
          "page_number": 57,
          "content": "Recommendations | Classa | Levelb\nIn patients with PAH associated with CTD,\ntreatment of the underlying condition according\nto current guidelines is\nrecommended166,167,419,524 | I | A",
          "bbox": [
            312.27500610351564,
            656.5499877929688,
            552.2750244140625,
            728.2045288085938
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "8. Pulmonary hypertension associated with left heart disease (group 2)",
      "start_page": 67,
      "end_page": 68,
      "content": "treated with therapies for PAH, including sildenaﬁl and bosentan;\nhowever, these are not approved by the EMA for use in infants\nwith group 3 PH and developmental lung diseases (BPD, CDH).\nTheir effects on outcomes in this population are unclear, and data\nenabling robust treatment recommendations are lacking. These chil-\ndren should be treated by multidisciplinary teams involving cardiolo-\ngists, neonatologists, pulmonologists, and nutritionists. Pulmonary\nhypertension in these infants may disappear with lung healing, al-\nthough long-term cardiovascular sequelae have been reported.611,612\n8. Pulmonary hypertension\nassociated with left heart disease\n(group 2)\n8.1. Deﬁnition, prognosis, and\npathophysiology\nAmong patients with LHD, PH and RV dysfunction are frequently\npresent and associated with high mortality.47 This includes patients\nwith HF with reduced, mildly reduced, or preserved ejection fraction\n(HFrEF, HFmrEF, or HFpEF), left-sided valvular heart disease, and\ncongenital/acquired cardiovascular conditions leading to post-\ncapillary PH.13,631–635 Arguably, PH-LHD represents the most preva-\nlent form of PH, accounting for 65–80% of cases.47\nConsistent with the general deﬁnitions of PH, PH-LHD (group 2\nPH) is deﬁned by an mPAP .20 mmHg and a PAWP .15 mmHg.\nWithin this haemodynamic condition of post-capillary PH, IpcPH is\ndeﬁned by PVR ≤2 WU and CpcPH by PVR .2 WU (Table 5).\nThe diastolic pressure gradient (DPG) (calculated as the difference\nbetween dPAP and PAWP) is no longer used to distinguish between\nIpcPH and CpcPH because of conﬂicting data on prognostication in\nLHD.142\nAcross the spectrum of LHD, increases in PAP and PVR are asso-\nciated with an increased disease burden and a worse out-\ncome.13,631,633,635 In a large patient cohort—predominantly with\npost-capillary PH—a PVR ≥2.2 WU was associated with adverse\noutcomes and considered abnormal.13 However, even within this\nsubgroup of patients with LHD and CpcPH, the risk of mortality in-\ncreases with progressive elevation in PVR. In patients with advanced\nHFrEF and those with HFpEF or valvular heart disease, a PVR\n.5 WU carries additional prognostic information and is considered\nclinically meaningful by physicians.142,450,631–639 Elevated PVR also\nappears to be associated with decreased survival in special situations,\nsuch as in patients undergoing interventions for correcting valvular\nheart disease,634 heart transplantation,142,633 or LVAD implant-\nation.142,637 Based on available data, a PVR .5 WU may indicate a\nsevere pre-capillary component, the presence of which may prompt\nphysicians to refer patients to PH centres for specialized care.\nThe prevalence of PH in patients with LHD is difﬁcult to assess and\ndepends on the methodology of diagnostic testing (echocardiog-\nraphy or invasive haemodynamics), cut-off values used to deﬁne\nPH, and populations studied. Observational studies suggest an esti-\nmated prevalence of PH of 40–72% in patients with HFrEF and\n36–83% in those with HFpEF.48,639–643 When PVR is used to deﬁne\nRecommendation Table 21 — Recommendations for\npaediatric pulmonary hypertension\nRecommendations\nClassa\nLevelb\nChildren\nIt is recommended to perform the diagnostic\nwork-up, including RHC and acute vasoreactivity\ntesting, and treat children with PH at centres with\nspeciﬁc expertise in paediatric PH\nI\nC\nIn children with PH, a comprehensive work-up for\nconﬁrming diagnosis and speciﬁc aetiology is\nrecommended (similar to that in adults, but\nadapted for age)\nI\nC\nFor conﬁrming PH diagnosis, RHC is recommended,\npreferably before initiating any PAH therapy\nI\nC\nIn children with IPAH/HPAH, acute vasoreactivity\ntesting is recommended to detect those who may\nbeneﬁt from CCB therapy\nI\nC\nIt is recommended to similarly deﬁne a positive\nresponse to acute vasoreactivity testing in children\nand adults by a reduction in mPAP ≥10 mmHg to\nreach an absolute value of mPAP ≤40 mmHg,\nwith an increased or unchanged CO\nI\nC\nIn children with PAH, a therapeutic strategy based\non risk stratiﬁcation and treatment response is\nrecommended, extrapolated from that in adults\nbut adapted for age\nI\nC\nIt is recommended to monitor the treatment\nresponse in children with PAH by serially assessing\na panel of data derived from clinical assessment,\nechocardiographic evaluation, biochemical\nmarkers, and exercise tolerance tests\nI\nC\nAchieving and maintaining a low-risk proﬁle\nshould be considered as an adequate treatment\nresponse for children with PAH\nIIa\nC\nInfants\nIt is recommended to screen infants with\nbronchopulmonary dysplasia for PH628,629\nI\nB\nIn infants with (or at risk of) bronchopulmonary\ndysplasia and PH, treating lung disease—including\nhypoxia, aspiration, and structural airway disease\n—and optimizing respiratory support is\nrecommended before initiating PAH therapy630\nI\nB\nContinued\nIn neonates and infants, a diagnostic and\ntherapeutic approach to PH distinct from that in\nolder children and adults should be considered,\ngiven the frequent association with developmental\nvascular and parenchymal lung disease\nIIa\nC\n© ESC/ERS 2022\nCCB, calcium channel blocker; CO, cardiac output; HPAH, heritable pulmonary arterial\nhypertension; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean\npulmonary arterial pressure; PAH, pulmonary arterial hypertension; PH, pulmonary\nhypertension; RHC, right heart catheterization.\naClass of recommendation.\nbLevel of evidence.\nESC/ERS Guidelines\n3685\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "recommended",
        "pulmonary hypertension",
        "hfref",
        "hfpef",
        "disease",
        "hypertension",
        "heart",
        "should be considered",
        "associated",
        "left",
        "diastolic",
        "older",
        "group",
        "catheterization",
        "calcium channel",
        "ejection fraction",
        "hfmref",
        "age",
        "pulmonary",
        "exercise"
      ],
      "tables": [
        {
          "title": "ESC/ERS Guidelines 3685",
          "page_number": 67,
          "content": "In neonates and infants, a diagnostic and\ntherapeutic approach to PH distinct from that in\nolder children and adults should be considered,\ngiven the frequent association with developmental\nvascular and parenchymal lung disease | IIa | C",
          "bbox": [
            312.2749938964844,
            59.5,
            552.2750244140625,
            119.5
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC/ERS Guidelines 3685",
          "page_number": 67,
          "content": "Recommendations |  | Classa | Levelb | \n | Children |  |  | \nIt is recommended to perform the diagnostic\nwork-up, including RHC and acute vasoreactivity\ntesting, and treat children with PH at centres with\nspecific expertise in paediatric PH |  | I | C | \nIn children with PH, a comprehensive work-up for\nconfirming diagnosis and specific aetiology is\nrecommended (similar to that in adults, but\nadapted for age) |  | I | C | \nFor confirming PH diagnosis, RHC is recommended,\npreferably before initiating any PAH therapy |  | I | C | \nIn children with IPAH/HPAH, acute vasoreactivity\ntesting is recommended to detect those who may\nbenefit from CCB therapy |  | I | C | \nIt is recommended to similarly define a positive\nresponse to acute vasoreactivity testing in children\nand adults by a reduction in mPAP ≥10 mmHg to\nreach an absolute value of mPAP ≤40 mmHg,\nwith an increased or unchanged CO |  | I | C | \nIn children with PAH, a therapeutic strategy based\non risk stratification and treatment response is\nrecommended, extrapolated from that in adults\nbut adapted for age |  | I | C | \nIt is recommended to monitor the treatment\nresponse in children with PAH by serially assessing\na panel of data derived from clinical assessment,\nechocardiographic evaluation, biochemical\nmarkers, and exercise tolerance tests |  | I | C | \nAchieving and maintaining a low-risk profile\nshould be considered as an adequate treatment\nresponse for children with PAH |  | IIa | C | \n | Infants |  |  | \nIt is recommended to screen infants with\nbronchopulmonary dysplasia for PH628,629 |  | I | B | \nIn infants with (or at risk of) bronchopulmonary\ndysplasia and PH, treating lung disease—including\nhypoxia, aspiration, and structural airway disease\n—and optimizing respiratory support is\nrecommended before initiating PAH therapy630 |  | I | B | ",
          "bbox": [
            48.0,
            210.25,
            287.9993469238281,
            718.9016390713779
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "9. Pulmonary hypertension associated with lung diseases and/or hypoxia (group 3)",
      "start_page": 72,
      "end_page": 75,
      "content": "9. Pulmonary hypertension\nassociated with lung diseases and/\nor hypoxia (group 3)\nPulmonary hypertension is frequently observed in patients with\nCOPD and/or emphysema, ILD, combined pulmonary ﬁbrosis and\nemphysema (CPFE), and hypoventilation syndromes.52,165,707,708\nPulmonary hypertension is uncommon in obstructive sleep apnoea\nunless other conditions coexist, such as COPD or daytime hypoven-\ntilation.709 At high altitude (.2500 m) hypoxia-induced PH is\nthought to affect .5% of the population, the development of PH\nbeing related to geography and genetic factors.710\nA PH screening study performed on a large cohort of .100\npatients with lymphangioleiomyomatosis conﬁrmed that PH is\nusually mild in that setting: from six patients (5.7%) present-\ning with pre-capillary PH, none had mPAP .30 mmHg and\nPH was associated with PFT alteration, suggesting that the\nrise in mPAP is associated with parenchymal involvement.711\nThus, PH in lymphangioleiomyomatosis is now classiﬁed in\ngroup 3 PH.1\nIn patients with lung disease, PH is categorized as non-severe or\nsevere, depending on haemodynamic ﬁndings (Figure 12). In the\n2015 ESC/ERS Guidelines for the diagnosis and treatment of\nPH, severe PH was deﬁned by mPAP .35 mmHg or mPAP\n≥25 mmHg with CI ,2.5 L/min/m2.25,26 However, two recent\nstudies have demonstrated that a PVR .5 WU is a better thresh-\nold for predicting worse prognosis in patients with PH associated\nwith both COPD and ILD.712,713 Based on these data, the current\nguidelines used PVR to distinguish between non-severe PH (PVR\nRecommendation Table 22 — Recommendations for pulmonary hypertension associated with left heart disease\nRecommendation Table 22A\nRecommendations\nClassa\nLevelb\nIn patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of suspected\nPH27,28\nI\nA\nRHC is recommended for suspected PH in patients with LHD, if it aids management decisions\nI\nC\nRHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair\nI\nC\nFor patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral\nto a PH centre for a complete diagnostic work-up is recommended29,47,142\nI\nC\nIn patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is\nrecommended\nI\nC\nWhen patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or\nﬂuid challenge, are treated with PAH drugs, close monitoring is recommended\nI\nC\nIn patients with PH at RHC, a borderline PAWP (13–15 mmHg) and features of HFpEF, additional testing with exercise or ﬂuid challenge\nmay be considered to uncover post-capillary PH133,143\nIIb\nC\nDrugs approved for PAH are not recommended in PH-LHDc 631,678,683,684,701,706\nIII\nA\n© ESC/ERS 2022\nRecommendation Table 22B\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nNo recommendation can be given for or against the use of PDE5is in patients\nwith HFpEF and combined post- and pre-capillary PH\nLow\nNone\n–\n–\nThe use of PDE5is in patients with HFpEF and isolated post-capillary PH is not\nrecommended\nLow\nConditional\nIII\nC\n© ESC/ERS 2022\nCpcPH, combined post- and pre-capillary PH; ERA, endothelin receptor antagonist; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with\nreduced ejection fraction; LHD, left heart disease; PAH, pulmonary arterial hypertension; PAWP, pulmonary arterial wedge pressure; PDE5is, phosphodiesterase 5 inhibitors; PH,\npulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right\nventricular; WU, Wood units.\naClass of recommendation.\nbLevel of evidence.\ncSafety concerns have been identiﬁed when ERAs are used in patients with HF (HFpEF and HFrEF, with or without PH) and when sildenaﬁl is used in patients with persistent PH after\ncorrection of valvular heart disease.\n3690\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n≤5 WU) and severe PH (PVR .5 WU). Whereas non-severe PH\nis common in advanced COPD and ILD deﬁned by spirometric cri-\nteria, severe PH is uncommon, occurring in 1–5% of cases of\nCOPD and ,10% of patients with advanced ILD, with limited\ndata in obesity hypoventilation syndrome.714,715 Even non-severe\nPH in lung disease negatively impacts symptoms and survival, and\nis associated with increased hospitalization.715–717 Patients with\nlung disease and severe PH have a worse outcome than those\nwith non-severe PH, providing evidence that this distinction has\nclinical signiﬁcance.51,712,713,718,719 It is noteworthy that develop-\ning severe PH is largely independent of spirometry but usually ac-\ncompanied by hypoxaemia, low PaCO2, and a signiﬁcant reduction\nin DLCO.51,714,718,719\nPulmonary hypertension presenting in patients with lung disease\nmay be due to a number of causes, including undiagnosed CTEPH\nor PAH.714,720 Cardiac comorbidities are also common in patients\nwith lung disease and may contribute to PH. A number of distinct\nphenotypes of PH in patients with lung disease, including a pulmon-\nary vascular phenotype, have been proposed.51,720 The pulmonary\nvascular phenotype is characterized by better preserved spirometry,\nlow DLCO, hypoxaemia, a range of parenchymal involvement on\nlung imaging, and a circulatory limitation to exercise.51,714,718–722\nRecent studies have shown that the clinical characteristics, disease\ntrajectory, response to treatment,451,718,719 and histological corre-\nlates723,724 of patients with severe PH and minor lung disease are dif-\nferent to those in patients with IPAH, including a poorer prognosis.\nRemodelling of airways, lung parenchyma, and vessels\nPrevalence\n~70%\n~20%\n~5–10%\nMostly ventilatory\nexercise limitation\nMostly circulatory\nexercise limitation\nRemodelling of pulmonary vessels\nRemodelling of airways and parenchyma\nHypoxaemia at rest and/or during exercise\nNo PH\nNon-severe PH\nSevere PH\n(PVR >5 WU)\nCOPD\nILD\nCPFE\nR\nEmphysema\nFibrosis\nVascular pruning\nCPFE\nFigure 12 Pathophysiology of pulmonary hypertension associated with lung disease (group 3). COPD, chronic obstructive pulmonary disease; CPFE,\ncombined pulmonary ﬁbrosis and emphysema; ILD, interstitial lung disease; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; WU,\nWood units. Shown are underlying lung diseases (upper panel); contributing pathogenic pulmonary alterations of airways, parenchyma, and vessels\n(middle panel); and the relation of airway/parenchymal remodelling and vascular remodelling to the degree of PH and its consequences for exercise\nlimitation (ventilatory vs. circulatory, lower panel).\nESC/ERS Guidelines\n3691\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n9.1. Diagnosis\nIn patients with lung disease, symptoms of PH, especially exertional\ndyspnoea, overlap with those of the underlying condition. Physical\nﬁndings may also be non-speciﬁc, for example: ankle swelling is com-\nmon during episodes of ventilatory failure in COPD, where activa-\ntion of the renin–angiotensin–aldosterone system may cause ﬂuid\nretention, usually in the setting of preserved RV function.\nNon-invasive tests—such as ECG showing right axis deviation or\nRV strain, elevated levels of BNP/NT-proBNP, CPET, or features on\ncross-sectional imaging—may suggest the diagnosis of PH in patients\nwith lung disease.725,726 Echocardiography remains the most widely\nused non-invasive diagnostic tool for assessing PH; however, the ac-\ncuracy of echocardiography in patients with advanced respiratory\ndiseases is low, with a TRV unmeasurable in .50% of patients in\nsome studies, and there is a tendency to overestimate PAP and mis-\nclassify patients with PH.86,87,727 More recent data suggest that a\nstepwise, composite, echocardiographic score can identify patients\nwith severe PH, with and without an estimate of TRV, using other echo-\ncardiographic features including RA area, RV:LV ratio, and LV eccentri-\ncity index.728 Where PH is suspected, combining echocardiography\nwith a contrast-enhanced CT may aid diagnostic assessment and disease\nclassiﬁcation.108,729–731 Pulmonary artery enlargement, RV outﬂow\nhypertrophy, and increased RV:LV ratio may suggest a diagnosis of\nPH.108 Ideally, assessments should be made or repeated when the pa-\ntient is clinically stable, as exacerbations can signiﬁcantly raise PAP.\nKey parts of evaluating suspected PH in lung disease include integrat-\ning: (1) the presence or absence of risk factors for PAH, CTEPH, or\nLHD; (2) clinical features, including disease trajectory (e.g. rapid recent\ndeterioration vs. gradual change over years, and oxygen requirements);\n(3) PFTs, including DLCO and blood gas analysis; (4) NT-proBNP mea-\nsurements, ECG, and echocardiography; and (5) cross-sectional imaging\nwith contrast-enhanced CT, SPECT, or V/Q lung scan and, in selected\ncases, cMRI732 to assess the need for RHC. Cardiopulmonary exercise\ntesting may be helpful in assessing ventilatory or cardiac limitation in pa-\ntients with lung disease,121,733 although data are limited regarding its\nclinical use in identifying patients with PH in lung disease.\nIndications for RHC in lung disease include assessment for surgical\ntreatments (selected patients considered for LTx and lung volume re-\nduction surgery), suspected PAH or CTEPH, and where further infor-\nmation will aid phenotyping of disease and consideration of therapeutic\ninterventions (Figure S3).712,718,734 Such testing should ideally be con-\nducted in PH centres when patients are clinically stable and treatment\nof underlying lung disease has been optimized. Consideration should be\ngiven to how pressure measurements are made, due to the impact of\nchanging intrathoracic pressures on pulmonary haemodynamics during\nthe respiratory cycle (see Section 5.1.12).735\n9.2. Therapy\nThe therapeutic approach to group 3 PH starts with optimizing the\ntreatment of the underlying lung disease, including supplementary oxy-\ngen and non-invasive ventilation, where indicated, as well as enrolment\ninto pulmonary rehabilitation programmes.736 There is limited and con-\nﬂicting evidence for the use of medication approved for PAH in patients\nwith group 3 PH, and these drugs may have variable and sometimes\ndetrimental effects on haemodynamics, exercise capacity, gas exchange,\nand outcomes in this patient population.181,737–740\n9.2.1. Pulmonary hypertension associated with\nchronic obstructive pulmonary disease or\nemphysema\nStudies using drugs approved for PAH in patients with PH associated\nwith COPD or emphysema have yielded conﬂicting results and are\nmostly limited by small sample size, short duration, and insufﬁcient\nhaemodynamic characterization of PH.739,741,742 In a 16 week RCT\nof 28 patients with COPD and severe PH conﬁrmed by RHC, silde-\nnaﬁl therapy resulted in statistically signiﬁcant improvements in PVR\nand quality of life.743 Registry data identiﬁed that ≏30% of patients\nwith COPD and severe PH, predominantly treated with PDE5is,\nhad improved WHO-FC, 6MWD, and PVR vs. baseline, and those\nwith a treatment response had improved transplant-free sur-\nvival.51,718 However, in the absence of large randomized trials, the\nevidence is insufﬁcient to support the general use of medication ap-\nproved for PAH in patients with COPD and PH. Patients with COPD\nand suspected or conﬁrmed severe PH should be referred to PH\ncentres for individual decision-making.\n9.2.2. Pulmonary hypertension associated with\ninterstitial lung disease\nNumerous phase 2 and phase 3 studies have investigated the use of\nERAs to treat ILD, all with negative results.740,744,745 In addition, the\nPDE5i sildenaﬁl has been investigated in phase 3 trials of patients with\nILD, also with negative results.746,747 Few data from RCTs are available\nfor patients with PH associated with ILD, and many of the studies per-\nformed for this indication748,749 suffered from the same limitations as\nthe aforementioned studies in PH associated with COPD. In addition,\nthere were several adverse safety signals: ambrisentan was associated\nwith an increased risk of clinical worsening in patients with ILD with\nand without PH,740,750 while riociguat was associated with an increased\nrisk of clinical worsening events, including potential excess mortality, in\npatients with PH associated with idiopathic interstitial pneumonia.181\nIn contrast, promising results have been obtained with the use of\ninhaled treprostinil. A phase 3 RCT (INCREASE) examined inhaled\ntreprostinil at a target dose of 72 µg given four times daily in 326 pa-\ntients with PH associated with ILD.734,751 The PH diagnosis was con-\nﬁrmed by RHC within 1 year prior to enrolment. At week 16, the\nplacebo-corrected 6MWD improved by 31 m with inhaled trepros-\ntinil. There were also improvements in NT-proBNP and clinical wor-\nsening events, the latter driven by a lower proportion of patients\nwhose 6MWD declined by .15% from baseline.\nGiven the signiﬁcant impact of even non-severe PH in patients\nwith lung disease, eligible patients should be referred for LTx evalu-\nation. In patients with ILD and PH, inhaled treprostinil may be con-\nsidered based on the ﬁndings from the INCREASE study, but\nfurther data are needed, especially on long-term outcomes. The rou-\ntine use of other medication approved for PAH is not recommended\nin patients with ILD and non-severe PH. For patients with severe PH\nand/or severe RV dysfunction, or where there is uncertainty regard-\ning the treatment of PH, referral to a PH centre is recommended for\ncareful evaluation, to facilitate entry into RCTs, and consider PAH\ntherapies on an individual basis (Figure S3). Registry data show that\nsome patients with group 3 PH are being treated with PAH medica-\ntion, predominantly PDE5is,718,752,753 but it is unclear if and to what\nextent these patients beneﬁt from this treatment.\n3692\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "heart failure",
        "lung",
        "echo",
        "recommended",
        "pulmonary hypertension",
        "ecg",
        "hfref",
        "hfpef",
        "valve repair",
        "echocardiography",
        "hypertension",
        "bnp",
        "associated",
        "diseases",
        "obesity",
        "hypoxia",
        "nt-probnp",
        "may be considered",
        "tricuspid",
        "catheterization",
        "group",
        "genetic",
        "ejection fraction",
        "pulmonary",
        "exercise"
      ],
      "tables": [
        {
          "title": "3690 ESC/ERS Guidelines",
          "page_number": 72,
          "content": "Recommendations | Classa | Levelb\nIn patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of suspected\nPH27,28 | I | A\nRHC is recommended for suspected PH in patients with LHD, if it aids management decisions | I | C\nRHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair | I | C\nFor patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral\nto a PH centre for a complete diagnostic work-up is recommended29,47,142 | I | C\nIn patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is\nrecommended | I | C\nWhen patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or\nfluid challenge, are treated with PAH drugs, close monitoring is recommended | I | C\nIn patients with PH at RHC, a borderline PAWP (13–15 mmHg) and features of HFpEF, additional testing with exercise or fluid challenge\nmay be considered to uncover post-capillary PH133,143 | IIb | C\nDrugs approved for PAH are not recommended in PH-LHDc 631,678,683,684,701,706 | III | A",
          "bbox": [
            42.99966195913461,
            93.62593078613281,
            547.2749674479167,
            316.0
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3690 ESC/ERS Guidelines",
          "page_number": 72,
          "content": " | GRADE |  |  | \nRecommendations | Quality of\nevidence | Strength of\nrecommendation | Classa | Levelb\nNo recommendation can be given for or against the use of PDE5is in patients\nwith HFpEF and combined post- and pre-capillary PH | Low | None | – | –\nThe use of PDE5is in patients with HFpEF and isolated post-capillary PH is not\nrecommended | Low | Conditional | III | C",
          "bbox": [
            42.99966195913461,
            369.6249656677246,
            547.2749674479167,
            477.0
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC/ERS Guidelines 3693",
          "page_number": 75,
          "content": "Recommendations | Classa | Levelb\nIf PH is suspected in patients with lung disease, it is recommended that echocardiographyc be performed and the results interpreted in\nconjunction with ABG, PFTs including DLCO, and CT imaging | I | C\nIn patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where\nindicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation | I | C\nIn patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH\ncentre is recommendedd | I | C\nIn patients with lung disease and severe PH, an individualized approach to treatment is recommended | I | C\nIt is recommended to refer eligible patients with lung disease and PH for LTx evaluation | I | C\nIn patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions | I | C\nInhaled treprostinil may be considered in patients with PH associated with ILD734 | IIb | B\nThe use of ambrisentan is not recommended in patients with PH associated with IPF740 | III | B\nThe use of riociguat is not recommended in patients with PH associated with IIP181 | III | B\nThe use of PAH medication is not recommended in patients with lung disease and non-severe PHe | III | C",
          "bbox": [
            47.99986572265625,
            248.1249542236328,
            552.2750244140625,
            520.4990234375
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC/ERS Guidelines 3693",
          "page_number": 75,
          "content": " | GRADE |  |  | \nRecommendations | Quality of\nevidence | Strength of\nrecommendation | Classa | Levelb\nPDE5is may be considered in patients with severe PH associated with ILD\n(individual decision-making in PH centres) | Very low | Conditional | IIb | C\nThe use of PDE5is in patients with ILD and non-severe PH is not recommended | Very low | Conditional | III | C",
          "bbox": [
            47.99986572265625,
            571.6249542236328,
            552.2750244140625,
            679.0
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "10. Chronic thrombo-embolic pulmonary hypertension (group 4)",
      "start_page": 75,
      "end_page": 78,
      "content": "9.2.3. Recommendations on the use of drugs\napproved for PAH in PH associated with lung disease\nThe recommendations on the use of drugs approved for PAH in pa-\ntients with PH associated with COPD and ILD have been established\nbased on key narrative questions 6 and 7 (Supplementary Data,\nSections 9.1 and 9.2, respectively).\nThe recommendations on the use of PDE5is in patients with se-\nvere PH associated with ILD are based on PICO question III\n(Supplementary Data, Section 9.3). There are no direct data from\nRCTs on the safety, tolerability, and efﬁcacy of PDE5is in patients\nwith PH associated with ILD. The indirect data included in the\nguidelines do not enable ﬁrm conclusions to be drawn. Given the\nlack of robust evidence, the Task Force members felt unable to pro-\nvide a recommendation for or against the use of PDE5is in patients\nwith ILD and severe PH, and recommend that these patients are re-\nferred to a PH centre for individualized decision-making.\n10. Chronic thrombo-embolic\npulmonary hypertension (group 4)\nAll\npatients\nwhose\nsymptoms\ncan\nbe\nattributed\nto\npost-thrombo-embolic ﬁbrotic obstructions within the PA are\nRecommendation Table 23 — Recommendations for pulmonary hypertension associated with lung disease and/or\nhypoxia\nRecommendation Table 23A\nRecommendations\nClassa\nLevelb\nIf PH is suspected in patients with lung disease, it is recommended that echocardiographyc be performed and the results interpreted in\nconjunction with ABG, PFTs including DLCO, and CT imaging\nI\nC\nIn patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where\nindicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation\nI\nC\nIn patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH\ncentre is recommendedd\nI\nC\nIn patients with lung disease and severe PH, an individualized approach to treatment is recommended\nI\nC\nIt is recommended to refer eligible patients with lung disease and PH for LTx evaluation\nI\nC\nIn patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions\nI\nC\nInhaled treprostinil may be considered in patients with PH associated with ILD734\nIIb\nB\nThe use of ambrisentan is not recommended in patients with PH associated with IPF740\nIII\nB\nThe use of riociguat is not recommended in patients with PH associated with IIP181\nIII\nB\nThe use of PAH medication is not recommended in patients with lung disease and non-severe PHe\nIII\nC\n© ESC/ERS 2022\nRecommendation Table 23B\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nPDE5is may be considered in patients with severe PH associated with ILD\n(individual decision-making in PH centres)\nVery low\nConditional\nIIb\nC\nThe use of PDE5is in patients with ILD and non-severe PH is not recommended\nVery low\nConditional\nIII\nC\n© ESC/ERS 2022\nABG, arterial blood gas analysis; CT, computed tomography; DLCO, Lung diffusion capacity for carbon monoxide; IIP, idiopathic interstitial pneumonia; IPF, idiopathic pulmonary\nﬁbrosis; ILD, interstitial lung disease; LTx, lung transplantation; PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; PFT, pulmonary function test; PH,\npulmonary hypertension; RHC, right heart catheterization.\naClass of recommendation.\nbLevel of evidence.\ncAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise pulmonary artery pressure.\ndThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.\neThis does not include inhaled treprostinil, which may be considered in patients with PH associated with ILD, irrespective of PH severity.\nESC/ERS Guidelines\n3693\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nconsidered to have CTEPD with or without PH; CTEPH remains the\npreferred term for patients with PH, as deﬁned in Section 3.1\n(Table 5).54 Chronic thrombo-embolic pulmonary disease describes\nsymptomatic patients with mismatched perfusion defects on V/Q\nscan and with signs of chronic, organized, ﬁbrotic clots on CTPA or\nDSA, such as ring-like stenoses, webs/slits, and chronic total occlusions\n(pouch lesions or tapered lesions), after at least 3 months of therapeut-\nic anticoagulation. Pulmonary hypertension in this setting is not only a\nconsequence of PA obstruction by organized ﬁbrotic clots but can also\nbe related to the associated microvasculopathy. In those patients with-\nout PH at rest, breathlessness could be due to exercise PH (see\ndeﬁnition in Section 3.1, Table 5) and/or increased dead space ventila-\ntion.54 Excluding ventilatory limitation, deconditioning and psychogenic\nhyperventilation syndrome by CPET and LV myocardial or valvular dis-\nease by echocardiography is of upmost importance when making\ntherapeutic decisions in patients with CTEPD without PH.\n10.1. Diagnosis\nChronic thrombo-embolic pulmonary hypertension is a common\nand important cause of PH, with a distinct management strategy.\nThus, the possibility of CTEPH should be carefully considered in all\npatients with PH (Figure 13). In the context of acute PE, CTEPH\nCTEPH diagnostic algorithm for symptomatic patients\nf\nPatients with confirmed CTEPH\nCTEPH suspected from history\nof PEa or risk factors for CTEPH\nf\nTr\nT eatment assessment by MDT at CTEPH centre\n(Class I)\nPH work-up\nN\nY\nPerfusion imaging\n(V/Q scan or new modalityb)\nAny mismatched\nperfusion defects\nf\nEchocardiography\nIntermediate or\nhigh probability of PH\nRefer to CTEPH/PH centre\nComprehensive work-upd\n(Table 14\nT\n, ReCo\n,\nTable 2)\nT\nAbnormal exercise tests\n(CPETc, st\n,\nress echocardiography)\nsuggestive for CTEPD\nf\nAND\nCTPA + D\nP\nSA\nwhen CTPA is inconclusi\nP\nve\nRHC\nAND\nFigure 13 Diagnostic strategy in chronic thrombo-embolic pulmonary hypertension. CPET, cardiopulmonary exercise test; CTEPD, chronic thrombo-\nembolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; CTPA, computed tomography pulmonary angiography; DECT,\ndual-energy computed tomography; DSA, digital subtraction angiography; MDT, multidisciplinary team; MRI, magnetic resonance imaging; N, no; PE, pul-\nmonary embolism; PETCO2, end-tidal partial pressure of carbon dioxide; PH, pulmonary hypertension; ReCo, recommendation; RHC, right heart cath-\neterization; sPAP, systolic pulmonary arterial pressure; V/Q, ventilation/perfusion; VE/VCO2, ventilatory equivalents for carbon dioxide; VO2/HR, oxygen\npulse; VO2, oxygen uptake; Y, yes. aCTEPH suspected from history of PE, including elevated sPAP on echocardiography and signs suggesting CTEPH on\nCTPA performed at the time of the acute PE (Section 5.1.7). bAlternative perfusion imaging techniques—such as iodine subtraction mapping, DECT, and\nMRI perfusion—are currently under evaluation. cTypical pattern, including low PETCO2, high VE/VCO2, low VO2/HR, and low peak VO2 (Section 5.1.11).\ndComprehensive work-up after 3 months of therapeutic anticoagulation or sooner in unstable or rapidly deteriorating patients. Ideally, CTPA, DSA, and\nRHC are performed in CTEPH centres, but they are sometimes performed in PH centres, depending on the country and organization.\n3694\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nshould be considered: (1) if radiological signs (detailed in Section\n5.1.7) suggest CTEPH on the CTPA performed to diagnose PE,112\nand/or if estimated sPAP is .60 mmHg112 on echocardiogram; (2)\nwhen dyspnoea or functional limitations persist in the clinical course\npost-PE;754 and (3) in asymptomatic patients with risk factors for\nCTEPH or a high CTEPH prediction score.755 Clinical conditions\nsuch as permanent intravascular devices (pacemaker, long-term cen-\ntral lines, ventriculoatrial shunts), inﬂammatory bowel diseases, es-\nsential\nthrombocythaemia,\npolycythaemia\nvera,\nsplenectomy,\nantiphospholipid syndrome, high-dose thyroid hormone replace-\nment, and malignancy are risk factors for CTEPH.54,103,756\nAlternative causes of PA obstructions (also included in group 4 of the\nPH classiﬁcation)—including PA sarcomas, other malignant tumours\n(e.g. renal carcinoma, uterine carcinoma, and germ-cell tumours of\nthe testis), non-malignant tumours (e.g. uterine leiomyoma), arteriitis\nwithout CTD, congenital or acquired PA stenoses, parasites (hydatid\ncyst), and foreign-body embolism—have to be considered in the differ-\nential diagnosis of CTEPD.757 They can be explored by speciﬁc addition-\nal imaging such as 18F-2-ﬂuoro-2-deoxy-D-glucose-positron emission\ntomography (PET) scan, which can provide additional information\nwhen PA sarcoma is suspected.758\nVentilation/perfusion scintigraphy207 remains the most effective\ntool in excluding CTEPD. Alternative perfusion imaging techniques\n—such as iodine subtraction mapping, DECT, and MRI perfusion—\nhave numerous theoretical advantages over V/Q but are more tech-\nnically challenging and expensive, have limited availability, and cur-\nrently lack multicentre validation.\nComputed tomography pulmonary angiography with bi-planar re-\nconstruction is broadly used for diagnosing CTEPD and assessing op-\nerability, but a negative CTPA, even if high quality, does not exclude\nCTEPD, as distal disease can be missed. Digital subtraction angiog-\nraphy is still used to assess treatment options when CTPA is incon-\nclusive. Selective segmental angiography, cone-beam CT, and area\ndetector CT allow for more accurate visualization of subsegmental\nvasculature and are useful for procedural guidance for BPA. The ben-\neﬁts of the new technologies require validating in prospective trials\nbefore being recommended for routine clinical use; a large,\nEuropean, multicentre study is currently ongoing.759\n10.2. Therapy\nThe CTEPH treatment algorithm includes a multimodal approach of\ncombinations of pulmonary endarterectomy (PEA), BPA, and medic-\nal therapies to target the mixed anatomical lesions: proximal, distal,\nand microvasculopathy, respectively (Figures 14 and 15).\nGeneral measures recommended for PAH also apply to CTEPH,\nincluding supervised exercise training, which is effective and safe in\ninoperable CTEPH patients,760 as well as early after PEA.761\nLifelong therapeutic anticoagulation is recommended for patients\nwith CTEPH, as recurrent pulmonary thrombo-embolism accompanied\nby insufﬁcient clot resolution are key pathophysiological features of this\ndisease. There are no RCTs in CTEPH with any of the approved anti-\ncoagulants; however, despite this lack of evidence, VKAs are recom-\nmended by experts, and are most widely used as background therapy\nfor patients with CTEPH. More recently, NOACs have more frequently\nbeen used as alternatives to VKAs, again, lacking evidence from RCTs. A\nretrospective case series from the UK and a multicentre prospective\nregistry (EXPERT) showed comparable bleeding rates for VKAs and\nNOACs in CTEPH, but recurrent venous thrombo-embolism rates\nwere higher in those receiving NOACs.762,763 In patients with antipho-\nspholipid syndrome (10% of the CTEPH population), VKAs are recom-\nmended.103,764,765 Screening for antiphospholipid syndrome should be\nperformed at CTEPH diagnosis. In the absence of any evidence in favour\nor against prolonged anticoagulation in patients with CTEPD without\nPH, long-term anticoagulant therapy is based on individual decision-\nmaking. It is recommended when the risk of PE recurrence is intermedi-\nate or high, thereby following the 2019 ESC/ERS Guidelines for the diag-\nnosis and management of acute pulmonary embolism (Table 11).103\n10.2.1. Surgical treatment\nSurgical PEA is the treatment of choice for patients with accessible\nPA lesions.102 As surgery may normalize pulmonary haemodynamics\n(65% decrease in PVR)766 and functional capacity, an expert multidis-\nciplinary team including an experienced PEA surgeon (on-site or\nclosely collaborating) is mandatory for evaluating operability and de-\nciding ﬁnal treatment.102\nOperability is based on team experience, accessibility of PA le-\nsions, correlation between severity of PH and degree of PA obstruc-\ntions, and comorbidities.767 The surgical technique is complex but\nwell standardized with .30 years of experience. It consists of a com-\nplete bilateral endarterectomy of the PAs down to segmental and\nsubsegmental levels in phases of deep hypothermic circulatory arrest\n(Figure 15).767,768 In CTEPH centres, surgical outcomes are favour-\nable, with peri-operative mortality rates ,2.5% due to improved\nmanagement of cardiac and pulmonary complications and well-\nestablished use of ECMO.768 Post-operative PH is frequently ob-\nserved (≏25%),766 but long-term outcomes after PEA surgery are\nexcellent regarding survival (averaging 90% at 3 years) and quality\nof life,769–771 even in patients with distal PA obstructions.772 On\nthe other hand, patients with proximal operable disease declining\nsurgery have a poor long-term outcome, with a 5 year survival of\n53%\ncompared\nwith\n83%\nin\npatients\nundergoing\nPEA.773\nTherefore, PEA should be offered to all operable patients with a fa-\nvourable risk:beneﬁt ratio, ideally during a personal consultation be-\ntween the patient and the PEA surgeon.102\nSelected symptomatic patients with CTEPD without PH can be\nsuccessfully treated by PEA, with clinical and haemodynamic im-\nprovements at rest and exercise.135,774 Those patients would require\ncareful discussion to balance risk and beneﬁt.\n10.2.2. Medical therapy\nTo manage the microvascular component of CTEPH (Figure 15),\nmedical therapies have been used off-label based on uncontrolled\nstudies and/or regional approvals. Meanwhile, three RCTs have suc-\ncessfully been conducted. The ﬁrst phase 3 RCT investigated the ef-\nﬁcacy of riociguat in patients with inoperable CTEPH or those with\npersistent/recurrent PH after PEA.775 Riociguat, after 16 weeks of\ntherapy, improved 6MWD and reduced PVR by 31% compared\nwith placebo, and is approved for this indication. Treprostinil s.c.\nwas investigated in a phase 3 RCT, which showed improved\n6MWD at week 24 in patients with inoperable CTEPH or those\nwith persistent/recurrent PH after PEA receiving a high dose com-\npared with a low dose;776 s.c. treprostinil is approved for this indica-\ntion. In a phase 2 study including only patients with inoperable\nCTEPH, macitentan 10 mg improved PVR and 6MWD vs. placebo\nESC/ERS Guidelines\n3695\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "mri",
        "anticoagulant",
        "angiography",
        "class i",
        "recommended",
        "pulmonary hypertension",
        "indication",
        "glucose",
        "anticoagulation",
        "hypertension",
        "echocardiography",
        "should be considered",
        "embolic",
        "may be considered",
        "thrombo",
        "catheterization",
        "group",
        "chronic",
        "systolic",
        "pacemaker",
        "pulmonary embolism",
        "pulmonary",
        "exercise"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "11. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5)",
      "start_page": 81,
      "end_page": 82,
      "content": "11. Pulmonary hypertension with\nunclear and/or multifactorial\nmechanisms (group 5)\nPulmonary hypertension with unclear and/or multifactorial mechan-\nisms (Table 24) includes several conditions that may be complicated\nby complex and sometimes overlapping pulmonary vascular\ninvolvement. Although group 5 PH represents less-studied forms\nof PH, it constitutes a signiﬁcant part of the worldwide burden\nof PH.1 Group 5 PH includes: haematological disorders, such as\nSCD and chronic myeloproliferative neoplasms; systemic disor-\nders, such as sarcoidosis; metabolic diseases, such as glycogen stor-\nage disease; and others, such as chronic renal failure, pulmonary\ntumour thrombotic microangiopathy, and ﬁbrosing mediastinitis.\nA common feature of these diseases is that the mechanisms of\nPH are poorly understood and contributing factors may include,\nalone or in combination: hypoxic pulmonary vasoconstriction, pul-\nmonary vascular remodelling, thrombosis, ﬁbrotic destruction and/\nor extrinsic compression of pulmonary vasculature, pulmonary\nvasculitis, high-output cardiac failure, and left HF. These patients\nneed careful assessment and treatment should be directed to the\nunderlying condition.\n11.1. Haematological disorders\nIn haemoglobinopathies and chronic haemolytic anaemias, including\nSCD, PH has emerged as a major cause of morbidity and mortality.\nThe prevalence of PH conﬁrmed by RHC was 6–10% in studies of\nadult patients with stable SCD.93,94,813 Patients with SCD with pre-\ncapillary PH are more commonly homozygous for haemoglobin S,\nwhile some have S-β0 thalassaemia (S-β0 thal) or haemoglobin\nSCD.814 Thrombotic lesions are a major component of PH related\nto SCD, more frequently in haemoglobin SCD.814 Patients with\nPH and SCD should be followed by multidisciplinary SCD and PH\nteams, since treatment of the anaemia is a key part of manage-\nment.814 There is a lack of data to support the use of PAH drugs\nin patients with SCD-associated PH. In a study in patients with\nSCD with TRV ≥2.7 m/s and a 6MWD of 150–500 m, sildenaﬁl\nshowed no treatment effect on 6MWD, TRV, or NT-proBNP, but\nappeared to increase hospitalization rates for pain.815 Preliminary\nevidence supports the short- and long-term beneﬁts of chronic\nblood-exchange transfusions in patients with pre-capillary PH com-\nplicating SCD.816 Pre-capillary PH complicating SCD has an import-\nant impact on survival, with an overall death rate of 2.0–5.3% in\ndifferent populations with similar follow-up (26 months and 18\nmonths, respectively).94,817 In β-thalassaemia, invasive haemodyna-\nmic evaluation conﬁrmed pre-capillary PH in 2.1% of cases, while a\npost-capillary proﬁle was found in 0.3%.818 Potential treatment strat-\negies\nare\nawaiting\nan\nenhanced\nunderstanding\nof\nthe\nRecommendation Table 24B\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nIn patients with CTEPH who are candidates for BPA, medical therapy should be\nconsidered prior to the intervention798\nVery low\nConditional\nIIa\nB\n© ESC/ERS 2022\nBPA, balloon pulmonary angioplasty; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; ERA, endothelin receptor\nantagonist; PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; PEA, pulmonary endarterectomy; PE, pulmonary embolism; PH, pulmonary hypertension;\ns.c., subcutaneous; sGC, soluble guanylate cyclase; VKA, vitamin K antagonist; WHO-FC, World Health Organization functional class.\naClass of recommendation.\nbLevel of evidence.\ncLong-term anticoagulant therapy is recommended when the risk of PE recurrence is intermediate or high,103 or when there is no history of venous thrombo-embolism.\nTable 24\nPulmonary hypertension with unclear and/\nor multifactorial mechanisms\nDisorders associated with\npulmonary hypertension\n1 Haematological disorders\nInherited and acquired chronic\nhaemolytic anaemia\n• Sickle cell disease\n• β-thalassaemia\n• Spherocytosis\n• Stomatocytosis\n• Autoimmune disorders\nChronic myeloproliferative\ndisorders\n• Chronic myelogenous\nleukaemia\n• Polycythaemia vera\n• Idiopathic myeloﬁbrosis\n• Essential thrombocytopenia\n• Others\n2 Systemic disorders\nSarcoidosis\nPulmonary Langerhans’s cell\nhistiocytosis\nNeuroﬁbromatosis type 1\n3 Metabolic disorders\nGlycogen storage disease\nGaucher disease\n4 Chronic renal failure with/\nwithout haemodialysis\n5 Pulmonary tumour thrombotic\nmicroangiopathy\n6 Fibrosis mediastinitis\n© ESC/ERS 2022\nESC/ERS Guidelines\n3699\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "anticoagulant",
        "scd",
        "unclear",
        "hypertension",
        "group",
        "age",
        "nt-probnp",
        "recommended",
        "pulmonary hypertension",
        "pulmonary embolism",
        "mechanisms",
        "pulmonary",
        "multifactorial"
      ],
      "tables": [
        {
          "title": "ESC/ERS Guidelines 3699",
          "page_number": 81,
          "content": " | GRADE |  |  | \nRecommendations | Quality of\nevidence | Strength of\nrecommendation | Classa | Levelb\nIn patients with CTEPH who are candidates for BPA, medical therapy should be\nconsidered prior to the intervention798 | Very low | Conditional | IIa | B",
          "bbox": [
            47.99978419712612,
            81.6259765625,
            552.2750244140625,
            164.0005859375
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC/ERS Guidelines 3699",
          "page_number": 81,
          "content": "Disorders associated with\npulmonary hypertension | \n1 Haematological disorders | Inherited and acquired chronic\nhaemolytic anaemia\n• Sickle cell disease\n• β-thalassaemia\n• Spherocytosis\n• Stomatocytosis\n• Autoimmune disorders\nChronic myeloproliferative\ndisorders\n• Chronic myelogenous\nleukaemia\n• Polycythaemia vera\n• Idiopathic myelofibrosis\n• Essential thrombocytopenia\n• Others\n2 Systemic disorders | Sarcoidosis\nPulmonary Langerhans’s cell\nhistiocytosis\nNeurofibromatosis type 1\n3 Metabolic disorders | Glycogen storage disease\nGaucher disease\n4 Chronic renal failure with/\nwithout haemodialysis | \n5 Pulmonary tumour thrombotic\nmicroangiopathy | \n6 Fibrosis mediastinitis | ",
          "bbox": [
            47.99978419712612,
            386.5,
            288.0,
            738.4979858398438
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "12. Definition of a pulmonary hypertension centre",
      "start_page": 83,
      "end_page": 85,
      "content": "Placebo-controlled, randomized trials are currently recruiting in\nwell-phenotyped subgroups of PH with unclear and/or multifactorial\nmechanisms, such as sarcoidosis-associated PH.\n12. Deﬁnition of a pulmonary\nhypertension centre\nWhile PH is not an uncommon condition, severe forms of PH, es-\npecially PAH and CTEPH, require highly specialized management.\nSince medical centres with multidisciplinary teams and a high vol-\nume of patients generally offer best standard of care, which trans-\nlates into better clinical outcomes, establishing PH centres is\nclinically and economically highly desirable and is supported by\npatient organizations and scientiﬁc societies. The purpose of a\nPH centre is to: receive new referrals; assess and investigate the\ncause of PH; carefully phenotype and routinely manage patients\nwith medical, interventional, and surgical approaches; work closely\nwith other health care providers to achieve the best outcomes for\npatients; undertake audits (reporting patient case mix and quality\nindicators); and be involved in clinical and translational research,\nand education. The requirements—comprising deﬁnition, multi-\ndisciplinary structure, number of cases, procedures, and stafﬁng le-\nvels, as well as the skills and resources needed in a PH referral\ncentre—are described below and in Figure 16. Criteria for paediatric\nand CTEPH centres are described elsewhere (Sections 7.8.3 and 10.3,\nrespectively).\nCo-ordinated by a core MDT member responsible for the multidisciplinary approach\nCore MDT\nExtended MDT\nSocial worker\nStudy nurse\nPaediatric cardiologist\nPsychologist\nAdult CHD specialist\nLung pathologist\nHepatologist\nPhysiotherapist\nRheumatologist\nIntensive care specialist\nThoracic radiologist\nPalliative care specialist\nCardiac radiologist\nLung transplant\nphysician/surgeonc\nClinical geneticist/\nGenetic counsellorc\nAt least 2 PH nurses\nNurse specialist\nFor diagnostic pulmonary\nangiography, embolization\nInterventional\nradiologist/cardiologist\nCardiologist/Pneumologist\nAt least 2 surgeons\n(ECMO)\nCardiothoracic surgeon\nCase managerb\nResponsible for data \ncollection, analysis, and\norganization of audit meetings\nData manager\nMDT meeting\nRegular, to discuss multidisciplinary aspects of individual patient care\nPatient empowerment and advocacy\nClear verbal, and written information for patients that describes diagnostic procedures and treatment options;\nshared decision-making; collaboration with advocacy group\nInteraction with external healthcare providers and other relevant stakeholders\nGP, local specialist, social services, rehabilitation centres, national health services, labs,\ninsurers, school, work, sport club, psychologist, etc.\nQuality control/Audits\nData collection/registration; monitoring of quality indicators; regular internal audits\nResearch, training, and education\nInvolvement in clinical and translational research: teaching courses on local, national, or international basis\nPatient care pathway and clinical management protocol\nSteps from diagnosis to follow-up including advanced disease, palliative stage, and end of life\nAt least 2 PH specialists treating\na sufficient number of patientsa\nResponsible for the\nco-ordination of care\non patient level\nGynaecologist/\nObstetrician\nCardiothoracic \nanaesthetist\nProcesses\nPulmonary hypertension centre\nworking \u000250% on PH care \nFigure 16 Pulmonary hypertension centre schematic. CHD, congenital heart disease; ECMO, extracorporeal membrane oxygenation; GP, general\npractitioner; MDT, multidisciplinary team; PH, pulmonary hypertension. aNumber adapted according to speciﬁc country characteristics. bCase manager\ncan be a nurse specialist, social worker, physiotherapist, or administrative assistant in function of the centre organization. cCan be located in partner cen-\ntres. Adapted from Biganzoli et al.846\nESC/ERS Guidelines\n3701\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n12.1. Facilities and skills required for a\npulmonary hypertension centre\nPulmonary hypertension centres care for a sufﬁcient number of pa-\ntients on PH therapy, as well as new referrals, to warrant this status.\nAccording to the 2015 ESC/ERS Guidelines for the diagnosis and\ntreatment of PH and the European Reference Network on rare re-\nspiratory diseases (ERN-LUNG) competency requirements, the\nideal number of patients seen by an adult centre each year is no few-\ner than 200, of which at least half have a ﬁnal diagnosis of PAH; a PH\ncentre follows at least 50 patients with PAH or CTEPH and receives\nat least two new referrals per month with documented PAH or\nCTEPH.25,26,837–839 These numbers can be adapted according to\nspeciﬁc country characteristics (small population, large geographical\narea) provided that strong working collaborations are established\nwith high-volume centres. This is currently facilitated by the availabil-\nity of secure virtual platforms (e.g. ERN clinical patient management\nsystem).840\nProper training of staff members includes core competencies, such\nas those outlined in the ERS Pulmonary Vascular Diseases Continuing\nProfessional Development framework,841 and builds on entrustable\nprofessional activities, described in the ESC Core Curriculum.842\nClinical, laboratory, and imaging facilities include: a ward where\nhealth care providers have expertise in PH; a specialist outpatient\nservice; an intermediate/ICU; 24/7 emergency care; an interventional\nradiology unit; diagnostic investigations, including echocardiography,\nCT scanning, nuclear medicine, MRI, exercise tests, and PFTs; a car-\ndiac catheterization laboratory; access to genetic counselling and\ntesting; and fast and easy access to cardiothoracic and vascular sur-\ngery. Key diagnostic procedures are performed in sufﬁcient numbers\nto guarantee expertise (e.g. ERN-LUNG requirements).837 In ana-\nlogy with the ‘advanced heart failure units’,843 PH centres offer the\nfull range of PAH therapies available in their country (including i.v./\ns.c. prostacyclin derivatives) and have early referral protocols to\nCTEPH, LTx, and rehabilitation centres. Since evaluation and early\navailability of new drugs and techniques are critical, PH centres par-\nticipate in collaborative clinical research.\nRegular multidisciplinary team meetings, including core members\nand on-demand invited members (extended multidisciplinary team)\nas needed (Figure 16), are required to establish and adapt individual\npatient care pathways. Case management (co-ordination of individ-\nual patient pathways) should include administrative, social, and care\nsupport. Remote accessibility of the PH centre by phone, mail, or\nother is a vital part of the care. Strategies have to be implemented\nin order to improve health literacy and shared decision-making,\nwith the support of dedicated patient decision tools. Transitioning\nfrom a paediatric PH centre to an adult PH centre requires adequate\nplanning to prevent gaps in care. Involving national and/or inter-\nnational patient associations helps to design patient-centric care\nand to spread medical knowledge among patients and their carers.\nPulmonary hypertension centres should record patients’ data\nusing local, national, or international patient registries, and be able\nto report process indicators (compliance with diagnostic and treat-\nment guidelines, including LTx) and outcome indicators, such as\nWHO-FC, exercise capacity, haemodynamics, quality of life, compli-\ncations, and survival. They should undergo regular audits to assess\nthe quality of delivered care.\n12.2. European Reference Network\nIn 2017, the European Commission launched European Reference\nNetworks (ERNs) for rare diseases that included the ERN-LUNG\nwith a PH core network. European Reference Networks are patient-\ncentred networks of commissioned centres offering guidance and\ncross-border best standard of care in the European Union. The\nPH network includes over 20 full members, contributing each year\n≏1500 new patients with PAH or CTEPH.844 It also includes UK\nsupporting centres, and afﬁliated partners (who do not necessarily\nhave to fulﬁl the minimum competency criteria of the ERN-LUNG\nPH network). The ERN-LUNG requires and monitors standards\nfor these centres.\n12.3. Patient associations and patient\nempowerment\nPulmonary hypertension centres should inform patients about pa-\ntient associations and encourage them to join such groups. Patient\nassociations are a valuable resource for managing patients, as they\nprovide educational and emotional support, and can have positive ef-\nfects on coping, conﬁdence, and outlook.845 It is recommended that\nPH centres collaborate with patient associations on initiatives to\nRecommendation Table 25 — Recommendations for\npulmonary hypertension centres\nRecommendations\nClassa\nLevelb\nIt is recommended that PH centres provide care\nby a multidisciplinary team (cardiologist,\npneumologist, rheumatologist, nurse specialist,\nradiologist, psychological and social work support,\nand appropriate on-call expertise)\nI\nC\nIt is recommended that PH centres have direct\nlinks and quick referral patterns to other services\n(such as genetic counselling, PEA/BPA, LTx, and\nadult congenital heart disease service)\nI\nC\nIt is recommended that PH centres maintain a\npatient registry\nI\nC\nIt is recommended that PH centres collaborate\nwith patient associations\nI\nC\nAccreditation of the PH centres should be\nconsidered (e.g. https://ec.europa.eu/health/ern/\nassessment_en)\nIIa\nC\nPH centres’ participation in collaborative clinical\nresearch should be considered\nIIa\nC\nPH centres should follow-up a sufﬁcient number\nof patients to maintain expertise (at least 50\npatients with PAH or CTEPH and at least two\nnew referrals per month with documented PAH\nor CTEPH), and consider establishing\ncollaborations with high-volume centres\nIIa\nC\n© ESC/ERS 2022\nBPA, balloon pulmonary angioplasty; CTEPH, chronic thrombo-embolic pulmonary\nhypertension; LTx, lung transplantation; PAH, pulmonary arterial hypertension; PEA,\npulmonary endarterectomy; PH, pulmonary hypertension.\naClass of recommendation.\nbLevel of evidence.\n3702\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "genetic",
        "mri",
        "angiography",
        "echocardiography",
        "hypertension",
        "heart failure",
        "definition",
        "should be considered",
        "recommended",
        "pulmonary hypertension",
        "centre",
        "pulmonary",
        "catheterization",
        "exercise"
      ],
      "tables": [
        {
          "title": "3702 ESC/ERS Guidelines",
          "page_number": 84,
          "content": "Recommendations | Classa | Levelb\nIt is recommended that PH centres provide care\nby a multidisciplinary team (cardiologist,\npneumologist, rheumatologist, nurse specialist,\nradiologist, psychological and social work support,\nand appropriate on-call expertise) | I | C\nIt is recommended that PH centres have direct\nlinks and quick referral patterns to other services\n(such as genetic counselling, PEA/BPA, LTx, and\nadult congenital heart disease service) | I | C\nIt is recommended that PH centres maintain a\npatient registry | I | C\nIt is recommended that PH centres collaborate\nwith patient associations | I | C\nAccreditation of the PH centres should be\nconsidered (e.g. https://ec.europa.eu/health/ern/\nassessment en)\n_ | IIa | C\nPH centres’ participation in collaborative clinical\nresearch should be considered | IIa | C\nPH centres should follow-up a sufficient number\nof patients to maintain expertise (at least 50\npatients with PAH or CTEPH and at least two\nnew referrals per month with documented PAH\nor CTEPH), and consider establishing\ncollaborations with high-volume centres | IIa | C",
          "bbox": [
            307.2799835205078,
            84.0009765625,
            547.2799682617188,
            400.99874114990234
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "13. Key messages",
      "start_page": 85,
      "end_page": 86,
      "content": "empower patients and improve the patient experience, addressing\nissues such as health literacy, digital skills, healthy lifestyles, mental\nhealth, and self-management. Health care can be delivered more ef-\nfectively and efﬁciently if patients are full partners in the process.\n13. Key messages\n(1) The haemodynamic deﬁnition of PH has been updated as\nmPAP .20 mmHg. The deﬁnition of PAH also implies a PVR\n.2 WU and PAWP ≤15 mmHg. These cut-off values better\nreﬂect the limits of normal ranges, but do not yet translate\ninto new therapeutic recommendations, since the efﬁcacy of\nPAH therapy in patients with PVD and an mPAP 21–\n24 mmHg and/or PVR 2–3 WU is still unknown.\n(2) The main diagnostic algorithm for PH has been simpliﬁed fol-\nlowing a three-step approach, from suspicion by ﬁrst-line phy-\nsicians, detection by echocardiography, and conﬁrmation with\nRHC in PH centres. Warning signs associated with worse out-\ncomes have been identiﬁed, which justify immediate referral\nand management in PH centres.\n(3) Screening strategies for PAH in patients with SSc and in those at\nrisk of HPAH are proposed based on the results of published\ncohort studies. Their implementation may shorten the time\nfrom symptom onset to diagnosis of PAH.\n(4) An improved recognition of CT and echocardiographic signs of\nCTEPH at the time of an acute PE event, together with a sys-\ntematic follow-up of patients with acute PE, as indicated in\nthe 2019 ESC/ERS Guidelines for the diagnosis and manage-\nment of acute pulmonary embolism, should help to remediate\nthe underdiagnosis of CTEPH.\n(5) The three-strata risk-stratiﬁcation assessment in PAH has been\nreﬁned after being validated in multiple registries. The MRI and\nechocardiographic criteria have been added to the ESC/ERS ta-\nble, reﬁning non-invasive evaluation at diagnosis.\n(6) A four-strata risk stratiﬁcation, dividing the large, intermediate-risk\ngroup into intermediate–low and intermediate–high risk, is pro-\nposed at follow-up.\n(7) The treatment algorithm for PAH has been simpliﬁed, with a\nclear focus on risk assessment, cardiopulmonary comorbidities,\nand treatment goals. Initial combination therapy and treatment\nescalation at follow-up when appropriate are current standards.\n(8) The Task Force has attempted to close the gap between paedi-\natric and adult PAH care, with therapeutic and follow-up strat-\negies based on risk stratiﬁcation and treatment response,\nextrapolated from that in adults but adapted for age.\n(9) The recommendations on sex-related issues in patients with\nPAH, including pregnancy, have been updated, with information\nand shared decision-making as key points.\n(10) The recommendations for rehabilitation and exercise pro-\ngrammes in PH have been updated following the release of add-\nitional supportive evidence.\n(11) For the ﬁrst time, there is a recommendation for PH medical\ntherapy in group 3 PH, based on a single positive RCT in pa-\ntients with ILD.\n(12) The concept of CTEPD with or without PH has been intro-\nduced, enabling further research on the natural history and\nmanagement in the absence of PH.\n(13) The treatment algorithm for CTEPH has been modiﬁed, includ-\ning multimodal therapy with surgery, PH drugs, and BPA.\n14. Gaps in evidence\n14.1. Pulmonary arterial hypertension\n(group 1)\n• The efﬁcacy and safety of PAH drugs in group 1 patients with an\nmPAP 21–24 mmHg, PVR 2–3 WU, and exercise PH has to be\nestablished.\n• The role of PAH drugs in different PAH subgroups, including\nschistosomiasis-associated PAH, needs to be explored.\n• Risk-stratiﬁcation assessment in PAH needs to be further pro-\nspectively validated through goal-orientated outcome studies,\nand optimized for patients with PAH and comorbidities.\n• New PAH phenotypes observed in patients with signiﬁcant cardio-\npulmonary comorbidities are common and should be the focus of\nmore research.\n• The importance of PAH patient phenotypes and the relevance of\ncomorbidities on treatment goals and outcomes must be further\nevaluated.\n• The impact of PAH therapies and treatment strategies on survival\nneeds to be further assessed.\n• Pulmonary arterial hypertension drugs targeting novel pathways\nare emerging and the impact of add-on use of this medication\non outcomes has to be evaluated in RCTs.\n• The role of RV imaging techniques (echocardiography, cMRI) in\ndiagnosing and stratifying risk in PAH needs to be further studied.\nThe proposed cut-off values for risk stratiﬁcation need to be prop-\nerly validated in multicentre studies.\n• The role of CPET in the early diagnosis of PAH in populations at\nrisk of developing PAH, and in assessing prognosis in PAH on\ntop of clinical and haemodynamic data, needs further investigation.\n• The role of exercise echocardiography and exercise RHC in pa-\ntients at risk of developing PAH, with abnormal CPET but normal\nrest echocardiogram, also needs further evaluation.\n• The use of mechanical circulatory support, particularly in revers-\nible PH or in patients with advanced right HF with an exit strategy\n(such as LTx), has to be further studied.\n• Differences in natural history and treatment response between\nadults and children should be further investigated.\n• Further studies are needed on the effects of PADN in PAH and in\nother PH groups.\n• The impact of centre volume, organization, and expertise on treat-\nment outcome needs further investigation.\n14.2. Pulmonary hypertension associated\nwith left heart disease (group 2)\n• The management of patients with group 2 PH needs further study\nwith RCTs.\n• Additional research is needed to facilitate non-invasive diagnosis of\nHFpEF-associated PH and distinguishing it from PAH.\n• The role of ﬂuid challenge and exercise testing to reveal left HF\nneeds further validation.\nESC/ERS Guidelines\n3703\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "hfpef",
        "messages",
        "mri",
        "echocardiography",
        "hypertension",
        "age",
        "pulmonary hypertension",
        "pulmonary embolism",
        "sex",
        "exercise"
      ],
      "tables": [
        {
          "title": "3704 ESC/ERS Guidelines",
          "page_number": 86,
          "content": "Recommendations |  | Classa | Levelb | \nRecommendations for right heart catheterization and vasoreactivity testing |  |  |  | \nRight heart catheterization |  |  |  | \nIt is recommended that RHC is performed to confirm the diagnosis of PH (especially PAH or CTEPH) and to support treatment\ndecisions |  | I | B | \nIn patients with suspected or known PH, it is recommended that RHC is performed in experienced centres |  | I | C | \nIt is recommended that RHC comprises a complete set of haemodynamics and is performed following standardized protocols |  | I | C | \n | Vasoreactivity testing |  |  | \nVasoreactivity testing is recommended in patients with I/H/DPAH to detect those who can be treated with high doses of a CCB |  | I | B | \nIt is recommended that vasoreactivity testing is performed at PH centres |  | I | C | \nIt is recommended to consider a positive response to vasoreactivity testing by a reduction in mPAP ≥10 mmHg to reach an absolute\nvalue of mPAP ≤40 mmHg with an increased or unchanged COc |  | I | C | \nInhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol are recommended for performing vasoreactivity testing |  | I | C | \nVasoreactivity testing, for identifying candidates for CCB therapy, is not recommended in patients with PAH other than I/H/DPAH and\nin PH groups 2, 3, 4, and 5 |  | III | C | ",
          "bbox": [
            42.999593098958336,
            467.5,
            547.2750203450521,
            738.1535089666194
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "14. Gaps in evidence",
      "start_page": 85,
      "end_page": 86,
      "content": "empower patients and improve the patient experience, addressing\nissues such as health literacy, digital skills, healthy lifestyles, mental\nhealth, and self-management. Health care can be delivered more ef-\nfectively and efﬁciently if patients are full partners in the process.\n13. Key messages\n(1) The haemodynamic deﬁnition of PH has been updated as\nmPAP .20 mmHg. The deﬁnition of PAH also implies a PVR\n.2 WU and PAWP ≤15 mmHg. These cut-off values better\nreﬂect the limits of normal ranges, but do not yet translate\ninto new therapeutic recommendations, since the efﬁcacy of\nPAH therapy in patients with PVD and an mPAP 21–\n24 mmHg and/or PVR 2–3 WU is still unknown.\n(2) The main diagnostic algorithm for PH has been simpliﬁed fol-\nlowing a three-step approach, from suspicion by ﬁrst-line phy-\nsicians, detection by echocardiography, and conﬁrmation with\nRHC in PH centres. Warning signs associated with worse out-\ncomes have been identiﬁed, which justify immediate referral\nand management in PH centres.\n(3) Screening strategies for PAH in patients with SSc and in those at\nrisk of HPAH are proposed based on the results of published\ncohort studies. Their implementation may shorten the time\nfrom symptom onset to diagnosis of PAH.\n(4) An improved recognition of CT and echocardiographic signs of\nCTEPH at the time of an acute PE event, together with a sys-\ntematic follow-up of patients with acute PE, as indicated in\nthe 2019 ESC/ERS Guidelines for the diagnosis and manage-\nment of acute pulmonary embolism, should help to remediate\nthe underdiagnosis of CTEPH.\n(5) The three-strata risk-stratiﬁcation assessment in PAH has been\nreﬁned after being validated in multiple registries. The MRI and\nechocardiographic criteria have been added to the ESC/ERS ta-\nble, reﬁning non-invasive evaluation at diagnosis.\n(6) A four-strata risk stratiﬁcation, dividing the large, intermediate-risk\ngroup into intermediate–low and intermediate–high risk, is pro-\nposed at follow-up.\n(7) The treatment algorithm for PAH has been simpliﬁed, with a\nclear focus on risk assessment, cardiopulmonary comorbidities,\nand treatment goals. Initial combination therapy and treatment\nescalation at follow-up when appropriate are current standards.\n(8) The Task Force has attempted to close the gap between paedi-\natric and adult PAH care, with therapeutic and follow-up strat-\negies based on risk stratiﬁcation and treatment response,\nextrapolated from that in adults but adapted for age.\n(9) The recommendations on sex-related issues in patients with\nPAH, including pregnancy, have been updated, with information\nand shared decision-making as key points.\n(10) The recommendations for rehabilitation and exercise pro-\ngrammes in PH have been updated following the release of add-\nitional supportive evidence.\n(11) For the ﬁrst time, there is a recommendation for PH medical\ntherapy in group 3 PH, based on a single positive RCT in pa-\ntients with ILD.\n(12) The concept of CTEPD with or without PH has been intro-\nduced, enabling further research on the natural history and\nmanagement in the absence of PH.\n(13) The treatment algorithm for CTEPH has been modiﬁed, includ-\ning multimodal therapy with surgery, PH drugs, and BPA.\n14. Gaps in evidence\n14.1. Pulmonary arterial hypertension\n(group 1)\n• The efﬁcacy and safety of PAH drugs in group 1 patients with an\nmPAP 21–24 mmHg, PVR 2–3 WU, and exercise PH has to be\nestablished.\n• The role of PAH drugs in different PAH subgroups, including\nschistosomiasis-associated PAH, needs to be explored.\n• Risk-stratiﬁcation assessment in PAH needs to be further pro-\nspectively validated through goal-orientated outcome studies,\nand optimized for patients with PAH and comorbidities.\n• New PAH phenotypes observed in patients with signiﬁcant cardio-\npulmonary comorbidities are common and should be the focus of\nmore research.\n• The importance of PAH patient phenotypes and the relevance of\ncomorbidities on treatment goals and outcomes must be further\nevaluated.\n• The impact of PAH therapies and treatment strategies on survival\nneeds to be further assessed.\n• Pulmonary arterial hypertension drugs targeting novel pathways\nare emerging and the impact of add-on use of this medication\non outcomes has to be evaluated in RCTs.\n• The role of RV imaging techniques (echocardiography, cMRI) in\ndiagnosing and stratifying risk in PAH needs to be further studied.\nThe proposed cut-off values for risk stratiﬁcation need to be prop-\nerly validated in multicentre studies.\n• The role of CPET in the early diagnosis of PAH in populations at\nrisk of developing PAH, and in assessing prognosis in PAH on\ntop of clinical and haemodynamic data, needs further investigation.\n• The role of exercise echocardiography and exercise RHC in pa-\ntients at risk of developing PAH, with abnormal CPET but normal\nrest echocardiogram, also needs further evaluation.\n• The use of mechanical circulatory support, particularly in revers-\nible PH or in patients with advanced right HF with an exit strategy\n(such as LTx), has to be further studied.\n• Differences in natural history and treatment response between\nadults and children should be further investigated.\n• Further studies are needed on the effects of PADN in PAH and in\nother PH groups.\n• The impact of centre volume, organization, and expertise on treat-\nment outcome needs further investigation.\n14.2. Pulmonary hypertension associated\nwith left heart disease (group 2)\n• The management of patients with group 2 PH needs further study\nwith RCTs.\n• Additional research is needed to facilitate non-invasive diagnosis of\nHFpEF-associated PH and distinguishing it from PAH.\n• The role of ﬂuid challenge and exercise testing to reveal left HF\nneeds further validation.\nESC/ERS Guidelines\n3703\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "hfpef",
        "mri",
        "echocardiography",
        "hypertension",
        "age",
        "pulmonary hypertension",
        "pulmonary embolism",
        "gaps",
        "evidence",
        "sex",
        "exercise"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "15. ‘What to do’ and ‘What not to do’ messages from the Guidelines",
      "start_page": 86,
      "end_page": 93,
      "content": "• Further studies focusing on PDE5is in patients with HFpEF and a\nCpcPH phenotype are needed and currently underway.\n• The effects that new HF medication (ARNIs, SGLT-2is) has on PH,\nthrough reverse remodelling of the LV, need further investigation.\n14.3. Pulmonary hypertension associated\nwith lung diseases and/or hypoxia\n(group 3)\n• The management of patients with group 3 PH has to be further\nstudied in RCTs.\n• Reﬁning phenotypes will be crucial, as this will inform development\nof trials.\n• Clinical relevance and therapeutic implications of severe PH in lung\ndisease need to be investigated.\n• Long-term data on the effects of inhaled treprostinil (and other\nPAH drugs) in patients with PH associated with lung disease are\nneeded.\n• The impact of the hypobaric and hypoxic environment of the .150\nmillion people living at .2500 m altitude has tobe clariﬁed, and studies\nneed to be performed to assess potential treatment strategies for PH.\n14.4. Chronic thrombo-embolic\npulmonary hypertension (group 4)\n• The differentiation between acute and chronic PE in imaging\n(CTPA) has to be improved.\n• In patients with suspected CTEPH, the diagnostic role of DECT or\niodine subtraction mapping vs. V/Q lung scintigraphy has to be\nvalidated.\n• The effect of drug therapy on the outcome of patients with\nCTEPH needs to be established.\n• The treatment goals in patients with CTEPH have to be clariﬁed, as\nit is still unclear if normalizing mPAP and PVR translates into im-\nproved outcomes.\n• The role of BPA vs. PEA should be further clariﬁed: which treat-\nment in which patient? Are they equivalent for the treatment of\nsegmental/subsegmental disease?\n• In inoperable CTEPH or persistent/recurrent PH after PEA, the\npotential role of combination therapy of PH drugs must be\nassessed.\n• The role of medical treatments as bridges to interventional and op-\nerative treatments needs to be formally tested.\n• Randomized controlled trials are needed to discriminate the ef-\nfects of PEA and early follow-up rehabilitation.\n• The effect of PEA, BPA, and medical therapy on patients with\nCTEPD without PH is not established.\n14.5. Pulmonary hypertension with\nunclear and/or multifactorial\nmechanisms (group 5)\n• Further research needs to inform management of group 5 PH,\nsuch as SCD-associated PH and sarcoidosis-associated PH.\n15. ‘What to do’ and ‘What not to do’ messages from the Guidelines\nRecommendations\nClassa\nLevelb\nRecommendations for right heart catheterization and vasoreactivity testing\nRight heart catheterization\nIt is recommended that RHC is performed to conﬁrm the diagnosis of PH (especially PAH or CTEPH) and to support treatment\ndecisions\nI\nB\nIn patients with suspected or known PH, it is recommended that RHC is performed in experienced centres\nI\nC\nIt is recommended that RHC comprises a complete set of haemodynamics and is performed following standardized protocols\nI\nC\nVasoreactivity testing\nVasoreactivity testing is recommended in patients with I/H/DPAH to detect those who can be treated with high doses of a CCB\nI\nB\nIt is recommended that vasoreactivity testing is performed at PH centres\nI\nC\nIt is recommended to consider a positive response to vasoreactivity testing by a reduction in mPAP ≥10 mmHg to reach an absolute\nvalue of mPAP ≤40 mmHg with an increased or unchanged COc\nI\nC\nInhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol are recommended for performing vasoreactivity testing\nI\nC\nVasoreactivity testing, for identifying candidates for CCB therapy, is not recommended in patients with PAH other than I/H/DPAH and\nin PH groups 2, 3, 4, and 5\nIII\nC\nContinued\n3704\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nRecommendations for diagnostic strategy\nEchocardiography\nEchocardiography is recommended as the ﬁrst-line, non-invasive, diagnostic investigation in suspected PH\nI\nB\nIt is recommended to assign an echocardiographic probability of PH, based on an abnormal TRV and the presence of other\nechocardiographic signs suggestive of PH (see Table 10)\nI\nB\nIt is recommended to maintain the current threshold for TRV (.2.8 m/s) for echocardiographic probability of PH according to the\nupdated haemodynamic deﬁnition\nI\nC\nImaging\nVentilation/perfusion or perfusion lung scan is recommended in patients with unexplained PH to assess for CTEPH\nI\nC\nCT pulmonary angiography is recommended in the work-up of patients with suspected CTEPH\nI\nC\nRoutine biochemistry, haematology, immunology, HIV testing, and thyroid function tests are recommended in all patients with PAH, to\nidentify associated conditions\nI\nC\nAbdominal ultrasound is recommended for the screening of portal hypertension\nI\nC\nOther diagnostic tests\nPulmonary function tests with DLCO are recommended in the initial evaluation of patients with PH\nI\nC\nOpen or thoracoscopic lung biopsy is not recommended in patients with PAH\nIII\nC\nRecommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic\npulmonary hypertension\nSystemic sclerosis\nIn patients with SSc, an annual evaluation of the risk of having PAH is recommended\nI\nB\nIn adult patients with SSc with .3 years’ disease duration, an FVC ≥40%, and a DLCO ,60%, the DETECT algorithm is recommended\nto identify asymptomatic patients with PAH\nI\nB\nIn patients with SSc, where breathlessness remains unexplained following non-invasive assessment, RHC is recommended to exclude\nPAH\nI\nC\nCTEPH/CTEPD\nIn patients with persistent or new-onset dyspnoea or exercise limitation following PE, further diagnostic evaluation to assess for\nCTEPH/CTEPD is recommended\nI\nC\nFor symptomatic patients with mismatched perfusion lung defects beyond 3 months of anticoagulation for acute PE, referral to a PH/\nCTEPH centre is recommended after considering the results of echocardiography, BNP/NT-proBNP, and/or CPET\nI\nC\nOther\nCounselling regarding the risk of PAH and annual screening are recommended in individuals who test positive for PAH-causing\nmutations and in ﬁrst-degree relatives of patients with HPAH\nI\nB\nIn patients referred for liver transplantation, echocardiography is recommended as a screening test for PH\nI\nC\nRecommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension\nIt is recommended to evaluate disease severity in patients with PAH with a panel of data derived from clinical assessment, exercise tests,\nbiochemical markers, echocardiography, and haemodynamic evaluations\nI\nB\nAchieving and maintaining a low-risk proﬁle on optimized medical therapy is recommended as a treatment goal in patients with PAH\nI\nB\nFor risk stratiﬁcation at the time of diagnosis, the use of a three-strata model (low, intermediate, and high risk) is recommended, taking\ninto account all available data including haemodynamics\nI\nB\nFor risk stratiﬁcation during follow-up, the use of a four-strata model (low, intermediate–low, intermediate–high, and high risk) based on\nWHO-FC, 6MWD, and BNP/NT-proBNP is recommended, with additional variables taken into account as necessary\nI\nB\nContinued\nESC/ERS Guidelines\n3705\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nRecommendations for general measures and special circumstances\nGeneral measures\nSupervised exercise training is recommended in patients with PAH under medical therapy\nI\nA\nPsychosocial support is recommended in patients with PAH\nI\nC\nImmunization of patients with PAH against SARS-CoV-2, inﬂuenza, and Streptococcus pneumoniae is recommended\nI\nC\nDiuretic treatment is recommended in patients with PAH with signs of RV failure and ﬂuid retention\nI\nC\nLong-term oxygen therapy is recommended in patients with PAH whose arterial blood oxygen pressure is ,8 kPa (60 mmHg)d\nI\nC\nIn the presence of iron-deﬁciency anaemia, correction of iron status is recommended in patients with PAH\nI\nC\nThe use of ACEis, ARBs, ARNIs, SGLT-2is, beta-blockers, or ivabradine is not recommended in patients with PAH unless required by\ncomorbidities (i.e. high blood pressure, coronary artery disease, left HF, or arrhythmias)\nIII\nC\nSpecial circumstances\nIn-ﬂight oxygen administration is recommended for patients using oxygen or whose arterial blood oxygen pressure is ,8 kPa\n(60 mmHg) at sea level\nI\nC\nRecommendations for women of childbearing potential\nIt is recommended that women of childbearing potential with PAH are counselled at the time of diagnosis about the risks and\nuncertainties associated with becoming pregnant; this should include advice against becoming pregnant, and referral for psychological\nsupport where needed\nI\nC\nIt is recommended to provide women of childbearing potential with PAH with clear contraceptive advice, considering the individual\nneeds of the woman but recognizing that the implications of contraceptive failure are signiﬁcant in PAH\nI\nC\nIt is recommended that women with PAH who consider pregnancy or who become pregnant receive prompt counselling in an\nexperienced PH centre, to facilitate genetic counselling and shared decision-making, and to provide psychological support to the patients\nand their families where needed\nI\nC\nFor women with PAH having termination of pregnancy, it is recommended that this be performed in PH centres, with psychological\nsupport provided to the patients and their families\nI\nC\nAs teratogenic potential has been reported in pre-clinical models for endothelin receptor antagonists and riociguat, these drugs are not\nrecommended during pregnancy\nIII\nB\nRecommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial\nhypertension\nHigh doses of CCBs are recommended in patients with IPAH, HPAH, or DPAH who are responders to acute vasoreactivity testing\nI\nC\nClose follow-up with complete reassessment after 3–4 months of therapy (including RHC) is recommended in patients with IPAH,\nHPAH, or DPAH treated with high doses of CCBs\nI\nC\nContinuing high doses of CCBs is recommended in patients with IPAH, HPAH, or DPAH in WHO-FC I or II with marked\nhaemodynamic improvement (mPAP ,30 mmHg and PVR ,4 WU)\nI\nC\nInitiating PAH therapy is recommended in patients who remain in WHO-FC III or IV or those without marked haemodynamic\nimprovement after high doses of CCBs\nI\nC\nCCBs are not recommended in patients without a vasoreactivity study or non-responders, unless prescribed for other indications (e.g.\nRaynaud’s phenomenon)\nIII\nC\nRecommendations for initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary\narterial hypertension without cardiopulmonary comorbiditiese\nInitial combination therapy with ambrisentan and tadalaﬁl is recommended\nI\nB\nInitial combination therapy with macitentan and tadalaﬁl is recommended\nI\nB\nInitial combination therapy with macitentan, tadalaﬁl, and selexipag is not recommended\nIII\nB\nContinued\n3706\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nRecommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary\narterial hypertension\nGeneral recommendation for sequential combination therapy\nIt is recommended to base treatment escalations on risk assessment and general treatment strategies (see treatment algorithm)\nI\nC\nEvidence from studies with a composite morbidity/mortality endpoint as the primary outcome measure\nThe addition of macitentan to PDE5is or oral/inhaled prostacyclin analogues is recommended to reduce the risk of morbidity/mortality\nevents\nI\nB\nThe addition of selexipag to ERAsf and/or PDE5is is recommended to reduce the risk of morbidity/mortality events\nI\nB\nThe addition of oral treprostinil to ERA or PDE5i/riociguat monotherapy is recommended to reduce the risk of morbidity/mortality\nevents\nI\nB\nThe addition of bosentan to sildenaﬁl is not recommended to reduce the risk of morbidity/mortality events\nIII\nB\nEvidence from studies with change in 6MWD as the primary outcome measure\nThe addition of sildenaﬁl to epoprostenol is recommended to improve exercise capacity\nI\nB\nEvidence from studies with safety of combination therapy as primary outcome measure\nCombining riociguat and PDE5is is not recommendedg\nIII\nB\nRecommendations for intensive care management for pulmonary arterial hypertension\nWhen managing patients with right HF in the ICU, it is recommended to involve physicians with expertise, treat causative factors, and\nuse supportive measures, including inotropes and vasopressors, ﬂuid management, and PAH drugs, as appropriate\nI\nC\nRecommendations for lung transplantation\nIt is recommended that potentially eligible candidates are referred for LTx evaluation when they have an inadequate response to oral\ncombination therapy, indicated by an intermediate–high or high risk or by a REVEAL risk score .7\nI\nC\nIt is recommended to list patients for LTx who present with a high risk of death or with a REVEAL risk score ≥10 despite receiving\noptimized medical therapy including s.c. or i.v. prostacyclin analogues\nI\nC\nRecommendations for pulmonary arterial hypertension associated with drugs or toxins\nIt is recommended to make a diagnosis of drug- or toxin-associated PAH in patients who had relevant exposure and in whom other\ncauses of PH have been excluded\nI\nC\nIn patients with suspected drug- or toxin-associated PAH, it is recommended to immediately discontinue the causative agent whenever\npossible\nI\nC\nRecommendations for pulmonary arterial hypertension associated with connective tissue disease\nIn patients with PAH associated with CTD, treatment of the underlying condition according to current guidelines is recommended\nI\nA\nIn patients with PAH associated with CTD, the same treatment algorithm as for patients with IPAH is recommended\nI\nC\nRecommendations for pulmonary arterial hypertension associated with human immunodeﬁciency virus infection\nIn patients with PAH associated with HIV infection, antiretroviral treatment according to current guidelines is recommended\nI\nA\nRecommendations for pulmonary arterial hypertension associated with portal hypertension\nEchocardiography is recommended in patients with liver disease or portal hypertension with signs or symptoms suggestive of PH, and as\na screening tool in patients evaluated for liver transplantation or transjugular portosystemic shunt\nI\nC\nIt is recommended that patients with PAH associated with portal hypertension are referred to centres with expertise in managing both\nconditions\nI\nC\nDrugs approved for PAH are not recommended for patients with portal hypertension and unclassiﬁed PH (i.e. elevated mPAP, high CO,\nand a normal PVR)\nIII\nC\nContinued\nESC/ERS Guidelines\n3707\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nRecommendations for shunt closure in patients with pulmonary-systemic ﬂow ratio .1.5:1 based on calculated pulmonary vascular\nresistance\nIn patients with an ASD, VSD, or PDA and a PVR ,3 WU, shunt closure is recommended\nI\nC\nIn patients with an ASD and a PVR .5 WU despite PAH treatment, shunt closure is not recommended\nIII\nC\nRecommendations for pulmonary arterial hypertension associated with adult congenital heart disease\nRisk assessment\nRisk assessment is recommended for patients with persistent PAH after defect closure\nI\nC\nTreatment\nBosentan is recommended in symptomatic patients with Eisenmenger syndrome to improve exercise capacity\nI\nB\nIn women with Eisenmenger syndrome, pregnancy is not recommended\nIII\nC\nIn patients with Eisenmenger syndrome, routine phlebotomy to lower elevated haematocrit is not recommended\nIII\nC\nRecommendations for pulmonary arterial hypertension with signs of venous/capillary involvement\nA combination of clinical and radiological ﬁndings, ABG, PFTs, and genetic testing is recommended to diagnose PAH with signs of venous\nand/or capillary involvement (PVOD/PCH)\nI\nA\nIdentiﬁcation of biallelic EIF2AK4 mutations is recommended to conﬁrm a diagnosis of heritable PVOD/PCH\nI\nA\nReferral of eligible patients with PVOD/PCH to a transplant centre for evaluation is recommended as soon as the diagnosis is established\nI\nC\nLung biopsy is not recommended to conﬁrm a diagnosis of PVOD/PCH\nIII\nC\nRecommendations for paediatric pulmonary hypertension\nChildren\nIt is recommended to perform the diagnostic work-up, including RHC and acute vasoreactivity testing, and treat children with PH at\ncentres with speciﬁc expertise in paediatric PH\nI\nC\nIn children with PH, a comprehensive work-up for conﬁrming diagnosis and speciﬁc aetiology is recommended (similar to that in adults,\nbut adapted for age)\nI\nC\nFor conﬁrming PH diagnosis, RHC is recommended, preferably before initiating any PAH therapy\nI\nC\nIn children with IPAH/HPAH, acute vasoreactivity testing is recommended to detect those who may beneﬁt from CCB therapy\nI\nC\nIt is recommended to similarly deﬁne a positive response to acute vasoreactivity testing in children and adults by a reduction in mPAP\n≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg, with an increased or unchanged CO\nI\nC\nIn children with PAH, a therapeutic strategy based on risk stratiﬁcation and treatment response is recommended, extrapolated from\nthat in adults, but adapted for age\nI\nC\nIt is recommended to monitor the treatment response in children with PAH by serially assessing a panel of data derived from clinical\nassessment, echocardiographic evaluation, biochemical markers, and exercise tolerance tests\nI\nC\nInfants\nIt is recommended to screen infants with bronchopulmonary dysplasia for PH\nI\nB\nIn infants with (or at risk of) bronchopulmonary dysplasia and PH, treating lung disease—including hypoxia, aspiration, and structural\nairway disease—and optimizing respiratory support is recommended before initiating PAH therapy\nI\nB\nRecommendations for pulmonary hypertension associated with left heart disease\nIn patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of\nsuspected PH\nI\nA\nRHC is recommended for suspected PH in patients with LHD, if it aids management decisions\nI\nC\nContinued\n3708\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nRHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair\nI\nC\nFor patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral\nto a PH centre for a complete diagnostic work-up is recommended\nI\nC\nIn patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is\nrecommended\nI\nC\nWhen patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or\nﬂuid challenge, are treated with PAH drugs, close monitoring is recommended\nI\nC\nDrugs approved for PAH are not recommended in PH-LHDh\nIII\nA\nRecommendations for pulmonary hypertension associated with lung disease and/or hypoxia\nIf PH is suspected in patients with lung disease, it is recommended that echocardiographyi be performed and results interpreted in\nconjunction with ABG, PFTs including DLCO, and CT imaging\nI\nC\nIn patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where\nindicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation\nI\nC\nIn patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH\ncentre is recommendedj\nI\nC\nIn patients with lung disease and severe PH, an individualized approach to treatment is recommended\nI\nC\nIt is recommended to refer eligible patients with lung disease and PH for LTx evaluation\nI\nC\nIn patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions\nI\nC\nThe use of ambrisentan is not recommended in patients with PH associated with IPF\nIII\nB\nThe use of riociguat is not recommended in patients with PH associated with IIP\nIII\nB\nThe use of PAH medication is not recommended in patients with lung disease and non-severe PHk\nIII\nC\nRecommendations for chronic thrombo-embolic pulmonary hypertension and chronic thrombo-embolic pulmonary disease without\npulmonary hypertension\nCTEPH\nLifelong, therapeutic doses of anticoagulation are recommended in all patients with CTEPH\nI\nC\nAntiphospholipid syndrome testing is recommended in patients with CTEPH\nI\nC\nIn patients with CTEPH and antiphospholipid syndrome, anticoagulation with VKAs is recommended\nI\nC\nIt is recommended that all patients with CTEPH are reviewed by a CTEPH team for the assessment of multimodality management\nI\nC\nPEA is recommended as the treatment of choice for patients with CTEPH and ﬁbrotic obstructions within pulmonary arteries accessible\nby surgery\nI\nB\nBPA is recommended in patients who are technically inoperable or have residual PH after PEA and distal obstructions amenable to BPA\nI\nB\nRiociguat is recommended for symptomatic patients with inoperable CTEPH or persistent/recurrent PH after PEA\nI\nB\nLong-term follow-up is recommended after PEA and BPA, as well as for patients with CTEPH established on medical therapy\nI\nC\nRecommendations for pulmonary hypertension centres\nIt is recommended that PH centres provide care by a multidisciplinary team (cardiologist, pneumologist, rheumatologist, nurse specialist,\nradiologist, psychological and social work support, appropriate on-call expertise)\nI\nC\nIt is recommended that PH centres have direct links and quick referral patterns to other services (such as genetic counselling, PEA/BPA,\nLTx, adult congenital heart disease service)\nI\nC\nContinued\nESC/ERS Guidelines\n3709\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n16. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.847 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations through associated quality-improvement initia-\ntives and benchmarking of care providers.848,849 As such, the role\nof QIs in improving care and outcomes for cardiovascular disease\nis increasingly being recognized by health care authorities, profes-\nsional organizations, payers, and the public.847\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established\nmethods for developing the ESC QIs for the quantiﬁcation of care\nand outcomes for cardiovascular diseases.847 To date, the ESC has\ndeveloped QI suites for a number of cardiovascular diseases850–852\nand embedded these in respective ESC Clinical Practice guide-\nlines.27,477,853,854 Furthermore, the ESC aims to integrate its QIs\nwith clinical registries such as the EurObservational Research\nProgramme and the European Uniﬁed Registries On Heart Care\nEvaluation and Randomized Trials (EuroHeart) project855 to provide\nreal-world data about the patterns and outcomes of care for cardio-\nvascular disease across Europe.\nIn parallel with the writing of this Clinical Practice Guideline, a pro-\ncess has been initiated to develop QIs for patients with PH using the\nIt is recommended that PH centres maintain a patient registry\nI\nC\nIt is recommended that PH centres collaborate with patient associations\nI\nC\n© ESC/ERS 2022\n6MWD, 6-minute walking distance; ABG, arterial blood gas analysis; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–\nneprilysin inhibitor; ASD, atrial septal defect; BNP/NT-proBNP, brain natriuretic peptide/N-terminal pro-brain natriuretic peptide; BPA, balloon pulmonary angioplasty; CCB,\ncalcium channel blocker; CpcPH, combined post- and pre-capillary pulmonary hypertension; CPET, cardiopulmonary exercise testing; CT, computed tomography; CTD, connective\ntissue disease; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon\nmonoxide; DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; FVC, forced vital capacity; HF, heart failure; HFpEF, heart failure with\npreserved ejection fraction; HIV, human immunodeﬁciency virus; HPAH, heritable pulmonary arterial hypertension; ICU, intensive care unit; I/H/DPAH, idiopathic, heritable,\ndrug-associated pulmonary arterial hypertension; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; IPF, idiopathic\npulmonary ﬁbrosis; i.v., intravenous; LHD, left heart disease; LTx, lung transplantation; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PAWP,\npulmonary arterial wedge pressure; PCH, pulmonary capillary haemangiomatosis; PDA, patent ductus arteriosus; PDE5i, phosphodiesterase 5 inhibitor; PE, pulmonary embolism;\nPEA, pulmonary endarterectomy; PFTs, pulmonary function tests; PH, pulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVOD,\npulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right ventricular; s.c., subcutaneous; SGLT-2i, sodium–glucose\ncotransporter-2 inhibitor; SSc, systemic sclerosis; TRV, tricuspid regurgitation velocity; VKA, vitamin K antagonist; VSD, ventricular septal defect; WHO-FC, World Health\nOrganization functional class; WU, Wood units.\naClass of recommendation.\nbLevel of evidence.\ncTesting should also be performed in patients with a baseline mPAP ≤40 mmHg, in whom the same responder criteria apply.\ndMeasured on at least two occasions.\neCardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF such as obesity, diabetes, coronary heart disease, a history of\nhypertension, and/or a low DLCO.\nfERA used in the GRIPHON study were bosentan and ambrisentan.\ngThe PATENT plus study investigated the combination of sildenaﬁl and riociguat; however, combining riociguat with any PDE5i is contraindicated.\nhSafety concerns have been identiﬁed when ERAs are used in patients with HF (HFpEF and HFrEF, with or without PH) and when sildenaﬁl is used in patients with persistent PH after\ncorrection of valvular heart disease.\niAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise pulmonary artery pressure.\njThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.\nkThis does not include inhaled treprostinil, which may be considered in patients with PH associated with ILD irrespective of PH severity.\n‘What to do’ and ‘What not to do’ messages developed with GRADE Evidence to Decision framework\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nIn patients with IPAH/HPAH/DPAH who present at low or intermediate risk of\ndeath, initial combination therapy with a PDE5i and an ERA is recommended\nLow\nConditional\nI\nB\nThe use of PDE5i in patients with HFpEF and isolated post-capillary PH is not\nrecommended\nLow\nConditional\nIII\nC\nThe use of PDE5i in patients with ILD and non-severe PH is not recommended\nVery low\nConditional\nIII\nC\n© ESC/ERS 2022\nDPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; HPAH, heritable pulmonary arterial hypertension; HFpEF, heart failure with preserved\nejection fraction; ILD, interstitial lung disease; PDE5i, phosphodiesterase 5 inhibitor; PH, pulmonary hypertension.\naClass of recommendation.\nbLevel of evidence.\n3710\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "elderly",
        "angiography",
        "blood pressure",
        "heart failure",
        "recommended",
        "what",
        "pulmonary hypertension",
        "hfref",
        "hfpef",
        "glucose",
        "scd",
        "valve repair",
        "anticoagulation",
        "hypertension",
        "bnp",
        "echocardiography",
        "guidelines",
        "coronary artery",
        "obesity",
        "nt-probnp",
        "arb",
        "may be considered",
        "tricuspid",
        "catheterization",
        "genetic",
        "guideline",
        "messages",
        "calcium channel",
        "ejection fraction",
        "diabetes"
      ],
      "tables": [
        {
          "title": "ESC/ERS Guidelines 3705",
          "page_number": 87,
          "content": "Recommendations for diagnostic strategy |  |  |  | \nEchocardiography |  |  |  | \nEchocardiography is recommended as the first-line, non-invasive, diagnostic investigation in suspected PH |  | I | B | \nIt is recommended to assign an echocardiographic probability of PH, based on an abnormal TRV and the presence of other\nechocardiographic signs suggestive of PH (see Table 10) |  | I | B | \nIt is recommended to maintain the current threshold for TRV (.2.8 m/s) for echocardiographic probability of PH according to the\nupdated haemodynamic definition |  | I | C | \n | Imaging |  |  | \nVentilation/perfusion or perfusion lung scan is recommended in patients with unexplained PH to assess for CTEPH |  | I | C | \nCT pulmonary angiography is recommended in the work-up of patients with suspected CTEPH |  | I | C | \nRoutine biochemistry, haematology, immunology, HIV testing, and thyroid function tests are recommended in all patients with PAH, to\nidentify associated conditions |  | I | C | \nAbdominal ultrasound is recommended for the screening of portal hypertension |  | I | C | \n | Other diagnostic tests |  |  | \nPulmonary function tests with DLCO are recommended in the initial evaluation of patients with PH |  | I | C | \nOpen or thoracoscopic lung biopsy is not recommended in patients with PAH |  | III | C | \nRecommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic\npulmonary hypertension |  |  |  | \n | Systemic sclerosis |  |  | \nIn patients with SSc, an annual evaluation of the risk of having PAH is recommended |  | I | B | \nIn adult patients with SSc with .3 years’ disease duration, an FVC ≥40%, and a DLCO ,60%, the DETECT algorithm is recommended\nto identify asymptomatic patients with PAH |  | I | B | \nIn patients with SSc, where breathlessness remains unexplained following non-invasive assessment, RHC is recommended to exclude\nPAH |  | I | C | \n | CTEPH/CTEPD |  |  | \nIn patients with persistent or new-onset dyspnoea or exercise limitation following PE, further diagnostic evaluation to assess for\nCTEPH/CTEPD is recommended |  | I | C | \nFor symptomatic patients with mismatched perfusion lung defects beyond 3 months of anticoagulation for acute PE, referral to a PH/\nCTEPH centre is recommended after considering the results of echocardiography, BNP/NT-proBNP, and/or CPET |  | I | C | \n | Other |  |  | \nCounselling regarding the risk of PAH and annual screening are recommended in individuals who test positive for PAH-causing\nmutations and in first-degree relatives of patients with HPAH |  | I | B | \nIn patients referred for liver transplantation, echocardiography is recommended as a screening test for PH |  | I | C | \n | Recommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension |  |  | \nIt is recommended to evaluate disease severity in patients with PAH with a panel of data derived from clinical assessment, exercise tests,\nbiochemical markers, echocardiography, and haemodynamic evaluations |  | I | B | \nAchieving and maintaining a low-risk profile on optimized medical therapy is recommended as a treatment goal in patients with PAH |  | I | B | \nFor risk stratification at the time of diagnosis, the use of a three-strata model (low, intermediate, and high risk) is recommended, taking\ninto account all available data including haemodynamics |  | I | B | \nFor risk stratification during follow-up, the use of a four-strata model (low, intermediate–low, intermediate–high, and high risk) based on\nWHO-FC, 6MWD, and BNP/NT-proBNP is recommended, with additional variables taken into account as necessary |  | I | B | ",
          "bbox": [
            48.0,
            61.00001220703125,
            552.2750574060389,
            715.1515502929688
          ],
          "function_potential": "raw"
        },
        {
          "title": "3706 ESC/ERS Guidelines",
          "page_number": 88,
          "content": "Recommendations for general measures and special circumstances |  |  |  | \nGeneral measures |  |  |  | \nSupervised exercise training is recommended in patients with PAH under medical therapy |  | I | A | \nPsychosocial support is recommended in patients with PAH |  | I | C | \nImmunization of patients with PAH against SARS-CoV-2, influenza, and Streptococcus pneumoniae is recommended |  | I | C | \nDiuretic treatment is recommended in patients with PAH with signs of RV failure and fluid retention |  | I | C | \nLong-term oxygen therapy is recommended in patients with PAH whose arterial blood oxygen pressure is ,8 kPa (60 mmHg)d |  | I | C | \nIn the presence of iron-deficiency anaemia, correction of iron status is recommended in patients with PAH |  | I | C | \nThe use of ACEis, ARBs, ARNIs, SGLT-2is, beta-blockers, or ivabradine is not recommended in patients with PAH unless required by\ncomorbidities (i.e. high blood pressure, coronary artery disease, left HF, or arrhythmias) |  | III | C | \n | Special circumstances |  |  | \nIn-flight oxygen administration is recommended for patients using oxygen or whose arterial blood oxygen pressure is ,8 kPa\n(60 mmHg) at sea level |  | I | C | \n | Recommendations for women of childbearing potential |  |  | \nIt is recommended that women of childbearing potential with PAH are counselled at the time of diagnosis about the risks and\nuncertainties associated with becoming pregnant; this should include advice against becoming pregnant, and referral for psychological\nsupport where needed |  | I | C | \nIt is recommended to provide women of childbearing potential with PAH with clear contraceptive advice, considering the individual\nneeds of the woman but recognizing that the implications of contraceptive failure are significant in PAH |  | I | C | \nIt is recommended that women with PAH who consider pregnancy or who become pregnant receive prompt counselling in an\nexperienced PH centre, to facilitate genetic counselling and shared decision-making, and to provide psychological support to the patients\nand their families where needed |  | I | C | \nFor women with PAH having termination of pregnancy, it is recommended that this be performed in PH centres, with psychological\nsupport provided to the patients and their families |  | I | C | \nAs teratogenic potential has been reported in pre-clinical models for endothelin receptor antagonists and riociguat, these drugs are not\nrecommended during pregnancy |  | III | B | \n | Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial\nhypertension |  |  | \nHigh doses of CCBs are recommended in patients with IPAH, HPAH, or DPAH who are responders to acute vasoreactivity testing |  | I | C | \nClose follow-up with complete reassessment after 3–4 months of therapy (including RHC) is recommended in patients with IPAH,\nHPAH, or DPAH treated with high doses of CCBs |  | I | C | \nContinuing high doses of CCBs is recommended in patients with IPAH, HPAH, or DPAH in WHO-FC I or II with marked\nhaemodynamic improvement (mPAP ,30 mmHg and PVR ,4 WU) |  | I | C | \nInitiating PAH therapy is recommended in patients who remain in WHO-FC III or IV or those without marked haemodynamic\nimprovement after high doses of CCBs |  | I | C | \nCCBs are not recommended in patients without a vasoreactivity study or non-responders, unless prescribed for other indications (e.g.\nRaynaud’s phenomenon) |  | III | C | \n | Recommendations for initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary\narterial hypertension without cardiopulmonary comorbiditiese |  |  | \nInitial combination therapy with ambrisentan and tadalafil is recommended |  | I | B | \nInitial combination therapy with macitentan and tadalafil is recommended |  | I | B | \nInitial combination therapy with macitentan, tadalafil, and selexipag is not recommended |  | III | B | ",
          "bbox": [
            42.9996021412037,
            61.00001220703125,
            547.2750077681108,
            728.1513616388494
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC/ERS Guidelines 3707",
          "page_number": 89,
          "content": "Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary\narterial hypertension |  |  |  | \nGeneral recommendation for sequential combination therapy |  |  |  | \nIt is recommended to base treatment escalations on risk assessment and general treatment strategies (see treatment algorithm) |  | I | C | \n | Evidence from studies with a composite morbidity/mortality endpoint as the primary outcome measure |  |  | \nThe addition of macitentan to PDE5is or oral/inhaled prostacyclin analogues is recommended to reduce the risk of morbidity/mortality\nevents |  | I | B | \nThe addition of selexipag to ERAsf and/or PDE5is is recommended to reduce the risk of morbidity/mortality events |  | I | B | \nThe addition of oral treprostinil to ERA or PDE5i/riociguat monotherapy is recommended to reduce the risk of morbidity/mortality\nevents |  | I | B | \nThe addition of bosentan to sildenafil is not recommended to reduce the risk of morbidity/mortality events |  | III | B | \n | Evidence from studies with change in 6MWD as the primary outcome measure |  |  | \nThe addition of sildenafil to epoprostenol is recommended to improve exercise capacity |  | I | B | \n | Evidence from studies with safety of combination therapy as primary outcome measure |  |  | \nCombining riociguat and PDE5is is not recommendedg |  | III | B | \n | Recommendations for intensive care management for pulmonary arterial hypertension |  |  | \nWhen managing patients with right HF in the ICU, it is recommended to involve physicians with expertise, treat causative factors, and\nuse supportive measures, including inotropes and vasopressors, fluid management, and PAH drugs, as appropriate |  | I | C | \n | Recommendations for lung transplantation |  |  | \nIt is recommended that potentially eligible candidates are referred for LTx evaluation when they have an inadequate response to oral\ncombination therapy, indicated by an intermediate–high or high risk or by a REVEAL risk score .7 |  | I | C | \nIt is recommended to list patients for LTx who present with a high risk of death or with a REVEAL risk score ≥10 despite receiving\noptimized medical therapy including s.c. or i.v. prostacyclin analogues |  | I | C | \n | Recommendations for pulmonary arterial hypertension associated with drugs or toxins |  |  | \nIt is recommended to make a diagnosis of drug- or toxin-associated PAH in patients who had relevant exposure and in whom other\ncauses of PH have been excluded |  | I | C | \nIn patients with suspected drug- or toxin-associated PAH, it is recommended to immediately discontinue the causative agent whenever\npossible |  | I | C | \n | Recommendations for pulmonary arterial hypertension associated with connective tissue disease |  |  | \nIn patients with PAH associated with CTD, treatment of the underlying condition according to current guidelines is recommended |  | I | A | \nIn patients with PAH associated with CTD, the same treatment algorithm as for patients with IPAH is recommended |  | I | C | \n | Recommendations for pulmonary arterial hypertension associated with human immunodeficiency virus infection |  |  | \nIn patients with PAH associated with HIV infection, antiretroviral treatment according to current guidelines is recommended |  | I | A | \n | Recommendations for pulmonary arterial hypertension associated with portal hypertension |  |  | \nEchocardiography is recommended in patients with liver disease or portal hypertension with signs or symptoms suggestive of PH, and as\na screening tool in patients evaluated for liver transplantation or transjugular portosystemic shunt |  | I | C | \nIt is recommended that patients with PAH associated with portal hypertension are referred to centres with expertise in managing both\nconditions |  | I | C | \nDrugs approved for PAH are not recommended for patients with portal hypertension and unclassified PH (i.e. elevated mPAP, high CO,\nand a normal PVR) |  | III | C | ",
          "bbox": [
            48.0,
            61.00001220703125,
            552.2750610351562,
            697.1515502929688
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3708 ESC/ERS Guidelines",
          "page_number": 90,
          "content": " | Recommendations for shunt closure in patients with pulmonary-systemic flow ratio .1.5:1 based on calculated pulmonary vascular\nresistance |  |  | \nIn patients with an ASD, VSD, or PDA and a PVR ,3 WU, shunt closure is recommended |  | I | C | \nIn patients with an ASD and a PVR .5 WU despite PAH treatment, shunt closure is not recommended |  | III | C | \nRecommendations for pulmonary arterial hypertension associated with adult congenital heart disease |  |  |  | \nRisk assessment |  |  |  | \nRisk assessment is recommended for patients with persistent PAH after defect closure |  | I | C | \n | Treatment |  |  | \nBosentan is recommended in symptomatic patients with Eisenmenger syndrome to improve exercise capacity |  | I | B | \nIn women with Eisenmenger syndrome, pregnancy is not recommended |  | III | C | \nIn patients with Eisenmenger syndrome, routine phlebotomy to lower elevated haematocrit is not recommended |  | III | C | \n | Recommendations for pulmonary arterial hypertension with signs of venous/capillary involvement |  |  | \nA combination of clinical and radiological findings, ABG, PFTs, and genetic testing is recommended to diagnose PAH with signs of venous\nand/or capillary involvement (PVOD/PCH) |  | I | A | \nIdentification of biallelic EIF2AK4 mutations is recommended to confirm a diagnosis of heritable PVOD/PCH |  | I | A | \nReferral of eligible patients with PVOD/PCH to a transplant centre for evaluation is recommended as soon as the diagnosis is established |  | I | C | \nLung biopsy is not recommended to confirm a diagnosis of PVOD/PCH |  | III | C | \nRecommendations for paediatric pulmonary hypertension |  |  |  | \nChildren |  |  |  | \nIt is recommended to perform the diagnostic work-up, including RHC and acute vasoreactivity testing, and treat children with PH at\ncentres with specific expertise in paediatric PH |  | I | C | \nIn children with PH, a comprehensive work-up for confirming diagnosis and specific aetiology is recommended (similar to that in adults,\nbut adapted for age) |  | I | C | \nFor confirming PH diagnosis, RHC is recommended, preferably before initiating any PAH therapy |  | I | C | \nIn children with IPAH/HPAH, acute vasoreactivity testing is recommended to detect those who may benefit from CCB therapy |  | I | C | \nIt is recommended to similarly define a positive response to acute vasoreactivity testing in children and adults by a reduction in mPAP\n≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg, with an increased or unchanged CO |  | I | C | \nIn children with PAH, a therapeutic strategy based on risk stratification and treatment response is recommended, extrapolated from\nthat in adults, but adapted for age |  | I | C | \nIt is recommended to monitor the treatment response in children with PAH by serially assessing a panel of data derived from clinical\nassessment, echocardiographic evaluation, biochemical markers, and exercise tolerance tests |  | I | C | \n | Infants |  |  | \nIt is recommended to screen infants with bronchopulmonary dysplasia for PH |  | I | B | \nIn infants with (or at risk of) bronchopulmonary dysplasia and PH, treating lung disease—including hypoxia, aspiration, and structural\nairway disease—and optimizing respiratory support is recommended before initiating PAH therapy |  | I | B | \n | Recommendations for pulmonary hypertension associated with left heart disease |  |  | \nIn patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of\nsuspected PH |  | I | A | \nRHC is recommended for suspected PH in patients with LHD, if it aids management decisions |  | I | C | ",
          "bbox": [
            42.999635858050844,
            61.00001220703125,
            547.2750195954975,
            704.1515447443181
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC/ERS Guidelines 3709",
          "page_number": 91,
          "content": "RHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair |  | I | C | \nFor patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral\nto a PH centre for a complete diagnostic work-up is recommended |  | I | C | \nIn patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is\nrecommended |  | I | C | \nWhen patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or\nfluid challenge, are treated with PAH drugs, close monitoring is recommended |  | I | C | \nDrugs approved for PAH are not recommended in PH-LHDh |  | III | A | \n | Recommendations for pulmonary hypertension associated with lung disease and/or hypoxia |  |  | \nIf PH is suspected in patients with lung disease, it is recommended that echocardiographyi be performed and results interpreted in\nconjunction with ABG, PFTs including DLCO, and CT imaging |  | I | C | \nIn patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where\nindicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation |  | I | C | \nIn patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH\ncentre is recommendedj |  | I | C | \nIn patients with lung disease and severe PH, an individualized approach to treatment is recommended |  | I | C | \nIt is recommended to refer eligible patients with lung disease and PH for LTx evaluation |  | I | C | \nIn patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions |  | I | C | \nThe use of ambrisentan is not recommended in patients with PH associated with IPF |  | III | B | \nThe use of riociguat is not recommended in patients with PH associated with IIP |  | III | B | \nThe use of PAH medication is not recommended in patients with lung disease and non-severe PHk |  | III | C | \n | Recommendations for chronic thrombo-embolic pulmonary hypertension and chronic thrombo-embolic pulmonary disease without\npulmonary hypertension |  |  | \nCTEPH |  |  |  | \nLifelong, therapeutic doses of anticoagulation are recommended in all patients with CTEPH |  | I | C | \nAntiphospholipid syndrome testing is recommended in patients with CTEPH |  | I | C | \nIn patients with CTEPH and antiphospholipid syndrome, anticoagulation with VKAs is recommended |  | I | C | \nIt is recommended that all patients with CTEPH are reviewed by a CTEPH team for the assessment of multimodality management |  | I | C | \nPEA is recommended as the treatment of choice for patients with CTEPH and fibrotic obstructions within pulmonary arteries accessible\nby surgery |  | I | B | \nBPA is recommended in patients who are technically inoperable or have residual PH after PEA and distal obstructions amenable to BPA |  | I | B | \nRiociguat is recommended for symptomatic patients with inoperable CTEPH or persistent/recurrent PH after PEA |  | I | B | \nLong-term follow-up is recommended after PEA and BPA, as well as for patients with CTEPH established on medical therapy |  | I | C | \n | Recommendations for pulmonary hypertension centres |  |  | \nIt is recommended that PH centres provide care by a multidisciplinary team (cardiologist, pneumologist, rheumatologist, nurse specialist,\nradiologist, psychological and social work support, appropriate on-call expertise) |  | I | C | \nIt is recommended that PH centres have direct links and quick referral patterns to other services (such as genetic counselling, PEA/BPA,\nLTx, adult congenital heart disease service) |  | I | C | ",
          "bbox": [
            48.0,
            59.5,
            552.2750396728516,
            735.1515558416194
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3710 ESC/ERS Guidelines",
          "page_number": 92,
          "content": "It is recommended that PH centres maintain a patient registry | I | C\nIt is recommended that PH centres collaborate with patient associations | I | C",
          "bbox": [
            42.99986049107143,
            59.5,
            547.2749633789062,
            108.5
          ],
          "function_potential": "raw"
        },
        {
          "title": "3710 ESC/ERS Guidelines",
          "page_number": 92,
          "content": "GRADE |  |  |  | \nRecommendations | Quality of\nevidence | Strength of\nrecommendation | Classa | Levelb\nIn patients with IPAH/HPAH/DPAH who present at low or intermediate risk of\ndeath, initial combination therapy with a PDE5i and an ERA is recommended | Low | Conditional | I | B\nThe use of PDE5i in patients with HFpEF and isolated post-capillary PH is not\nrecommended | Low | Conditional | III | C\nThe use of PDE5i in patients with ILD and non-severe PH is not recommended | Very low | Conditional | III | C",
          "bbox": [
            42.99986049107143,
            405.5,
            547.2749633789062,
            537.5
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "16. Quality indicators",
      "start_page": 92,
      "end_page": 94,
      "content": "16. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.847 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations through associated quality-improvement initia-\ntives and benchmarking of care providers.848,849 As such, the role\nof QIs in improving care and outcomes for cardiovascular disease\nis increasingly being recognized by health care authorities, profes-\nsional organizations, payers, and the public.847\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established\nmethods for developing the ESC QIs for the quantiﬁcation of care\nand outcomes for cardiovascular diseases.847 To date, the ESC has\ndeveloped QI suites for a number of cardiovascular diseases850–852\nand embedded these in respective ESC Clinical Practice guide-\nlines.27,477,853,854 Furthermore, the ESC aims to integrate its QIs\nwith clinical registries such as the EurObservational Research\nProgramme and the European Uniﬁed Registries On Heart Care\nEvaluation and Randomized Trials (EuroHeart) project855 to provide\nreal-world data about the patterns and outcomes of care for cardio-\nvascular disease across Europe.\nIn parallel with the writing of this Clinical Practice Guideline, a pro-\ncess has been initiated to develop QIs for patients with PH using the\nIt is recommended that PH centres maintain a patient registry\nI\nC\nIt is recommended that PH centres collaborate with patient associations\nI\nC\n© ESC/ERS 2022\n6MWD, 6-minute walking distance; ABG, arterial blood gas analysis; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–\nneprilysin inhibitor; ASD, atrial septal defect; BNP/NT-proBNP, brain natriuretic peptide/N-terminal pro-brain natriuretic peptide; BPA, balloon pulmonary angioplasty; CCB,\ncalcium channel blocker; CpcPH, combined post- and pre-capillary pulmonary hypertension; CPET, cardiopulmonary exercise testing; CT, computed tomography; CTD, connective\ntissue disease; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon\nmonoxide; DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; FVC, forced vital capacity; HF, heart failure; HFpEF, heart failure with\npreserved ejection fraction; HIV, human immunodeﬁciency virus; HPAH, heritable pulmonary arterial hypertension; ICU, intensive care unit; I/H/DPAH, idiopathic, heritable,\ndrug-associated pulmonary arterial hypertension; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; IPF, idiopathic\npulmonary ﬁbrosis; i.v., intravenous; LHD, left heart disease; LTx, lung transplantation; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PAWP,\npulmonary arterial wedge pressure; PCH, pulmonary capillary haemangiomatosis; PDA, patent ductus arteriosus; PDE5i, phosphodiesterase 5 inhibitor; PE, pulmonary embolism;\nPEA, pulmonary endarterectomy; PFTs, pulmonary function tests; PH, pulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVOD,\npulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right ventricular; s.c., subcutaneous; SGLT-2i, sodium–glucose\ncotransporter-2 inhibitor; SSc, systemic sclerosis; TRV, tricuspid regurgitation velocity; VKA, vitamin K antagonist; VSD, ventricular septal defect; WHO-FC, World Health\nOrganization functional class; WU, Wood units.\naClass of recommendation.\nbLevel of evidence.\ncTesting should also be performed in patients with a baseline mPAP ≤40 mmHg, in whom the same responder criteria apply.\ndMeasured on at least two occasions.\neCardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF such as obesity, diabetes, coronary heart disease, a history of\nhypertension, and/or a low DLCO.\nfERA used in the GRIPHON study were bosentan and ambrisentan.\ngThe PATENT plus study investigated the combination of sildenaﬁl and riociguat; however, combining riociguat with any PDE5i is contraindicated.\nhSafety concerns have been identiﬁed when ERAs are used in patients with HF (HFpEF and HFrEF, with or without PH) and when sildenaﬁl is used in patients with persistent PH after\ncorrection of valvular heart disease.\niAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise pulmonary artery pressure.\njThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.\nkThis does not include inhaled treprostinil, which may be considered in patients with PH associated with ILD irrespective of PH severity.\n‘What to do’ and ‘What not to do’ messages developed with GRADE Evidence to Decision framework\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nIn patients with IPAH/HPAH/DPAH who present at low or intermediate risk of\ndeath, initial combination therapy with a PDE5i and an ERA is recommended\nLow\nConditional\nI\nB\nThe use of PDE5i in patients with HFpEF and isolated post-capillary PH is not\nrecommended\nLow\nConditional\nIII\nC\nThe use of PDE5i in patients with ILD and non-severe PH is not recommended\nVery low\nConditional\nIII\nC\n© ESC/ERS 2022\nDPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; HPAH, heritable pulmonary arterial hypertension; HFpEF, heart failure with preserved\nejection fraction; ILD, interstitial lung disease; PDE5i, phosphodiesterase 5 inhibitor; PH, pulmonary hypertension.\naClass of recommendation.\nbLevel of evidence.\n3710\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nESC methodology and through collaboration with domain experts\nand the Heart Failure Association of the ESC. Such QIs may be\nused for evaluating the quality of care for patients with PH, and en-\nable important aspects of care delivery to be captured. These QIs,\nalongside their speciﬁcations and development process, will be pub-\nlished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online in-\ncluding key narrative question (1-8) and PICO questions (I-IV).\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Marc Humbert*,\nFaculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre,\nFrance, Service de Pneumologie et Soins Intensifs Respiratoires,\nCentre de Référence de l’Hypertension Pulmonaire, Hôpital\nBicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre,\nFrance, INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le\nPlessis-Robinson, France; Gabor Kovacs, University Clinic of\nInternal Medicine, Division of Pulmonology, Medical University of\nGraz, Graz, Austria, Ludwig Boltzmann Institute for Lung Vascular\nResearch,\nGraz,\nAustria;\nMarius\nM.\nHoeper,\nRespiratory\nMedicine,\nHannover\nMedical\nSchool,\nHanover,\nGermany,\nBiomedical Research in End-stage and Obstructive Lung Disease\n(BREATH), member of the German Centre of Lung Research\n(DZL), Hanover, Germany; Roberto Badagliacca, Dipartimento\ndi Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari,\nSapienza\nUniversità\ndi\nRoma,\nRoma,\nItaly,\nDipartimento\nCardio-Toraco-Vascolare e\nChirurgia dei\nTrapianti\nd’Organo,\nPoliclinico Umberto I, Roma, Italy; Rolf M.F. Berger, Center for\nCongenital Heart Diseases, Beatrix Children’s Hospital, Dept of\nPaediatric\nCardiology,\nUniversity\nMedical\nCenter\nGroningen,\nUniversity of Groningen, Groningen, Netherlands; Margarita\nBrida, Department of Sports and Rehabilitation Medicine, Medical\nFaculty University of Rijeka, Rijeka, Croatia, Adult Congenital Heart\nCentre and National Centre for Pulmonary Hypertension, Royal\nBrompton & Hareﬁeld Hospitals, Guys & St Thomas’s NHS Trust,\nLondon,\nUnited\nKingdom;\nJørn\nCarlsen,\nDepartment\nof\nCardiology,\nCopenhagen\nUniversity\nHospital,\nRigshospitalet,\nCopenhagen, Denmark, Department of Clinical Medicine; Faculty of\nHealth\nand\nMedical\nSciences,\nUniversity\nof\nCopenhagen,\nCopenhagen, Denmark; Andrew J.S. Coats, Faculty of Medicine,\nUniversity of Warwick, Coventry, United Kingdom, Faculty of\nMedicine,\nMonash\nUniversity\nMelbourne,\nAustralia;\nPilar\nEscribano-Subias, Pulmonary Hypertension Unit, Cardiology\nDepartment, Hospital Universitario 12 de Octubre, Madrid, Spain,\nCIBER-CV (Centro de Investigaciones Biomédicas En Red de enfer-\nmedades CardioVasculares), Instituto de Salud Carlos III, Madrid,\nSpain, Facultad de Medicina, Universidad Complutense, Madrid,\nSpain; Pisana Ferrari (Italy), ESC Patient Forum, Sophia Antipolis,\nFrance, AIPI, Associazione Italiana Ipertensione Polmonare, Bologna,\nItaly; Diogenes S. Ferreira, Alergia e Imunologia, Hospital de\nClinicas, Universidade Federal do Parana, Curitiba, Brazil; Hossein\nArdeschir\nGhofrani,\nDepartment\nof\nInternal\nMedicine,\nUniversity\nHospital\nGiessen,\nJustus-Liebig\nUniversity,\nGiessen,\nGermany, Department of Pneumology, Kerckhoff Klinik, Bad\nNauheim, Germany, Department of Medicine, Imperial College\nLondon, London, United Kingdom; George Giannakoulas,\nCardiology\nDepartment,\nAristotle\nUniversity\nof\nThessaloniki,\nAHEPA University Hospital, Thessaloniki, Greece; David G. Kiely,\nDepartment of Infection, Immunity and Cardiovascular Disease,\nUniversity\nof\nShefﬁeld,\nShefﬁeld,\nUnited\nKingdom,\nShefﬁeld\nPulmonary Vascular Disease Unit, Shefﬁeld Teaching Hospitals NHS\nFoundation Trust, Shefﬁeld, United Kingdom, Insigneo Institute,\nUniversity of Shefﬁeld, Shefﬁeld, United Kingdom; Eckhard\nMayer,\nThoracic\nSurgery,\nKerckhoff\nClinic,\nBad\nNauheim,\nGermany; Gergely Meszaros (Hungary), ESC Patient Forum,\nSophia\nAntipolis,\nFrance,\nEuropean\nLung\nFoundation\n(ELF),\nShefﬁeld, United Kingdom; Blin Nagavci, Institute for Evidence in\nMedicine, Faculty of Medicine and Medical Center, University of\nFreiburg, Freiburg, Germany; Karen M. Olsson, Clinic of\nRespiratory Medicine, Hannover Medical School, member of the\nGerman Center of Lung Research (DZL), Hannover, Germany;\nJoanna Pepke-Zaba, Pulmonary Vascular Diseases Unit, Royal\nPapworth\nHospital,\nCambridge,\nUnited\nKingdom;\nJennifer\nK. Quint, NHLI, Imperial College London, London, United\nKingdom; Göran Rådegran, Department of Cardiology, Clinical\nSciences\nLund,\nFaculty\nof\nMedicine,\nLund,\nSweden,\nThe\nHaemodynamic Lab, The Section for Heart Failure and Valvular\nDisease, VO. Heart and Lung Medicine, Skåne University Hospital,\nLund, Sweden; Gerald Simonneau, Faculté Médecine, Université\nParis Saclay, Le Kremlin-Bicêtre, France, Centre de Référence de\nl’Hypertension\nPulmonaire,\nHopital\nMarie-Lannelongue,\nLe\nPlessis-Robinson, France; Olivier Sitbon, Faculty of Medicine,\nUniversité Paris-Saclay, Le Kremlin-Bicêtre, France, Service de\nPneumologie et Soins Intensifs Respiratoires, Centre de Référence\nde l’Hypertension Pulmonaire, Hôpital Bicêtre, Assistance Publique\nHôpitaux de Paris, Le Kremlin-Bicêtre, France, INSERM UMR_S\n999,\nHôpital Marie-Lannelongue,\nLe\nPlessis-Robinson,\nFrance;\nThomy Tonia, Institute of Social and Preventive Medicine,\nUniversity of Bern, Bern, Switzerland; Mark Toshner, Heart Lung\nResearch Institute, Dept of Medicine, University of Cambridge,\nCambridge,\nUnited\nKingdom,\nRoyal\nPapworth\nNHS\nTrust;\nJean-Luc Vachiery, Department of Cardiology, Pulmonary\nVascular Diseases and Heart Failure Clinic, HUB Hôpital Erasme,\nBrussels, Belgium; and Anton Vonk Noordegraaf, Pulmonology,\nAmsterdam UMC, Amsterdam, Netherlands.\n* Marc Humbert is supported by the Investissement d’Avenir pro-\ngramme managed by the French National Research Agency under\nthe grant contract ANR-18-RHUS-0006 (DESTINATION 2024).\n20. Appendix\nESC/ERS Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nESC/ERS Guidelines\n3711\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "elderly",
        "heart failure",
        "recommended",
        "pulmonary hypertension",
        "quality",
        "hfref",
        "hfpef",
        "glucose",
        "hypertension",
        "bnp",
        "obesity",
        "nt-probnp",
        "arb",
        "may be considered",
        "tricuspid",
        "catheterization",
        "guideline",
        "calcium channel",
        "indicators",
        "ejection fraction",
        "diabetes",
        "pulmonary embolism",
        "exercise"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "17. Supplementary data",
      "start_page": 93,
      "end_page": 94,
      "content": "ESC methodology and through collaboration with domain experts\nand the Heart Failure Association of the ESC. Such QIs may be\nused for evaluating the quality of care for patients with PH, and en-\nable important aspects of care delivery to be captured. These QIs,\nalongside their speciﬁcations and development process, will be pub-\nlished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online in-\ncluding key narrative question (1-8) and PICO questions (I-IV).\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Marc Humbert*,\nFaculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre,\nFrance, Service de Pneumologie et Soins Intensifs Respiratoires,\nCentre de Référence de l’Hypertension Pulmonaire, Hôpital\nBicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre,\nFrance, INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le\nPlessis-Robinson, France; Gabor Kovacs, University Clinic of\nInternal Medicine, Division of Pulmonology, Medical University of\nGraz, Graz, Austria, Ludwig Boltzmann Institute for Lung Vascular\nResearch,\nGraz,\nAustria;\nMarius\nM.\nHoeper,\nRespiratory\nMedicine,\nHannover\nMedical\nSchool,\nHanover,\nGermany,\nBiomedical Research in End-stage and Obstructive Lung Disease\n(BREATH), member of the German Centre of Lung Research\n(DZL), Hanover, Germany; Roberto Badagliacca, Dipartimento\ndi Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari,\nSapienza\nUniversità\ndi\nRoma,\nRoma,\nItaly,\nDipartimento\nCardio-Toraco-Vascolare e\nChirurgia dei\nTrapianti\nd’Organo,\nPoliclinico Umberto I, Roma, Italy; Rolf M.F. Berger, Center for\nCongenital Heart Diseases, Beatrix Children’s Hospital, Dept of\nPaediatric\nCardiology,\nUniversity\nMedical\nCenter\nGroningen,\nUniversity of Groningen, Groningen, Netherlands; Margarita\nBrida, Department of Sports and Rehabilitation Medicine, Medical\nFaculty University of Rijeka, Rijeka, Croatia, Adult Congenital Heart\nCentre and National Centre for Pulmonary Hypertension, Royal\nBrompton & Hareﬁeld Hospitals, Guys & St Thomas’s NHS Trust,\nLondon,\nUnited\nKingdom;\nJørn\nCarlsen,\nDepartment\nof\nCardiology,\nCopenhagen\nUniversity\nHospital,\nRigshospitalet,\nCopenhagen, Denmark, Department of Clinical Medicine; Faculty of\nHealth\nand\nMedical\nSciences,\nUniversity\nof\nCopenhagen,\nCopenhagen, Denmark; Andrew J.S. Coats, Faculty of Medicine,\nUniversity of Warwick, Coventry, United Kingdom, Faculty of\nMedicine,\nMonash\nUniversity\nMelbourne,\nAustralia;\nPilar\nEscribano-Subias, Pulmonary Hypertension Unit, Cardiology\nDepartment, Hospital Universitario 12 de Octubre, Madrid, Spain,\nCIBER-CV (Centro de Investigaciones Biomédicas En Red de enfer-\nmedades CardioVasculares), Instituto de Salud Carlos III, Madrid,\nSpain, Facultad de Medicina, Universidad Complutense, Madrid,\nSpain; Pisana Ferrari (Italy), ESC Patient Forum, Sophia Antipolis,\nFrance, AIPI, Associazione Italiana Ipertensione Polmonare, Bologna,\nItaly; Diogenes S. Ferreira, Alergia e Imunologia, Hospital de\nClinicas, Universidade Federal do Parana, Curitiba, Brazil; Hossein\nArdeschir\nGhofrani,\nDepartment\nof\nInternal\nMedicine,\nUniversity\nHospital\nGiessen,\nJustus-Liebig\nUniversity,\nGiessen,\nGermany, Department of Pneumology, Kerckhoff Klinik, Bad\nNauheim, Germany, Department of Medicine, Imperial College\nLondon, London, United Kingdom; George Giannakoulas,\nCardiology\nDepartment,\nAristotle\nUniversity\nof\nThessaloniki,\nAHEPA University Hospital, Thessaloniki, Greece; David G. Kiely,\nDepartment of Infection, Immunity and Cardiovascular Disease,\nUniversity\nof\nShefﬁeld,\nShefﬁeld,\nUnited\nKingdom,\nShefﬁeld\nPulmonary Vascular Disease Unit, Shefﬁeld Teaching Hospitals NHS\nFoundation Trust, Shefﬁeld, United Kingdom, Insigneo Institute,\nUniversity of Shefﬁeld, Shefﬁeld, United Kingdom; Eckhard\nMayer,\nThoracic\nSurgery,\nKerckhoff\nClinic,\nBad\nNauheim,\nGermany; Gergely Meszaros (Hungary), ESC Patient Forum,\nSophia\nAntipolis,\nFrance,\nEuropean\nLung\nFoundation\n(ELF),\nShefﬁeld, United Kingdom; Blin Nagavci, Institute for Evidence in\nMedicine, Faculty of Medicine and Medical Center, University of\nFreiburg, Freiburg, Germany; Karen M. Olsson, Clinic of\nRespiratory Medicine, Hannover Medical School, member of the\nGerman Center of Lung Research (DZL), Hannover, Germany;\nJoanna Pepke-Zaba, Pulmonary Vascular Diseases Unit, Royal\nPapworth\nHospital,\nCambridge,\nUnited\nKingdom;\nJennifer\nK. Quint, NHLI, Imperial College London, London, United\nKingdom; Göran Rådegran, Department of Cardiology, Clinical\nSciences\nLund,\nFaculty\nof\nMedicine,\nLund,\nSweden,\nThe\nHaemodynamic Lab, The Section for Heart Failure and Valvular\nDisease, VO. Heart and Lung Medicine, Skåne University Hospital,\nLund, Sweden; Gerald Simonneau, Faculté Médecine, Université\nParis Saclay, Le Kremlin-Bicêtre, France, Centre de Référence de\nl’Hypertension\nPulmonaire,\nHopital\nMarie-Lannelongue,\nLe\nPlessis-Robinson, France; Olivier Sitbon, Faculty of Medicine,\nUniversité Paris-Saclay, Le Kremlin-Bicêtre, France, Service de\nPneumologie et Soins Intensifs Respiratoires, Centre de Référence\nde l’Hypertension Pulmonaire, Hôpital Bicêtre, Assistance Publique\nHôpitaux de Paris, Le Kremlin-Bicêtre, France, INSERM UMR_S\n999,\nHôpital Marie-Lannelongue,\nLe\nPlessis-Robinson,\nFrance;\nThomy Tonia, Institute of Social and Preventive Medicine,\nUniversity of Bern, Bern, Switzerland; Mark Toshner, Heart Lung\nResearch Institute, Dept of Medicine, University of Cambridge,\nCambridge,\nUnited\nKingdom,\nRoyal\nPapworth\nNHS\nTrust;\nJean-Luc Vachiery, Department of Cardiology, Pulmonary\nVascular Diseases and Heart Failure Clinic, HUB Hôpital Erasme,\nBrussels, Belgium; and Anton Vonk Noordegraaf, Pulmonology,\nAmsterdam UMC, Amsterdam, Netherlands.\n* Marc Humbert is supported by the Investissement d’Avenir pro-\ngramme managed by the French National Research Agency under\nthe grant contract ANR-18-RHUS-0006 (DESTINATION 2024).\n20. Appendix\nESC/ERS Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nESC/ERS Guidelines\n3711\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "data",
        "hypertension",
        "heart failure",
        "pulmonary hypertension",
        "supplementary"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "18. Data availability statement",
      "start_page": 93,
      "end_page": 94,
      "content": "ESC methodology and through collaboration with domain experts\nand the Heart Failure Association of the ESC. Such QIs may be\nused for evaluating the quality of care for patients with PH, and en-\nable important aspects of care delivery to be captured. These QIs,\nalongside their speciﬁcations and development process, will be pub-\nlished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online in-\ncluding key narrative question (1-8) and PICO questions (I-IV).\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Marc Humbert*,\nFaculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre,\nFrance, Service de Pneumologie et Soins Intensifs Respiratoires,\nCentre de Référence de l’Hypertension Pulmonaire, Hôpital\nBicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre,\nFrance, INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le\nPlessis-Robinson, France; Gabor Kovacs, University Clinic of\nInternal Medicine, Division of Pulmonology, Medical University of\nGraz, Graz, Austria, Ludwig Boltzmann Institute for Lung Vascular\nResearch,\nGraz,\nAustria;\nMarius\nM.\nHoeper,\nRespiratory\nMedicine,\nHannover\nMedical\nSchool,\nHanover,\nGermany,\nBiomedical Research in End-stage and Obstructive Lung Disease\n(BREATH), member of the German Centre of Lung Research\n(DZL), Hanover, Germany; Roberto Badagliacca, Dipartimento\ndi Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari,\nSapienza\nUniversità\ndi\nRoma,\nRoma,\nItaly,\nDipartimento\nCardio-Toraco-Vascolare e\nChirurgia dei\nTrapianti\nd’Organo,\nPoliclinico Umberto I, Roma, Italy; Rolf M.F. Berger, Center for\nCongenital Heart Diseases, Beatrix Children’s Hospital, Dept of\nPaediatric\nCardiology,\nUniversity\nMedical\nCenter\nGroningen,\nUniversity of Groningen, Groningen, Netherlands; Margarita\nBrida, Department of Sports and Rehabilitation Medicine, Medical\nFaculty University of Rijeka, Rijeka, Croatia, Adult Congenital Heart\nCentre and National Centre for Pulmonary Hypertension, Royal\nBrompton & Hareﬁeld Hospitals, Guys & St Thomas’s NHS Trust,\nLondon,\nUnited\nKingdom;\nJørn\nCarlsen,\nDepartment\nof\nCardiology,\nCopenhagen\nUniversity\nHospital,\nRigshospitalet,\nCopenhagen, Denmark, Department of Clinical Medicine; Faculty of\nHealth\nand\nMedical\nSciences,\nUniversity\nof\nCopenhagen,\nCopenhagen, Denmark; Andrew J.S. Coats, Faculty of Medicine,\nUniversity of Warwick, Coventry, United Kingdom, Faculty of\nMedicine,\nMonash\nUniversity\nMelbourne,\nAustralia;\nPilar\nEscribano-Subias, Pulmonary Hypertension Unit, Cardiology\nDepartment, Hospital Universitario 12 de Octubre, Madrid, Spain,\nCIBER-CV (Centro de Investigaciones Biomédicas En Red de enfer-\nmedades CardioVasculares), Instituto de Salud Carlos III, Madrid,\nSpain, Facultad de Medicina, Universidad Complutense, Madrid,\nSpain; Pisana Ferrari (Italy), ESC Patient Forum, Sophia Antipolis,\nFrance, AIPI, Associazione Italiana Ipertensione Polmonare, Bologna,\nItaly; Diogenes S. Ferreira, Alergia e Imunologia, Hospital de\nClinicas, Universidade Federal do Parana, Curitiba, Brazil; Hossein\nArdeschir\nGhofrani,\nDepartment\nof\nInternal\nMedicine,\nUniversity\nHospital\nGiessen,\nJustus-Liebig\nUniversity,\nGiessen,\nGermany, Department of Pneumology, Kerckhoff Klinik, Bad\nNauheim, Germany, Department of Medicine, Imperial College\nLondon, London, United Kingdom; George Giannakoulas,\nCardiology\nDepartment,\nAristotle\nUniversity\nof\nThessaloniki,\nAHEPA University Hospital, Thessaloniki, Greece; David G. Kiely,\nDepartment of Infection, Immunity and Cardiovascular Disease,\nUniversity\nof\nShefﬁeld,\nShefﬁeld,\nUnited\nKingdom,\nShefﬁeld\nPulmonary Vascular Disease Unit, Shefﬁeld Teaching Hospitals NHS\nFoundation Trust, Shefﬁeld, United Kingdom, Insigneo Institute,\nUniversity of Shefﬁeld, Shefﬁeld, United Kingdom; Eckhard\nMayer,\nThoracic\nSurgery,\nKerckhoff\nClinic,\nBad\nNauheim,\nGermany; Gergely Meszaros (Hungary), ESC Patient Forum,\nSophia\nAntipolis,\nFrance,\nEuropean\nLung\nFoundation\n(ELF),\nShefﬁeld, United Kingdom; Blin Nagavci, Institute for Evidence in\nMedicine, Faculty of Medicine and Medical Center, University of\nFreiburg, Freiburg, Germany; Karen M. Olsson, Clinic of\nRespiratory Medicine, Hannover Medical School, member of the\nGerman Center of Lung Research (DZL), Hannover, Germany;\nJoanna Pepke-Zaba, Pulmonary Vascular Diseases Unit, Royal\nPapworth\nHospital,\nCambridge,\nUnited\nKingdom;\nJennifer\nK. Quint, NHLI, Imperial College London, London, United\nKingdom; Göran Rådegran, Department of Cardiology, Clinical\nSciences\nLund,\nFaculty\nof\nMedicine,\nLund,\nSweden,\nThe\nHaemodynamic Lab, The Section for Heart Failure and Valvular\nDisease, VO. Heart and Lung Medicine, Skåne University Hospital,\nLund, Sweden; Gerald Simonneau, Faculté Médecine, Université\nParis Saclay, Le Kremlin-Bicêtre, France, Centre de Référence de\nl’Hypertension\nPulmonaire,\nHopital\nMarie-Lannelongue,\nLe\nPlessis-Robinson, France; Olivier Sitbon, Faculty of Medicine,\nUniversité Paris-Saclay, Le Kremlin-Bicêtre, France, Service de\nPneumologie et Soins Intensifs Respiratoires, Centre de Référence\nde l’Hypertension Pulmonaire, Hôpital Bicêtre, Assistance Publique\nHôpitaux de Paris, Le Kremlin-Bicêtre, France, INSERM UMR_S\n999,\nHôpital Marie-Lannelongue,\nLe\nPlessis-Robinson,\nFrance;\nThomy Tonia, Institute of Social and Preventive Medicine,\nUniversity of Bern, Bern, Switzerland; Mark Toshner, Heart Lung\nResearch Institute, Dept of Medicine, University of Cambridge,\nCambridge,\nUnited\nKingdom,\nRoyal\nPapworth\nNHS\nTrust;\nJean-Luc Vachiery, Department of Cardiology, Pulmonary\nVascular Diseases and Heart Failure Clinic, HUB Hôpital Erasme,\nBrussels, Belgium; and Anton Vonk Noordegraaf, Pulmonology,\nAmsterdam UMC, Amsterdam, Netherlands.\n* Marc Humbert is supported by the Investissement d’Avenir pro-\ngramme managed by the French National Research Agency under\nthe grant contract ANR-18-RHUS-0006 (DESTINATION 2024).\n20. Appendix\nESC/ERS Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nESC/ERS Guidelines\n3711\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "data",
        "hypertension",
        "heart failure",
        "statement",
        "pulmonary hypertension",
        "availability"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "19. Author information",
      "start_page": 93,
      "end_page": 94,
      "content": "ESC methodology and through collaboration with domain experts\nand the Heart Failure Association of the ESC. Such QIs may be\nused for evaluating the quality of care for patients with PH, and en-\nable important aspects of care delivery to be captured. These QIs,\nalongside their speciﬁcations and development process, will be pub-\nlished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online in-\ncluding key narrative question (1-8) and PICO questions (I-IV).\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Marc Humbert*,\nFaculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre,\nFrance, Service de Pneumologie et Soins Intensifs Respiratoires,\nCentre de Référence de l’Hypertension Pulmonaire, Hôpital\nBicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre,\nFrance, INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le\nPlessis-Robinson, France; Gabor Kovacs, University Clinic of\nInternal Medicine, Division of Pulmonology, Medical University of\nGraz, Graz, Austria, Ludwig Boltzmann Institute for Lung Vascular\nResearch,\nGraz,\nAustria;\nMarius\nM.\nHoeper,\nRespiratory\nMedicine,\nHannover\nMedical\nSchool,\nHanover,\nGermany,\nBiomedical Research in End-stage and Obstructive Lung Disease\n(BREATH), member of the German Centre of Lung Research\n(DZL), Hanover, Germany; Roberto Badagliacca, Dipartimento\ndi Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari,\nSapienza\nUniversità\ndi\nRoma,\nRoma,\nItaly,\nDipartimento\nCardio-Toraco-Vascolare e\nChirurgia dei\nTrapianti\nd’Organo,\nPoliclinico Umberto I, Roma, Italy; Rolf M.F. Berger, Center for\nCongenital Heart Diseases, Beatrix Children’s Hospital, Dept of\nPaediatric\nCardiology,\nUniversity\nMedical\nCenter\nGroningen,\nUniversity of Groningen, Groningen, Netherlands; Margarita\nBrida, Department of Sports and Rehabilitation Medicine, Medical\nFaculty University of Rijeka, Rijeka, Croatia, Adult Congenital Heart\nCentre and National Centre for Pulmonary Hypertension, Royal\nBrompton & Hareﬁeld Hospitals, Guys & St Thomas’s NHS Trust,\nLondon,\nUnited\nKingdom;\nJørn\nCarlsen,\nDepartment\nof\nCardiology,\nCopenhagen\nUniversity\nHospital,\nRigshospitalet,\nCopenhagen, Denmark, Department of Clinical Medicine; Faculty of\nHealth\nand\nMedical\nSciences,\nUniversity\nof\nCopenhagen,\nCopenhagen, Denmark; Andrew J.S. Coats, Faculty of Medicine,\nUniversity of Warwick, Coventry, United Kingdom, Faculty of\nMedicine,\nMonash\nUniversity\nMelbourne,\nAustralia;\nPilar\nEscribano-Subias, Pulmonary Hypertension Unit, Cardiology\nDepartment, Hospital Universitario 12 de Octubre, Madrid, Spain,\nCIBER-CV (Centro de Investigaciones Biomédicas En Red de enfer-\nmedades CardioVasculares), Instituto de Salud Carlos III, Madrid,\nSpain, Facultad de Medicina, Universidad Complutense, Madrid,\nSpain; Pisana Ferrari (Italy), ESC Patient Forum, Sophia Antipolis,\nFrance, AIPI, Associazione Italiana Ipertensione Polmonare, Bologna,\nItaly; Diogenes S. Ferreira, Alergia e Imunologia, Hospital de\nClinicas, Universidade Federal do Parana, Curitiba, Brazil; Hossein\nArdeschir\nGhofrani,\nDepartment\nof\nInternal\nMedicine,\nUniversity\nHospital\nGiessen,\nJustus-Liebig\nUniversity,\nGiessen,\nGermany, Department of Pneumology, Kerckhoff Klinik, Bad\nNauheim, Germany, Department of Medicine, Imperial College\nLondon, London, United Kingdom; George Giannakoulas,\nCardiology\nDepartment,\nAristotle\nUniversity\nof\nThessaloniki,\nAHEPA University Hospital, Thessaloniki, Greece; David G. Kiely,\nDepartment of Infection, Immunity and Cardiovascular Disease,\nUniversity\nof\nShefﬁeld,\nShefﬁeld,\nUnited\nKingdom,\nShefﬁeld\nPulmonary Vascular Disease Unit, Shefﬁeld Teaching Hospitals NHS\nFoundation Trust, Shefﬁeld, United Kingdom, Insigneo Institute,\nUniversity of Shefﬁeld, Shefﬁeld, United Kingdom; Eckhard\nMayer,\nThoracic\nSurgery,\nKerckhoff\nClinic,\nBad\nNauheim,\nGermany; Gergely Meszaros (Hungary), ESC Patient Forum,\nSophia\nAntipolis,\nFrance,\nEuropean\nLung\nFoundation\n(ELF),\nShefﬁeld, United Kingdom; Blin Nagavci, Institute for Evidence in\nMedicine, Faculty of Medicine and Medical Center, University of\nFreiburg, Freiburg, Germany; Karen M. Olsson, Clinic of\nRespiratory Medicine, Hannover Medical School, member of the\nGerman Center of Lung Research (DZL), Hannover, Germany;\nJoanna Pepke-Zaba, Pulmonary Vascular Diseases Unit, Royal\nPapworth\nHospital,\nCambridge,\nUnited\nKingdom;\nJennifer\nK. Quint, NHLI, Imperial College London, London, United\nKingdom; Göran Rådegran, Department of Cardiology, Clinical\nSciences\nLund,\nFaculty\nof\nMedicine,\nLund,\nSweden,\nThe\nHaemodynamic Lab, The Section for Heart Failure and Valvular\nDisease, VO. Heart and Lung Medicine, Skåne University Hospital,\nLund, Sweden; Gerald Simonneau, Faculté Médecine, Université\nParis Saclay, Le Kremlin-Bicêtre, France, Centre de Référence de\nl’Hypertension\nPulmonaire,\nHopital\nMarie-Lannelongue,\nLe\nPlessis-Robinson, France; Olivier Sitbon, Faculty of Medicine,\nUniversité Paris-Saclay, Le Kremlin-Bicêtre, France, Service de\nPneumologie et Soins Intensifs Respiratoires, Centre de Référence\nde l’Hypertension Pulmonaire, Hôpital Bicêtre, Assistance Publique\nHôpitaux de Paris, Le Kremlin-Bicêtre, France, INSERM UMR_S\n999,\nHôpital Marie-Lannelongue,\nLe\nPlessis-Robinson,\nFrance;\nThomy Tonia, Institute of Social and Preventive Medicine,\nUniversity of Bern, Bern, Switzerland; Mark Toshner, Heart Lung\nResearch Institute, Dept of Medicine, University of Cambridge,\nCambridge,\nUnited\nKingdom,\nRoyal\nPapworth\nNHS\nTrust;\nJean-Luc Vachiery, Department of Cardiology, Pulmonary\nVascular Diseases and Heart Failure Clinic, HUB Hôpital Erasme,\nBrussels, Belgium; and Anton Vonk Noordegraaf, Pulmonology,\nAmsterdam UMC, Amsterdam, Netherlands.\n* Marc Humbert is supported by the Investissement d’Avenir pro-\ngramme managed by the French National Research Agency under\nthe grant contract ANR-18-RHUS-0006 (DESTINATION 2024).\n20. Appendix\nESC/ERS Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nESC/ERS Guidelines\n3711\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "keywords": [
        "hypertension",
        "heart failure",
        "pulmonary hypertension",
        "author",
        "information"
      ],
      "tables": []
    }
  ]
}